In	O	O
this	O	O
work	O	O
,	O	O
to	O	O
evaluate	O	O
the	O	O
relative	O	O
free	O	O
energies	O	O
of	O	O
hydration	O	O
and	O	O
binding	O	O
to	O	O
thrombin	O	O
for	O	O
some	O	O
benzamidine	O	B-IUPAC
derivatives	O	B-MODIFIER
,	O	O
we	O	O
used	O	O
the	O	O
finite	O	O
difference	O	O
thermodynamic	O	O
integration	O	O
(	O	O
FDTI	O	O
)	O	O
algorithm	O	O
within	O	O
the	O	O
Discover	O	O
program	O	O
of	O	O
MSI	O	O
.	O	O
The	O	O
acids	O	O
were	O	O
coupled	O	O
with	O	O
diethyl	O	O
glutamate	O	O
,	O	O
followed	O	O
by	O	O
saponification	O	O
,	O	O
to	O	O
give	O	O
the	O	O
10	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
alkyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8,10	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dideazaminopterins	I-IUPAC	I-IUPAC
.	O	O
Structure	O	O
-	O	O
activity	O	O
analysis	O	O
at	O	O
adenosine	O	O
receptors	O	O
indicated	O	O
that	O	O
pyridyl	O	O
,	O	O
furyl	O	O
,	O	O
benzofuryl	O	O
,	O	O
and	O	O
thienyl	O	O
groups	O	O
at	O	O
the	O	O
4	O	O
-	O	O
position	O	O
resulted	O	O
in	O	O
,	O	O
at	O	O
most	O	O
,	O	O
only	O	O
moderate	O	O
selectivity	O	O
for	O	O
A3	O	O
adenosine	O	O
receptors	O	O
.	O	O
The	O	O
target	O	O
compounds	O	O
9-12	O	O
were	O	O
obtained	O	O
by	O	O
an	O	O
N1	O	O
regioselective	O	O
intramolecular	O	O
cyclization	O	O
reaction	O	O
of	O	O
silylated	O	O
5-8	O	O
using	O	O
trimethylsilyl	O	B-IUPAC
trifluoromethanesulfonate	O	I-IUPAC
(	O	O
TMS	O	O
triflate	O	O
)	O	O
as	O	O
the	O	O
catalyst	O	O
.	O	O
Saponification	O	O
of	O	O
the	O	O
antifolate	O	O
esters	O	O
so	O	O
produced	O	O
gave	O	O
the	O	O
desired	O	O
analogues	O	O
.	O	O
13,24	B-IUPAC	O
-	I-IUPAC	O
Cyclo	I-IUPAC	O
-	I-IUPAC	O
18,21	I-IUPAC	O
-	I-IUPAC	O
dinorcholanes	I-IUPAC	O
containing	O	O
a	O	O
ketone	O	O
or	O	O
conjugated	O	O
ketone	O	O
group	O	O
at	O	O
C	O	O
-	O	O
20	O	O
,	O	O
C	O	O
-	O	O
22	O	O
,	O	O
C	O	O
-	O	O
23	O	O
,	O	O
or	O	O
C	O	O
-	O	O
24	O	O
were	O	O
prepared	O	O
as	O	O
conformationally	O	O
constrained	O	O
analogues	O	O
of	O	O
these	O	O
anesthetic	O	O
steroids	O	O
and	O	O
were	O	O
used	O	O
to	O	O
probe	O	O
for	O	O
alternate	O	O
locations	O	O
for	O	O
the	O	O
D	O	O
-	O	O
ring	O	O
hydrogen	O	O
-	O	O
bond	O	O
-	O	O
accepting	O	O
carbonyl	B-IUPAC	O
group	B-MODIFIER	O
.	O	O
We	O	O
propose	O	O
that	O	O
neonicotinoids	O	O
with	O	O
a	O	O
protonated	O	O
N	O	O
-	O	O
unsubstituted	O	O
imine	O	O
or	O	O
equivalent	O	O
substituent	O	O
recognize	O	O
the	O	O
anionic	O	O
subsite	O	O
of	O	O
the	O	O
mammalian	O	O
alpha4beta2	O	O
nAChR	O	O
whereas	O	O
the	O	O
negatively	O	O
charged	O	O
(	O	O
delta	O	O
(	O	O
-	O	O
)	O	O
)	O	O
tip	O	O
of	O	O
the	O	O
neonicotinoid	O	O
insecticides	O	O
interacts	O	O
with	O	O
a	O	O
putative	O	O
cationic	O	O
subsite	O	O
of	O	O
the	O	O
insect	O	O
nAChR	O	O
.	O	O
The	O	O
best	O	O
calpain	O	O
I	O	O
inhibitor	O	O
in	O	O
this	O	O
study	O	O
was	O	O
Z	O	O
-	O	O
Leu	O	O
-	O	O
Nva	O	O
-	O	O
CONH	O	O
-	O	O
CH2	O	O
-	O	O
2	O	O
-	O	O
pyridyl	O	O
(	O	O
Ki	O	O
=	O	O
19	O	O
nM	O	O
)	O	O
.	O	O
Thymidylate	O	O
synthase	O	O
inhibition	O	O
was	O	O
studied	O	O
with	O	O
two	O	O
forms	O	O
of	O	O
the	O	O
enzyme	O	O
differing	O	O
in	O	O
sensitivities	O	O
toward	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
5'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
monophosphate	I-IUPAC	I-IUPAC
(	O	O
FdUMP	O	O
)	O	O
,	O	O
isolated	O	O
from	O	O
parental	O	O
and	O	O
FdUrd	O	O
-	O	O
resistant	O	O
L1210	O	O
cell	O	O
lines	O	O
.	O	O
A	O	O
comparison	O	O
of	O	O
the	O	O
PNMT	O	O
inhibitory	O	O
potency	O	O
of	O	O
the	O	O
enantiomers	O	O
of	O	O
these	O	O
3	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
fluoromethyl	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
,	O	O
3	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
hydroxymethyl	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
,	O	O
and	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloromethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
THIQs	I-IUPAC	I-IUPAC
indicates	O	I-IUPAC
that	O	O
all	O	O
of	O	O
the	O	O
3	O	O
-	O	O
substituted	O	B-MODIFIER
-	O	O
THIQs	O	O
displayed	O	O
similar	O	O
inhibitory	O	O
potency	O	O
for	O	O
PNMT	O	O
.	O	O
These	O	O
compounds	O	O
behave	O	O
as	O	O
potent	O	O
antagonists	O	O
of	O	O
the	O	O
Grb2	O	O
-	O	O
Shc	O	O
interaction	O	O
.	O	O
This	O	O
mixture	O	O
was	O	O
rearranged	O	O
by	O	O
heating	O	O
with	O	O
molecular	O	O
sieve	O	O
in	O	O
refluxing	O	O
toluene	O	O
to	O	O
give	O	O
a	O	O
6	O	O
:	O	O
1	O	O
mixture	O	O
of	O	O
2	O	O
and	O	O
3	O	O
.	O	O
The	O	O
5	O	B-IUPAC
-	O	I-IUPAC
isoxazolol	O	I-IUPAC
isomer	O	B-MODIFIER
of	O	O
10	O	O
,	O	O
compound	O	O
12	O	O
,	O	O
showed	O	O
a	O	O
reduced	O	O
receptor	O	O
affinity	O	O
(	O	O
IC50	O	O
=	O	O
26	O	O
+	O	O
/	O	O
-	O	O
7	O	O
microM	O	O
)	O	O
and	O	O
a	O	O
very	O	O
low	O	O
relative	O	O
efficacy	O	O
.	O	O
At	O	O
the	O	O
N	O	O
-	O	O
1	O	O
position	O	O
"	O	O
standard	O	O
"	O	O
substitution	O	O
was	O	O
employed	O	O
with	O	O
the	O	O
ethyl	B-IUPAC	O
,	O	O
cyclopropyl	B-IUPAC	B-IUPAC
,	O	O
and	O	O
p	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluorophenyl	I-IUPAC	I-IUPAC
groups	B-MODIFIER	B-MODIFIER
being	O	O
used	O	O
.	O	O
A	O	O
potential	O	O
H	O	O
-	O	O
bonding	O	O
interaction	O	O
between	O	O
the	O	O
pyridyl	O	O
nitrogen	O	O
free	O	O
electron	O	O
pair	O	O
and	O	O
the	O	O
suitably	O	O
positioned	O	O
1,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydropyridine	I-IUPAC	I-IUPAC
NH	B-MODIFIER	O
moiety	I-MODIFIER	O
may	O	O
stablize	O	O
this	O	O
rotamer	O	O
orientation	O	O
.	O	O
Affinity	O	O
was	O	O
determined	O	O
in	O	O
radioligand	O	O
binding	O	O
assays	O	O
at	O	O
rat	O	O
brain	O	O
A1	O	O
and	O	O
A2A	O	O
receptors	O	O
using	O	O
[	O	O
3H	O	O
]	O	O
-	O	O
(	O	O
R	O	O
)	O	O
-	O	O
PIA	O	O
(	O	O
[	B-IUPAC	B-IUPAC
3H	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phenylisopropyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
adenosine	I-IUPAC	I-IUPAC
)	O	O
and	O	O
[	O	O
3H	O	O
]	O	O
CGS	O	O
21680	O	O
(	O	O
[	B-IUPAC	B-IUPAC
3H	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxy	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
ethylaminol	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carbamoyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
adenosine	I-IUPAC	I-IUPAC
)	O	O
,	O	O
respectively	O	O
.	O	O
Hydrolysis	O	O
of	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dichloroquinazoline	I-IUPAC	I-IUPAC
to	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
quinazolinol	I-IUPAC	I-IUPAC
was	O	O
followed	O	O
by	O	O
condensation	O	O
with	O	O
the	O	O
appropriate	O	O
N	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dialkylalkylenediamine	I-IUPAC	I-IUPAC
to	O	O
give	O	O
an	O	O
array	O	O
of	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
dialkylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
alkyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
quinazolinols	I-IUPAC	I-IUPAC
(	O	O
IXa	O	O
)	O	O
.	O	O
It	O	O
was	O	O
more	O	O
potent	O	O
than	O	O
,	O	O
and	O	O
equally	O	O
efficacious	O	O
to	O	O
,	O	O
L	O	O
-	O	O
glutamate	O	O
in	O	O
[	O	O
3H	O	O
]	O	O
MK801	O	O
binding	O	O
.	O	O
These	O	O
findings	O	O
motivated	O	O
us	O	O
to	O	O
search	O	O
for	O	O
the	O	O
preparation	O	O
of	O	O
new	O	O
selective	O	O
radioligands	O	O
for	O	O
the	O	O
A	O	O
(	O	O
3	O	O
)	O	O
subtype	O	O
;	O	O
hence	O	O
,	O	O
a	O	O
procedure	O	O
to	O	O
introduce	O	O
a	O	O
tritiated	O	O
alkylamino	O	O
group	O	O
in	O	O
these	O	O
molecules	O	O
was	O	O
carried	O	O
out	O	O
.	O	O
Compound	O	O
6	O	O
,	O	O
but	O	O
not	O	O
7	O	O
,	O	O
proved	O	O
to	O	O
be	O	O
a	O	O
very	O	O
potent	O	O
agonist	O	O
(	O	O
EC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
0.13	O	O
microM	O	O
)	O	O
at	O	O
the	O	O
kainate	O	O
-	O	O
preferring	O	O
GluR5	O	O
subunit	O	O
,	O	O
equipotent	O	O
with	O	O
(	B-IUPAC	B-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tert	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyisothiazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propionic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
[	O	O
(	O	O
S	O	O
)	O	O
-	O	O
Thio	O	O
-	O	O
ATPA	O	O
,	O	O
4	O	O
]	O	O
and	O	O
almost	O	O
4	O	O
times	O	O
more	O	O
potent	O	O
than	O	O
(	B-IUPAC	B-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tert	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyisoxazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propionic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
[	O	O
(	O	O
S	O	O
)	O	O
-	O	O
ATPA	O	O
,	O	O
3	O	O
]	O	O
.	O	O
Four	O	O
selected	O	O
acronycine	O	O
derivatives	O	O
(	O	O
17,19	O	O
,	O	O
21	O	O
,	O	O
and	O	O
22	O	O
)	O	O
were	O	O
evaluated	O	O
in	O	O
vivo	O	O
against	O	O
murine	O	O
P388	O	O
leukemia	O	O
and	O	O
colon	O	O
38	O	O
adenocarcinoma	O	O
implanted	O	O
in	O	O
mice	O	O
.	O	O
Potent	O	O
delta	O	O
-	O	O
agonists	O	O
and	O	O
bifunctional	O	O
compounds	O	O
with	O	O
high	O	O
delta	O	O
-	O	O
and	O	O
mu	O	O
-	O	O
opioid	O	O
receptor	O	O
affinities	O	O
were	O	O
obtained	O	O
by	O	O
varying	O	O
the	O	O
spacer	O	O
length	O	O
[	O	O
none	O	O
,	O	O
NH	O	O
-	O	O
CH	O	O
(	O	O
2	O	O
)	O	O
,	O	O
NH	O	O
-	O	O
CH	O	O
(	O	O
2	O	O
)	O	O
-	O	O
CH	O	O
(	O	O
2	O	O
)	O	O
,	O	O
Gly	O	O
-	O	O
NH	O	O
-	O	O
CH	O	O
(	O	O
2	O	O
)	O	O
]	O	O
and	O	O
C	O	O
-	O	O
terminal	O	O
aromatic	O	O
nucleus	O	O
[	O	B-IUPAC
1H	B-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
benzimidazole	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
2	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
yl	I-PARTIUPAC	I-IUPAC
,	O	O
phenyl	B-PARTIUPAC	B-IUPAC
(	O	O
Ph	O	O
)	O	O
and	O	O
benzyl	B-IUPAC	O
groups	B-MODIFIER	O
]	O	O
.	O	O
Alkenes	O	O
4d	O	O
and	O	O
4e	O	O
were	O	O
cyclized	O	O
to	O	O
heterocycles	O	O
12	O	O
and	O	O
13	O	O
.	O	O
However	O	O
,	O	O
its	O	O
clinical	O	O
potential	O	O
is	O	O
limited	O	O
by	O	O
acute	O	O
toxicity	O	O
of	O	O
the	O	O
free	O	O
ligand	O	O
(	O	O
but	O	O
not	O	O
Fe3+	O	O
complex	O	O
)	O	O
at	O	O
high	O	O
dosage	O	O
.	O	O
In	O	O
addition	O	O
,	O	O
2a	O	O
possesses	O	O
a	O	O
carbomethoxy	O	O
substituent	O	O
adjacent	O	O
to	O	O
the	O	O
aryl	O	O
ring	O	O
,	O	O
whereas	O	O
(	O	O
3S	O	O
,	O	O
4R	O	O
)	O	O
-	O	O
3	O	O
contains	O	O
a	O	O
[	B-IUPAC	O
3,4	I-IUPAC	O
-	I-IUPAC	O
(	I-IUPAC	O
methylenedioxy	I-IUPAC	O
)	I-IUPAC	O
phenoxy	I-IUPAC	O
]	I-IUPAC	O
methyl	I-IUPAC	O
group	B-MODIFIER	O
.	O	O
In	O	O
the	O	O
catalytic	O	O
hydrogenation	O	O
of	O	O
10	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
ethoxalylfolic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
5	O	O
)	O	O
,	O	O
the	O	O
initial	O	O
product	O	O
10	O	O
-	O	O
(	O	O
EtO2CCO	O	O
)	O	O
-	O	O
THF	O	O
(	O	O
22	O	O
)	O	O
rearranged	O	O
readily	O	O
to	O	O
give	O	O
5	O	O
-	O	O
(	O	O
EtO2CCO	O	O
)	O	O
-	O	O
THF	O	O
(	O	O
21	O	O
)	O	O
.	O	O
This	O	O
leads	O	O
to	O	O
the	O	O
formation	O	O
of	O	O
a	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyoxazaphosphorine	I-IUPAC	I-IUPAC
ring	O	B-MODIFIER
with	O	O
R	O	O
=	O	O
H	O	O
(	O	O
3a	O	O
coming	O	O
from	O	O
compounds	O	O
2a	O	O
,	O	O
c	O	O
)	O	O
or	O	O
(	O	O
CH	O	O
(	O	O
2	O	O
)	O	O
)	O	O
(	O	O
2	O	O
)	O	O
Cl	O	O
(	O	O
3b	O	O
coming	O	O
from	O	O
compounds	O	O
2b	O	O
,	O	O
d	O	O
)	O	O
and	O	O
to	O	O
the	O	O
release	O	O
of	O	O
ammonia	O	O
or	O	O
chloroethylamine	O	O
.	O	O
The	O	O
results	O	O
of	O	O
this	O	O
study	O	O
indicate	O	O
that	O	O
MTX	O	O
and	O	O
DCM	O	O
esters	O	O
are	O	O
not	O	O
therapeutically	O	O
equivalent	O	O
in	O	O
mice	O	O
,	O	O
despite	O	O
the	O	O
high	O	O
serum	O	O
esterase	O	O
activity	O	O
in	O	O
this	O	O
species	O	O
,	O	O
and	O	O
that	O	O
an	O	O
up	O	O
to	O	O
10	O	O
-	O	O
fold	O	O
reduction	O	O
in	O	O
total	O	O
administered	O	O
dose	O	O
on	O	O
the	O	O
q3dX3	O	O
schedule	O	O
is	O	O
feasible	O	O
by	O	O
this	O	O
approach	O	O
.	O	O
Treatment	O	O
of	O	O
5	O	O
with	O	O
mercuric	O	O
chloride	O	O
furnished	O	O
the	O	O
toyocamycin	O	O
analogue	O	O
7	O	O
.	O	O
The	O	O
amine	O	O
4	O	O
shows	O	O
about	O	O
7	O	O
-	O	O
fold	O	O
lower	O	O
affinity	O	O
than	O	O
DA	O	O
for	O	O
both	O	O
sites	O	O
and	O	O
is	O	O
not	O	O
able	O	O
to	O	O
discriminate	O	O
between	O	O
the	O	O
two	O	O
subtypes	O	O
of	O	O
DA	O	O
receptors	O	O
.	O	O
Compound	O	O
9	O	O
,	O	O
in	O	O
which	O	O
a	O	O
phenolic	O	O
group	O	O
is	O	O
in	O	O
the	O	O
same	O	O
region	O	O
of	O	O
space	O	O
as	O	O
the	O	O
acidic	O	O
NH	O	O
of	O	O
1	O	O
,	O	O
exhibited	O	O
the	O	O
best	O	O
alpha	O	O
2	O	O
-	O	O
adrenoceptor	O	O
affinity	O	O
of	O	O
any	O	O
of	O	O
the	O	O
compounds	O	O
studied	O	O
(	O	O
PNMT	O	O
Ki	O	O
=	O	O
0.98	O	O
microM	O	O
,	O	O
alpha	O	O
2	O	O
Ki	O	O
=	O	O
0.078	O	O
microM	O	O
,	O	O
selectivity	O	O
=	O	O
0.080	O	O
)	O	O
.	O	O
Interestingly	O	O
,	O	O
methoxyethoxy	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
of	O	O
16j	O	O
is	O	O
0.02	O	O
microM	O	O
;	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
of	O	O
17h	O	O
is	O	O
0.01	O	O
microM	O	O
)	O	O
and	O	O
ethoxyethoxy	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
of	O	O
17j	O	O
is	O	O
0.02	O	O
micro	O	O
M	O	O
)	O	O
analogues	O	O
showed	O	O
the	O	O
most	O	O
potent	O	O
activity	O	O
,	O	O
suggesting	O	O
that	O	O
the	O	O
inserted	O	O
oxygen	O	O
atom	O	O
significantly	O	O
interacts	O	O
with	O	O
beta	O	O
-	O	O
PDGFR	O	O
.	O	O
Reductive	O	O
alkylation	O	O
of	O	O
THF	O	O
with	O	O
glyoxylic	O	O
acid	O	O
and	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxypentanal	I-IUPAC	I-IUPAC
,	O	O
respectively	O	O
,	O	O
gave	O	O
5	O	O
-	O	O
(	O	O
HO2CCH2	O	O
)	O	O
-	O	O
THF	O	O
(	O	O
24	O	O
)	O	O
and	O	O
5	O	O
-	O	O
[	O	O
HO	O	O
(	O	O
CH2	O	O
)	O	O
5	O	O
]	O	O
-	O	O
THF	O	O
(	O	O
25	O	O
)	O	O
.	O	O
ATP	O	O
2	O	O
-	O	O
thioethers	O	O
displayed	O	O
pD2	O	O
values	O	O
in	O	O
the	O	O
range	O	O
of	O	O
6-8	O	O
in	O	O
smooth	O	O
muscle	O	O
assay	O	O
systems	O	O
for	O	O
activity	O	O
at	O	O
P2Y	O	O
-	O	O
receptors	O	O
.	O	O
All	O	O
of	O	O
the	O	O
isozymes	O	O
tested	O	O
possessed	O	O
measurable	O	O
activity	O	O
with	O	O
phenethyl	O	O
chloride	O	O
.	O	O
Thf2	O	O
-	O	O
FU	O	O
was	O	O
found	O	O
to	O	O
be	O	O
effective	O	O
against	O	O
murine	O	O
solid	O	O
tumors	O	O
and	O	O
it	O	O
was	O	O
less	O	O
toxic	O	O
than	O	O
Thf	O	O
-	O	O
FU	O	O
when	O	O
given	O	O
orally	O	O
.	O	O
The	O	O
dedifferentiation	O	O
agent	O	O
"	O	O
reversine	O	O
"	O	O
[	O	B-IUPAC
2	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
morpholinoanilino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyclohexyladenine	I-IUPAC	I-IUPAC
2	I-IUPAC	O
]	O	O
was	O	O
found	O	O
to	O	O
be	O	O
a	O	O
moderately	O	O
potent	O	O
antagonist	O	O
for	O	O
the	O	O
human	O	O
A	O	O
(	O	O
3	O	O
)	O	O
adenosine	O	O
receptor	O	O
(	O	O
AR	O	O
)	O	O
with	O	O
a	O	O
K	O	O
(	O	O
i	O	O
)	O	O
value	O	O
of	O	O
0.66	O	O
microM	O	O
.	O	O
In	O	O
contrast	O	O
to	O	O
the	O	O
parent	O	O
compound	O	O
ACPA	O	O
(	O	O
2	O	O
)	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
6.3	O	O
microM	O	O
)	O	O
,	O	O
none	O	O
of	O	O
the	O	O
analogues	O	O
described	O	O
showed	O	O
detectable	O	O
inhibitory	O	O
effect	O	O
on	O	O
[	B-IUPAC	O
(	I-IUPAC	O
3	I-IUPAC	O
)	I-IUPAC	O
H	I-IUPAC	O
]	I-IUPAC	O
kainic	I-IUPAC	O
acid	I-IUPAC	O
receptor	O	O
binding	O	O
.	O	O
The	O	O
analog	O	O
was	O	O
purified	O	O
by	O	O
desalting	O	O
on	O	O
Sephadex	O	O
G	O	O
-	O	O
15	O	O
in	O	O
50%	O	O
HOAc	O	O
and	O	O
gel	O	O
filtration	O	O
on	O	O
Sephadex	O	O
G	O	O
-	O	O
25	O	O
and	O	O
LH	O	O
-	O	O
20	O	O
.	O	O
The	O	O
most	O	O
active	O	O
compound	O	O
,	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
iodoethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
(	O	O
12a	O	O
,	O	O
ID50	O	O
=	O	O
0.1	O	O
micrograms	O	O
/	O	O
mL	O	O
)	O	O
,	O	O
which	O	O
exhibited	O	O
antiviral	O	O
activity	O	O
(	O	O
HSV	O	O
-	O	O
1	O	O
)	O	O
100	O	O
-	O	O
fold	O	O
higher	O	O
than	O	O
that	O	O
of	O	O
the	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
iodoethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
analogue	B-MODIFIER	B-MODIFIER
(	O	O
11a	O	O
)	O	O
,	O	O
was	O	O
less	O	O
active	O	O
than	O	O
IVDU	O	O
or	O	O
acyclovir	O	O
(	O	O
ID50	O	O
=	O	O
0.01-0.1	O	O
micrograms	O	O
/	O	O
mL	O	O
range	O	O
)	O	O
.	O	O
These	O	O
were	O	O
8	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
O6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
benzylguanines	I-IUPAC	I-IUPAC
bearing	O	O
electron	O	O
-	O	O
withdrawing	O	O
groups	O	O
at	O	O
the	O	O
8	O	O
-	O	O
position	O	O
(	O	O
e.g.	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aza	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzylguanine	I-IUPAC	I-IUPAC
and	O	O
O6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
benzyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bromoguanine	I-IUPAC	I-IUPAC
)	O	O
and	O	O
5	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
benzyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
pyrimidines	I-IUPAC	I-IUPAC
bearing	O	O
electron	O	O
-	O	O
withdrawing	O	O
groups	O	O
at	O	O
the	O	O
5	O	O
-	O	O
position	O	O
(	O	O
e.g.	O	O
2,4	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
diamino	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
6	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
(	I-PARTIUPAC	I-IUPAC
benzyloxy	I-PARTIUPAC	I-IUPAC
)	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
5	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
nitroso	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	O
and	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
benzyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
nitropyrimidine	I-IUPAC	I-IUPAC
)	O	O
.	O	O
These	O	O
were	O	O
evaluated	O	O
in	O	O
human	O	O
foreskin	O	O
fibroblast	O	O
cells	O	O
challenged	O	O
with	O	O
the	O	O
vaccinia	O	O
virus	O	O
or	O	O
cowpox	O	O
virus	O	O
.	O	O
Other	O	O
compounds	O	O
in	O	O
this	O	O
series	O	O
showed	O	O
moderate	O	O
activities	O	O
(	O	O
IC50	O	O
&	O	O
gt	O	O
;	O	O
100	O	O
nM	O	O
)	O	O
on	O	O
the	O	O
type	O	O
II	O	O
enzyme	O	O
.	O	O
These	O	O
findings	O	O
are	O	O
consistent	O	O
with	O	O
the	O	O
hypothesis	O	O
that	O	O
the	O	O
diol	O	O
epoxide	O	O
metabolites	O	O
of	O	O
these	O	O
dihydrodiols	O	O
are	O	O
the	O	O
active	O	O
carcinogenic	O	O
forms	O	O
of	O	O
the	O	O
parent	O	O
hydrocarbons	O	O
.	O	O
In	O	O
mouse	O	O
permanent	O	O
middle	O	O
cerebral	O	O
artery	O	O
occlusion	O	O
focal	O	O
ischemia	O	O
,	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzothiazolyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
thio	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
adenosine	I-IUPAC	I-IUPAC
(	O	O
NNC	O	O
21-0136	O	O
,	O	O
12	O	O
)	O	O
exhibited	O	O
significant	O	O
neuroprotection	O	O
at	O	O
the	O	O
remarkably	O	O
low	O	O
total	O	O
intraperitoneal	O	O
dose	O	O
of	O	O
0.1	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
a	O	O
dose	O	O
at	O	O
which	O	O
no	O	O
cardiovascular	O	O
effects	O	O
are	O	O
observed	O	O
in	O	O
conscious	O	O
rats	O	O
.	O	O
For	O	O
9	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
RS	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diazidopropyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
adenine	I-IUPAC	I-IUPAC
and	O	O
some	O	O
di	B-MODIFIER	O
-	I-MODIFIER	O
and	O	O
trihydroxybutyl	B-MODIFIER	O
analogues	I-MODIFIER	O
of	O	O
DHPA	O	O
,	O	O
viz	O	O
.	O	O
Compound	O	O
21	O	O
also	O	O
effectively	O	O
suppresses	O	O
seizures	O	O
induced	O	O
in	O	O
Swiss	O	O
mice	O	O
by	O	O
maximal	O	O
electroshock	O	O
(	O	O
MES	O	O
)	O	O
and	O	O
pentylenetetrazole	O	O
(	O	O
PTZ	O	O
)	O	O
.	O	O
The	O	O
irreversible	O	O
inactivation	O	O
of	O	O
the	O	O
hormone	O	O
-	O	O
binding	O	O
site	O	O
by	O	O
the	O	O
four	O	O
haloacetamides	O	O
was	O	O
prevented	O	O
by	O	O
treatment	O	O
of	O	O
the	O	O
cytosol	O	O
with	O	O
the	O	O
thiol	O	O
-	O	O
specific	O	O
reagent	O	O
methyl	O	B-IUPAC
methanethiosulfonate	O	I-IUPAC
,	O	O
suggesting	O	O
that	O	O
the	O	O
target	O	O
of	O	O
these	O	O
compounds	O	O
was	O	O
probably	O	O
the	O	O
-	O	O
SH	O	O
of	O	O
cysteines	O	O
.	O	O
Also	O	O
,	O	O
4c	O	O
,	O	O
d	O	O
were	O	O
evaluated	O	O
for	O	O
their	O	O
ability	O	O
to	O	O
compete	O	O
against	O	O
agonist	O	O
and	O	O
antagonist	O	O
radioligands	O	O
at	O	O
cloned	O	O
human	O	O
5	O	O
-	O	O
HT2A	O	O
,	O	O
5	O	O
-	O	O
HT2B	O	O
,	O	O
and	O	O
5	O	O
-	O	O
HT2C	O	O
receptors	O	O
.	O	O
Against	O	O
P	O	O
.	O	O
Alkoxymethyl	O	O
,	O	O
acyloxymethyl	O	B-IUPAC
,	O	O
and	O	O
mixed	O	O
alkylalkoxymethyl	O	O
or	O	O
alkylacyloxymethyl	O	B-IUPAC
derivatives	O	B-MODIFIER
of	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylhydantoin	I-IUPAC	I-IUPAC
exhibit	O	O
anticonvulsant	O	O
activity	O	O
.	O	O
The	O	O
central	O	O
metal	O	O
ions	O	O
exert	O	O
pronounced	O	O
effects	O	O
in	O	O
a	O	O
divergent	O	O
manner	O	O
:	O	O
gallium	O	O
(	O	O
III	O	O
)	O	O
enhances	O	O
,	O	O
whereas	O	O
iron	O	O
(	O	O
III	O	O
)	O	O
weakens	O	O
the	O	O
cytotoxicity	O	O
of	O	O
the	O	O
ligands	O	O
.	O	O
In	O	O
summary	O	O
,	O	O
the	O	O
4,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
triamine	I-IUPAC	I-IUPAC
motif	B-MODIFIER	O
was	O	O
shown	O	O
to	O	O
facilitate	O	O
entry	O	O
of	O	O
polyamine	O	O
conjugates	O	O
into	O	O
cells	O	O
containing	O	O
active	O	O
polyamine	O	O
transporters	O	O
.	O	O
Lipophilic	O	O
methotrexate	O	O
(	O	O
MTX	O	O
)	O	O
and	O	O
3'	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
5'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dichloromethotrexate	I-IUPAC	I-IUPAC
(	O	O
DCM	O	O
)	O	O
diesters	B-MODIFIER	O
were	O	O
prepared	O	O
by	O	O
HCl	O	O
-	O	O
catalyzed	O	O
esterification	O	O
or	O	O
by	O	O
neutral	O	O
esterification	O	O
using	O	O
cesium	O	O
carbonate	O	O
and	O	O
an	O	O
alkyl	O	O
or	O	O
aralkyl	O	O
halide	O	O
in	O	O
Me2SO	O	O
.	O	O
A	O	O
cellular	O	O
debenzylation	O	O
process	O	O
was	O	O
observed	O	O
in	O	O
L1210	O	O
cells	O	O
with	O	O
6	O	O
and	O	O
generated	O	O
"	O	O
free	O	O
"	O	O
homospermidine	O	O
.	O	O
For	O	O
ligands	O	O
with	O	O
a	O	O
log	O	O
Dligand	O	O
=	O	O
-	O	O
1	O	O
,	O	O
a	O	O
linear	O	O
relationship	O	O
exists	O	O
with	O	O
a	O	O
value	O	O
of	O	O
the	O	O
slope	O	O
2.53	O	O
,	O	O
whereas	O	O
with	O	O
ligands	O	O
with	O	O
a	O	O
log	O	O
Dligand	O	O
&	O	O
lt	O	O
;	O	O
-	O	O
1	O	O
,	O	O
a	O	O
linear	O	O
relationship	O	O
exists	O	O
with	O	O
a	O	O
slope	O	O
of	O	O
0.49	O	O
.	O	O
,	O	O
by	O	O
the	O	O
action	O	O
of	O	O
converting	O	O
enzyme	O	O
on	O	O
the	O	O
nonapeptide	O	O
IV	O	O
,	O	O
and	O	O
(	O	O
b	O	O
)	O	O
that	O	O
III	O	O
may	O	O
also	O	O
be	O	O
acting	O	O
as	O	O
inhibitor	O	O
of	O	O
the	O	O
converting	O	O
enzyme	O	O
by	O	O
the	O	O
feedback	O	O
mechanism	O	O
.	O	O
In	O	O
a	O	O
structure	O	O
-	O	O
activity	O	O
comparison	O	O
it	O	O
was	O	O
found	O	O
that	O	O
the	O	O
oxygen	O	O
atom	O	O
in	O	O
the	O	O
2	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
(	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
-	I-MODIFIER	O
oxy	I-MODIFIER	O
)	I-MODIFIER	O
ethyl	I-MODIFIER	B-IUPAC
group	B-MODIFIER	B-MODIFIER
at	O	O
the	O	O
1	O	O
-	O	O
position	O	O
of	O	O
the	O	O
benzimidazole	O	O
nucleus	O	O
played	O	O
an	O	O
important	O	O
role	O	O
for	O	O
potent	O	O
antihistaminic	O	O
activity	O	O
,	O	O
especially	O	O
in	O	O
vivo	O	O
.	O	O
f	O	O
.	O	O
/	O	O
100	O	O
mL	O	O
of	O	O
tissue	O	O
)	O	O
.	O	O
In	O	O
rat	O	O
experiments	O	O
,	O	O
the	O	O
(	O	O
18	O	O
)	O	O
F	O	O
-	O	O
labeled	O	O
candidate	O	O
showed	O	O
desirable	O	O
properties	O	O
for	O	O
PET	O	O
AChE	O	O
measurement	O	O
:	O	O
high	O	O
brain	O	O
uptake	O	O
of	O	O
the	O	O
authentic	O	O
ester	O	O
,	O	O
high	O	O
AChE	O	O
specificity	O	O
,	O	O
a	O	O
moderate	O	O
hydrolysis	O	O
rate	O	O
,	O	O
and	O	O
low	O	O
membrane	O	O
permeability	O	O
(	O	O
metabolic	O	O
trapping	O	O
)	O	O
of	O	O
the	O	O
metabolite	O	O
.	O	O
The	O	O
synthesis	O	O
and	O	O
in	O	O
vitro	O	O
sigma	O	O
receptor	O	O
activity	O	O
of	O	O
the	O	O
two	O	O
diastereomers	O	O
of	O	O
U50	O	O
,	O	O
488	O	O
[	O	O
(	O	O
+	O	O
/	O	O
-	O	O
)	O	O
-	O	O
2	O	O
]	O	O
,	O	O
namely	O	O
,	O	O
(	B-IUPAC	B-IUPAC
1R	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
2S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
+	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cis	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dichloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrrolidinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
cyclohexyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
benzeneacet	I-IUPAC	I-IUPAC
ami	I-IUPAC	O
de	I-IUPAC	O
[	B-PARTIUPAC	O
(	I-PARTIUPAC	O
+	I-PARTIUPAC	O
)	I-PARTIUPAC	O
-	I-PARTIUPAC	O
1	I-PARTIUPAC	O
]	I-PARTIUPAC	O
and	O	O
(	B-IUPAC	B-IUPAC
1S	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
2R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cis	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dichloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrrolidinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
cyclohexyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
benzeneacetamide	I-IUPAC	I-IUPAC
[	O	O
(	O	O
-	O	O
)	O	O
-	O	O
1	O	O
]	O	O
,	O	O
are	O	O
described	O	O
.	O	O
The	O	O
structure	O	O
-	O	O
activity	O	O
findings	O	O
led	O	O
to	O	O
a	O	O
refinement	O	O
of	O	O
a	O	O
model	O	O
of	O	O
the	O	O
nonprostanoid	O	O
PGI2	O	O
mimetic	O	O
pharmacophore	O	O
.	O	O
The	O	O
crystal	O	O
structure	O	O
and	O	O
final	O	O
molecular	O	O
structure	O	O
of	O	O
one	O	O
of	O	O
these	O	O
,	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyhexahydroazepin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tolylsulfonylurea	I-IUPAC	I-IUPAC
(	O	O
5	O	O
)	O	O
,	O	O
were	O	O
determined	O	O
using	O	O
single	O	O
-	O	O
crystal	O	O
X	O	O
-	O	O
ray	O	O
techniques	O	O
.	O	O
At	O	O
physiological	O	O
pH	O	O
,	O	O
the	O	O
spatial	O	O
arrangement	O	O
of	O	O
the	O	O
three	O	O
charges	O	O
of	O	O
DL	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
tetrazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ylglycine	I-IUPAC	I-IUPAC
(	O	O
5	O	O
)	O	O
could	O	O
be	O	O
viewed	O	O
as	O	O
similar	O	O
to	O	O
those	O	O
found	O	O
in	O	O
certain	O	O
conformations	O	O
of	O	O
the	O	O
two	O	O
excitatory	O	O
amino	O	O
acids	O	O
(	O	O
EAAs	O	O
)	O	O
-	O	O
-	O	O
aspartic	O	O
and	O	O
glutamic	O	O
acids	O	O
.	O	O
In	O	O
order	O	O
to	O	O
study	O	O
the	O	O
toxicities	O	O
of	O	O
4	O	O
and	O	O
5	O	O
released	O	O
under	O	O
drug	O	O
metabolizing	O	O
conditions	O	O
independently	O	O
of	O	O
the	O	O
production	O	O
of	O	O
a	O	O
toxic	O	O
mustard	O	O
the	O	O
analogs	B-MODIFIER	O
18	O	O
[	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
diethylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,3,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxazaphosphorine	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxide	I-IUPAC	I-IUPAC
]	O	O
and	O	O
6	O	B-IUPAC
[	O	I-IUPAC
2	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
diethylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trifluoromethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,3,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxazaphosphorine	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxide	I-IUPAC	I-IUPAC
]	O	O
were	O	O
also	O	O
synthesized	O	O
.	O	O
Primary	O	O
and	O	O
secondary	O	O
amines	O	O
bound	O	O
with	O	O
lower	O	O
affinity	O	O
than	O	O
tertiary	O	O
amines	O	O
.	O	O
Conformational	O	O
studies	O	O
(	O	O
NMR	O	O
,	O	O
X	O	O
-	O	O
ray	O	O
crystallography	O	O
)	O	O
of	O	O
the	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
pyrazinylcarboxamidobenzoates	I-IUPAC	I-IUPAC
indicate	O	I-IUPAC
that	O	O
the	O	O
preferred	O	O
conformation	O	O
exhibits	O	O
a	O	O
trans	O	O
-	O	O
amide	O	O
bond	O	O
and	O	O
an	O	O
internal	O	O
hydrogen	O	O
bond	O	O
between	O	O
the	O	O
quinoxaline	O	O
N1	O	O
and	O	O
HN	O	O
amide	O	O
which	O	O
locks	O	O
the	O	O
torsional	O	O
angle	O	O
between	O	O
C2	O	O
and	O	O
CO	O	O
in	O	O
the	O	O
s	O	O
-	O	O
trans	O	O
conformation	O	O
.	O	O
Kinetic	O	O
comparison	O	O
of	O	O
the	O	O
iodomethylene	O	O
lactone	O	O
3	O	O
with	O	O
the	O	O
corresponding	O	O
protio	O	O
lactone	O	O
25	O	O
indicates	O	O
that	O	O
the	O	O
iodine	O	O
accelerates	O	O
the	O	O
rate	O	O
of	O	O
chymotrypsin	O	O
acylation	O	O
but	O	O
produces	O	O
an	O	O
acyl	O	O
enzyme	O	O
that	O	O
is	O	O
more	O	O
hydrolytically	O	O
labile	O	O
than	O	O
that	O	O
formed	O	O
from	O	O
lactone	O	O
25	O	O
.	O	O
Also	O	O
,	O	O
both	O	O
folic	O	O
acid	O	O
and	O	O
5	O	O
-	O	O
(	O	O
CHO	O	O
)	O	O
-	O	O
THF	O	O
were	O	O
reductively	O	O
alkylated	O	O
with	O	O
formaldehyde	O	O
to	O	O
give	O	O
10	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methylfolic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
6	O	O
)	O	O
and	O	O
5	O	O
-	O	O
(	O	O
CHO	O	O
)	O	O
-	O	O
10	O	O
-	O	O
(	O	O
CH3	O	O
)	O	O
-	O	O
THF	O	O
(	O	O
28	O	O
)	O	O
,	O	O
respectively	O	O
.	O	O
The	O	O
structural	O	O
assignments	O	O
for	O	O
6f	O	O
and	O	O
6g	O	O
are	O	O
made	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
1H	O	O
and	O	O
13C	O	O
NMR	O	O
spectral	O	O
analyses	O	O
of	O	O
the	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
methylthio	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
nicotinates	I-IUPAC	I-IUPAC
(	O	O
7f	O	O
,	O	O
g	O	O
)	O	O
prepared	O	O
from	O	O
6f	O	O
and	O	O
6g	O	O
by	O	O
treatment	O	O
with	O	O
MeI	O	O
/	O	O
K2CO3	O	O
.	O	O
Oral	O	O
administration	O	O
of	O	O
CV	O	O
-	O	O
11974	O	O
to	O	O
conscious	O	O
normotensive	O	O
rats	O	O
at	O	O
1	O	O
mg	O	O
/	O	O
kg	O	O
resulted	O	O
in	O	O
long	O	O
-	O	O
lasting	O	O
inhibition	O	O
of	O	O
the	O	O
AII	O	O
-	O	O
induced	O	O
pressor	O	O
response	O	O
.	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
Quinolyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
glycine	I-IUPAC	I-IUPAC
hydrazide	I-IUPAC	I-IUPAC
(	O	O
18	O	O
)	O	O
and	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
quinolylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
butyric	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
hydrazide	I-IUPAC	I-IUPAC
(	O	O
24	O	O
)	O	O
,	O	O
which	O	O
are	O	O
bioisosteres	O	O
of	O	O
compounds	O	O
1	O	O
and	O	O
23	O	O
,	O	O
showed	O	O
loss	O	O
of	O	O
antitubercular	O	O
activity	O	O
at	O	O
low	O	O
concentrations	O	O
.	O	O
The	O	O
rank	O	O
order	O	O
of	O	O
potency	O	O
of	O	O
agonists	O	O
was	O	O
[	O	O
Nle	O	O
(	O	O
10	O	O
)	O	O
]	O	O
NKA	O	O
(	O	O
4-10	O	O
)	O	O
approximately	O	O
[	O	O
p	O	O
-	O	O
F	O	O
-	O	O
Phe	O	O
(	O	O
6	O	O
)	O	O
,	O	O
Nle	O	O
(	O	O
10	O	O
)	O	O
]	O	O
NKA	O	O
(	O	O
4-10	O	O
)	O	O
&	O	O
gt	O	O
;	O	O
[	O	O
p	O	O
-	O	O
NH	O	O
(	O	O
2	O	O
)	O	O
-	O	O
Phe	O	O
(	O	O
6	O	O
)	O	O
,	O	O
Nle	O	O
(	O	O
10	O	O
)	O	O
]	O	O
NKA	O	O
(	O	O
4-10	O	O
)	O	O
&	O	O
gt	O	O
;	O	O
[	O	O
p	O	O
-	O	O
Cl	O	O
-	O	O
Phe	O	O
(	O	O
6	O	O
)	O	O
,	O	O
Nle	O	O
(	O	O
10	O	O
)	O	O
]	O	O
NKA	O	O
(	O	O
4-10	O	O
)	O	O
&	O	O
gt	O	O
;	O	O
[	O	O
p	O	O
-	O	O
NO	O	O
(	O	O
2	O	O
)	O	O
-	O	O
Phe	O	O
(	O	O
6	O	O
)	O	O
,	O	O
Nle	O	O
(	O	O
10	O	O
)	O	O
]	O	O
NKA	O	O
(	O	O
4-10	O	O
)	O	O
&	O	O
gt	O	O
;	O	O
[	O	O
Trp	O	O
(	O	O
6	O	O
)	O	O
,	O	O
Nle	O	O
(	O	O
10	O	O
)	O	O
]	O	O
NKA	O	O
(	O	O
4-10	O	O
)	O	O
.	O	O
Analogues	O	O
22	O	O
and	O	O
23	O	O
were	O	O
also	O	O
more	O	O
potent	O	O
than	O	O
astressin	O	O
at	O	O
reversing	O	O
intracisternal	O	O
CRF	O	O
-	O	O
and	O	O
abdominal	O	O
surgery	O	O
-	O	O
induced	O	O
delay	O	O
of	O	O
gastric	O	O
emptying	O	O
in	O	O
conscious	O	O
rats	O	O
.	O	O
3D	O	O
QSAR	O	O
models	O	O
were	O	O
derived	O	O
for	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
pyridinylguanidines	I-IUPAC	I-IUPAC
(	O	O
training	O	O
set	O	O
N	O	O
=	O	O
25	O	O
,	O	O
test	O	O
set	O	O
N	O	O
=	O	O
8	O	O
)	O	O
,	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aminoarylguanidines	I-IUPAC	I-IUPAC
and	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aminoarylbenzamidines	I-IUPAC	I-IUPAC
(	O	O
training	O	O
set	O	O
N	O	O
=	O	O
29	O	O
,	O	O
test	O	O
set	O	O
N	O	O
=	O	O
8	O	O
)	O	O
,	O	O
thiophene	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxamindines	I-IUPAC	I-IUPAC
(	O	O
training	O	O
set	O	O
N	O	O
=	O	O
64	O	O
,	O	O
test	O	O
set	O	O
N	O	O
=	O	O
19	O	O
)	O	O
,	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
naphthamidines	I-IUPAC	I-IUPAC
(	O	O
training	O	O
set	O	O
N	O	O
=	O	O
32	O	O
,	O	O
test	O	O
set	O	O
N	O	O
=	O	O
8	O	O
)	O	O
,	O	O
and	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
isoquinolinylguanidines	I-IUPAC	I-IUPAC
(	O	O
training	O	O
set	O	O
N	O	O
=	O	O
29	O	O
,	O	O
test	O	O
set	O	O
N	O	O
=	O	O
7	O	O
)	O	O
.	O	O
However	O	O
,	O	O
like	O	O
4c	O	O
,	O	O
e	O	O
,	O	O
4d	O	O
did	O	O
not	O	O
significantly	O	O
affect	O	O
the	O	O
binding	O	O
of	O	O
the	O	O
competitive	O	O
NMDA	O	O
antagonist	O	O
,	O	O
[	O	O
3H	O	O
]	O	O
CPP	O	O
,	O	O
or	O	O
the	O	O
noncompetitive	O	O
NMDA	O	O
antagonist	O	O
,	O	O
[	O	O
3H	O	O
]	O	O
MK	O	O
-	O	O
801	O	O
.	O	O
The	O	O
phenolic	O	O
compound	O	O
7	O	O
,	O	O
however	O	O
,	O	O
could	O	O
be	O	O
phosphorylated	O	O
only	O	O
by	O	O
using	O	O
the	O	O
phosphoramidite	O	O
method	O	O
.	O	O
Calpain	O	O
I	O	O
was	O	O
also	O	O
effectively	O	O
inhibited	O	O
,	O	O
but	O	O
very	O	O
low	O	O
Ki	O	O
values	O	O
were	O	O
observed	O	O
with	O	O
a	O	O
smaller	O	O
number	O	O
of	O	O
inhibitors	O	O
than	O	O
with	O	O
calpain	O	O
II	O	O
.	O	O
Cytosine	O	O
,	O	O
adenine	O	O
,	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloropurine	I-IUPAC	I-IUPAC
,	O	O
thymine	O	O
,	O	O
and	O	O
(	B-IUPAC	B-IUPAC
Z	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butene	I-IUPAC	I-IUPAC
gave	O	O
compounds	O	O
4c	O	O
-	O	O
f	O	O
,	O	O
which	O	O
,	O	O
after	O	O
hydrolysis	O	O
,	O	O
afforded	O	O
alcohols	O	O
4a	O	O
,	O	O
4b	O	O
,	O	O
4g	O	O
,	O	O
and	O	O
4h	O	O
.	O	O
The	O	O
5	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
halo	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
6	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
alkoxy	I-PARTIUPAC	I-IUPAC
(	O	O
or	O	O
azido	B-PARTIUPAC	B-PARTIUPAC
)	O	O
-	B-PARTIUPAC	B-PARTIUPAC
5,6	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
dihydro	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
3'	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
azido	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
3'	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
deoxythymidines	I-PARTIUPAC	I-PARTIUPAC
,	O	O
which	O	O
differ	O	O
in	O	O
configuration	O	O
at	O	O
the	O	O
C	O	O
-	O	O
5	O	O
and	O	O
C	O	O
-	O	O
6	O	O
positions	O	O
,	O	O
were	O	O
synthesized	O	O
by	O	O
the	O	O
regiospecific	O	O
addition	O	O
of	O	O
XR	O	O
(	O	O
X	O	O
=	O	O
Br	O	O
,	O	O
Cl	O	O
,	O	O
I	O	O
;	O	O
R	O	O
=	O	O
alkoxy	O	O
,	O	O
azido	O	O
)	O	O
to	O	O
the	O	O
5,6	O	O
-	O	O
olefinic	O	O
bond	O	O
of	O	O
AZT	O	O
.	O	O
Compounds	O	O
18	O	O
and	O	O
23b	O	O
were	O	O
active	O	O
at	O	O
concentrations	O	O
very	O	O
similar	O	O
to	O	O
pyrazofurin	O	O
but	O	O
are	O	O
less	O	O
toxic	O	O
to	O	O
the	O	O
cells	O	O
than	O	O
pyrazofurin	O	O
.	O	O
The	O	O
binding	O	O
affinities	O	O
of	O	O
des	O	O
-	O	O
AA	O	O
(	O	O
1,2,5	O	O
)	O	O
-	O	O
[	O	O
DTrp	O	O
(	O	O
8	O	O
)	O	O
,	O	O
IAmp	O	O
(	O	O
9	O	O
)	O	O
]	O	O
-	O	O
SRIF	O	O
(	O	O
c	O	O
[	O	O
H	O	O
-	O	O
Cys	O	O
-	O	O
Lys	O	O
-	O	O
Phe	O	O
-	O	O
Phe	O	O
-	O	O
DTrp	O	O
-	O	O
IAmp	O	O
-	O	O
Thr	O	O
-	O	O
Phe	O	O
-	O	O
Thr	O	O
-	O	O
Ser	O	O
-	O	O
Cys	O	O
-	O	O
OH	O	O
]	O	O
,	O	O
CH	O	O
-	O	O
275	O	O
)	O	O
(	O	O
7	O	O
)	O	O
,	O	O
des	O	O
-	O	O
AA	O	O
(	O	O
1,5	O	O
)	O	O
-	O	O
[	O	O
Tyr	O	O
(	O	O
2	O	O
)	O	O
,	O	O
DTrp	O	O
(	O	O
8	O	O
)	O	O
,	O	O
IAmp	O	O
(	O	O
9	O	O
)	O	O
]	O	O
-	O	O
SRIF	O	O
(	O	O
CH	O	O
-	O	O
288	O	O
)	O	O
(	O	O
16	O	O
)	O	O
,	O	O
des	O	O
-	O	O
AA	O	O
(	O	O
1,2,5	O	O
)	O	O
-	O	O
[	O	O
Tyr	O	O
(	O	O
7	O	O
)	O	O
,	O	O
DTrp	O	O
(	O	O
8	O	O
)	O	O
,	O	O
IAmp	O	O
(	O	O
9	O	O
)	O	O
]	O	O
-	O	O
SRIF	O	O
(	O	O
23	O	O
)	O	O
,	O	O
and	O	O
des	O	O
-	O	O
AA	O	O
(	O	O
1,2,5	O	O
)	O	O
-	O	O
[	O	O
DTrp	O	O
(	O	O
8	O	O
)	O	O
,	O	O
IAmp	O	O
(	O	O
9	O	O
)	O	O
,	O	O
Tyr	O	O
(	O	O
11	O	O
)	O	O
]	O	O
-	O	O
SRIF	O	O
(	O	O
25	O	O
)	O	O
are	O	O
about	O	O
(	O	O
1	O	O
)	O	O
/	O	O
(	O	O
7	O	O
)	O	O
,	O	O
(	O	O
1	O	O
)	O	O
/	O	O
(	O	O
4	O	O
)	O	O
,	O	O
(	O	O
1	O	O
)	O	O
/	O	O
(	O	O
125	O	O
)	O	O
,	O	O
and	O	O
(	O	O
1	O	O
)	O	O
/	O	O
(	O	O
4	O	O
)	O	O
that	O	O
of	O	O
SRIF	O	O
-	O	O
28	O	O
(	O	O
1	O	O
)	O	O
to	O	O
sst1	O	O
,	O	O
respectively	O	O
,	O	O
about	O	O
(	O	O
1	O	O
)	O	O
/	O	O
(	O	O
65	O	O
)	O	O
,	O	O
(	O	O
1	O	O
)	O	O
/	O	O
(	O	O
130	O	O
)	O	O
,	O	O
&	O	O
lt	O	O
;	O	O
(	O	O
1	O	O
)	O	O
/	O	O
(	O	O
1000	O	O
)	O	O
,	O	O
and	O	O
&	O	O
lt	O	O
;	O	O
(	O	O
1	O	O
)	O	O
/	O	O
(	O	O
150	O	O
)	O	O
that	O	O
of	O	O
1	O	O
to	O	O
sst3	O	O
,	O	O
respectively	O	O
,	O	O
and	O	O
about	O	O
or	O	O
less	O	O
than	O	O
(	O	O
1	O	O
)	O	O
/	O	O
(	O	O
1000	O	O
)	O	O
that	O	O
of	O	O
1	O	O
to	O	O
the	O	O
other	O	O
three	O	O
human	O	O
SRIF	O	O
receptor	O	O
subtypes	O	O
.	O	O
avium	O	O
DHFR	O	O
,	O	O
and	O	O
55	O	O
nM	O	O
against	O	O
rat	O	O
DHFR	O	O
.	O	O
The	O	O
ability	O	O
to	O	O
inhibit	O	O
reuptake	O	O
of	O	O
dopamine	O	O
in	O	O
comparison	O	O
to	O	O
cocaine	O	O
is	O	O
generally	O	O
decreased	O	O
in	O	O
this	O	O
series	O	O
but	O	O
for	O	O
one	O	O
compound	O	O
.	O	O
The	O	O
amines	O	O
(	O	O
+	O	O
)	O	O
-	O	O
and	O	O
(	O	O
-	O	O
)	O	O
-	O	O
14a	O	O
,	O	O
incorporating	O	O
the	O	O
D1	O	O
pharmacophore	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethylamine	I-IUPAC	I-IUPAC
in	O	O
a	O	O
trans	O	O
extended	O	O
conformation	O	O
,	O	O
and	O	O
their	O	O
derivatives	O	O
displayed	O	O
D1	O	O
and	O	O
D2	O	O
affinity	O	O
in	O	O
the	O	O
nanomolar	O	O
range	O	O
.	O	O
The	O	O
results	O	O
suggest	O	O
the	O	O
existence	O	O
of	O	O
a	O	O
biphasic	O	O
relationship	O	O
between	O	O
the	O	O
distribution	O	O
coefficient	O	O
values	O	O
of	O	O
the	O	O
chelator	O	O
and	O	O
the	O	O
corresponding	O	O
iron	O	O
(	O	O
III	O	O
)	O	O
complexes	O	O
.	O	O
N	O	O
-	O	O
Oxidation	O	O
of	O	O
1,5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dimethylisoquinoline	I-IUPAC	I-IUPAC
,	O	O
followed	O	O
by	O	O
rearrangement	O	O
with	O	O
acetic	O	O
anhydride	O	O
,	O	O
gave	O	O
,	O	O
after	O	O
acid	O	O
hydrolysis	O	O
,	O	O
1,5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyisoquinoline	I-IUPAC	I-IUPAC
,	O	O
which	O	O
was	O	O
converted	O	O
to	O	O
its	O	O
acetate	O	O
and	O	O
then	O	O
oxidized	O	O
to	O	O
yield	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
acetoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylisoquinoline	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxaldehyde	I-IUPAC	I-IUPAC
(	O	O
32	O	O
)	O	O
.	O	O
Conversely	O	O
,	O	O
(	B-IUPAC	B-IUPAC
1R	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
2R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chlorobenzylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
imidazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
cyclopropane	I-IUPAC	I-IUPAC
(	O	O
10a	O	O
)	O	O
with	O	O
the	O	O
(	O	O
1R	O	O
)	O	O
-	O	O
trans	O	O
structure	O	O
was	O	O
selective	O	O
for	O	O
the	O	O
H4	O	O
receptor	O	O
(	O	O
Ki	O	O
=	O	O
118	O	O
nM	O	O
)	O	O
compared	O	O
to	O	O
the	O	O
H3	O	O
receptor	O	O
(	O	O
Ki	O	O
&	O	O
gt	O	O
;	O	O
10	O	O
(	O	O
3	O	O
)	O	O
nM	O	O
)	O	O
.	O	O
To	O	O
substantiate	O	O
that	O	O
the	O	O
(	B-IUPAC	O
131	I-IUPAC	O
)	I-IUPAC	O
I	I-IUPAC	O
-	I-IUPAC	O
(	I-IUPAC	O
hetero	I-IUPAC	O
)	I-IUPAC	O
arylmethylene	I-IUPAC	O
group	B-MODIFIER	O
at	O	O
the	O	O
O	O	O
(	O	O
6	O	O
)	O	O
-	O	O
position	O	O
of	O	O
guanine	O	O
is	O	O
transferred	O	O
to	O	O
MGMT	O	O
,	O	O
both	O	O
the	O	O
glucose	O	O
conjugated	O	O
inhibitors	O	O
ITGG	O	O
and	O	O
IBGG	O	O
and	O	O
the	O	O
corresponding	O	O
nonglucose	O	O
conjugated	O	O
compounds	O	O
ITG	O	O
and	O	O
IBG	O	O
were	O	O
labeled	O	O
with	O	O
iodine	O	O
-	O	O
131	O	O
.	O	O
The	O	O
N	O	O
-	O	O
N	O	O
-	O	O
N	O	O
spacings	O	O
appear	O	O
to	O	O
be	O	O
an	O	O
important	O	O
factor	O	O
in	O	O
their	O	O
sigma	O	O
-	O	O
2	O	O
subtype	O	O
selectivity	O	O
.	O	O
This	O	O
and	O	O
the	O	O
subsequent	O	O
publication	O	O
look	O	O
at	O	O
the	O	O
AMPA	O	O
antagonist	O	O
aspects	O	O
of	O	O
this	O	O
SAR	O	O
.	O	O
In	O	O
a	O	O
displacement	O	O
experiment	O	O
of	O	O
[	O	O
(	O	O
123	O	O
)	O	O
I	O	O
]	O	O
ZIENT	O	O
in	O	O
a	O	O
cynomolgus	O	O
monkey	O	O
,	O	O
radioactivity	O	O
was	O	O
reduced	O	O
by	O	O
39%	O	O
in	O	O
the	O	O
diencephalon	O	O
at	O	O
101	O	O
min	O	O
following	O	O
injection	O	O
of	O	O
citalopram	O	O
.	O	O
Compound	O	O
4a	O	O
was	O	O
prepared	O	O
via	O	O
selective	O	O
bromination	O	O
of	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
furan	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
nicotinonitrile	I-IUPAC	I-IUPAC
(	O	O
2a	O	O
)	O	O
with	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
bromosuccinimide	I-IUPAC	I-IUPAC
,	O	O
followed	O	O
by	O	O
Suzuki	O	O
coupling	O	O
with	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
cyanophenylboronic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
.	O	O
Moderate	O	O
activity	O	O
was	O	O
observed	O	O
with	O	O
2a	O	O
and	O	O
2b	O	O
while	O	O
1d	O	O
and	O	O
2c	O	O
were	O	O
essentially	O	O
inactive	O	O
.	O	O
Several	O	O
of	O	O
the	O	O
new	O	O
indoles	O	O
showed	O	O
selectivity	O	O
for	O	O
the	O	O
alpha	O	O
(	O	O
1	O	O
)	O	O
beta	O	O
(	O	O
2	O	O
)	O	O
gamma	O	O
(	O	O
2	O	O
)	O	O
subtype	O	O
compared	O	O
with	O	O
the	O	O
alpha	O	O
(	O	O
3	O	O
)	O	O
beta	O	O
(	O	O
2	O	O
)	O	O
gamma	O	O
(	O	O
2	O	O
)	O	O
and	O	O
alpha	O	O
(	O	O
5	O	O
)	O	O
beta	O	O
(	O	O
3	O	O
)	O	O
gamma	O	O
(	O	O
2	O	O
)	O	O
subtypes	O	O
(	O	O
e.g.	O	O
:	O	O
4t	O	O
and	O	O
7c	O	O
bind	O	O
to	O	O
these	O	O
three	O	O
BzR	O	O
isoforms	O	O
with	O	O
K	O	O
(	O	O
i	O	O
)	O	O
values	O	O
of	O	O
14	O	O
nM	O	O
,	O	O
283	O	O
nM	O	O
,	O	O
239	O	O
nM	O	O
,	O	O
and	O	O
9	O	O
nM	O	O
,	O	O
1960	O	O
nM	O	O
,	O	O
95	O	O
nM	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O
With	O	O
a	O	O
thiochroman	O	O
unit	O	O
,	O	O
the	O	O
most	O	O
active	O	O
acids	O	O
in	O	O
decreasing	O	O
order	O	O
of	O	O
activity	O	O
in	O	O
the	O	O
ODC	O	O
assay	O	O
were	O	O
7	O	O
greater	O	O
than	O	O
9	O	O
greater	O	O
than	O	O
8	O	O
.	O	O
ethanolamine	I-IUPAC	O
complex	B-MODIFIER	O
(	O	O
8	O	O
)	O	O
,	O	O
and	O	O
(	B-IUPAC	B-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
adamantane	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carbonyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylpropionic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
15	O	O
)	O	O
show	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
,	O	O
astrocyte	O	O
-	O	O
selective	O	O
antiproliferative	O	O
activity	O	O
in	O	O
the	O	O
concentration	O	O
range	O	O
0.1-10	O	O
microM	O	O
.	O	O
Two	O	O
alkylating	O	O
glucocorticoids	O	O
have	O	O
been	O	O
synthesized	O	O
in	O	O
order	O	O
to	O	O
test	O	O
the	O	O
possibility	O	O
of	O	O
alkylating	O	O
glucocorticoid	O	O
receptors	O	O
.	O	O
Comparison	O	O
of	O	O
the	O	O
HPLC	O	O
retention	O	O
times	O	O
,	O	O
diode	O	O
array	O	O
UV	O	O
,	O	O
and	O	O
chemical	O	O
ion	O	O
mass	O	O
spectral	O	O
characteristics	O	O
of	O	O
these	O	O
products	O	O
with	O	O
those	O	O
of	O	O
synthetic	O	O
standards	O	O
led	O	O
us	O	O
to	O	O
propose	O	O
the	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydropyridinium	I-IUPAC	I-IUPAC
species	O	B-MODIFIER
2,3	O	B-IUPAC
-	O	I-IUPAC
MPDP+	O	I-IUPAC
and	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
cyano	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,3,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydropyridine	I-IUPAC	I-IUPAC
as	O	O
tentative	O	O
structure	O	O
assignments	O	O
for	O	O
the	O	O
dihydropyridinium	O	O
metabolite	O	O
and	O	O
the	O	O
cyano	O	O
adduct	O	O
,	O	O
respectively	O	O
.	O	O
Glycosylation	O	O
of	O	O
persilylated	O	O
as	O	O
well	O	O
as	O	O
nonsilylated	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
bromoallopurinol	I-IUPAC	I-IUPAC
with	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,3,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tri	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzoyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ribofuranose	I-IUPAC	I-IUPAC
(	O	O
4	O	O
)	O	O
provided	O	O
the	O	O
key	O	O
intermediate	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
bromo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2,3,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tri	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzoyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ribofuranosyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
(	O	O
5a	O	O
)	O	O
.	O	O
All	O	O
of	O	O
the	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	O	O
substituted	B-MODIFIER	B-MODIFIER
-	O	O
5,6	B-IUPAC	O
-	I-IUPAC	O
dihydro	I-IUPAC	O
compounds	B-MODIFIER	O
were	O	O
inactive	O	O
,	O	O
except	O	O
for	O	O
the	O	O
approximately	O	O
equipotent	O	O
6	O	O
-	O	O
OMe	O	O
and	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
azido	I-IUPAC	I-IUPAC
diastereomeric	I-IUPAC	B-MODIFIER
mixtures	B-MODIFIER	O
which	O	O
were	O	O
2-3	O	O
log	O	O
units	O	O
less	O	O
active	O	O
than	O	O
the	O	O
reference	O	O
drug	O	O
AZT	O	O
.	O	O
for	O	O
the	O	O
PAF	O	O
-	O	O
induced	O	O
mortality	O	O
test	O	O
in	O	O
mice	O	O
)	O	O
.	O	O
A	O	O
series	O	O
of	O	O
aza	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
H	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenanthridin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
were	O	O
synthesized	O	O
and	O	O
evaluated	O	O
as	O	O
inhibitors	O	O
of	O	O
poly	O	O
ADP	O	O
-	O	O
ribose	O	O
polymerase	O	O
-	O	O
1	O	O
(	O	O
PARP	O	O
-	O	O
1	O	O
)	O	O
.	O	O
Significant	O	O
antitetrabenazine	O	O
activity	O	O
is	O	O
associated	O	O
only	O	O
with	O	O
derivatives	O	O
where	O	O
the	O	O
arylmethyl	O	O
group	O	O
is	O	O
ortho	O	O
to	O	O
the	O	O
piperidine	O	O
ring	O	O
.	O	O
Application	O	O
of	O	O
lactam	O	O
constraints	O	O
in	O	O
the	O	O
C	O	O
-	O	O
terminus	O	O
of	O	O
GHRH	O	O
(	O	O
1-29	O	O
)	O	O
-	O	O
NH2	O	O
identified	O	O
cyclo	O	O
(	O	O
25-29	O	O
)	O	O
[	O	O
MeTyr1	O	O
,	O	O
Ala15	O	O
,	O	O
DAsp25	O	O
,	O	O
Nle27	O	O
,	O	O
Orn29+	O	O
+	O	O
+	O	O
]	O	O
-	O	O
hGHRH	O	O
(	O	O
1-29	O	O
)	O	O
-	O	O
NH2	O	O
(	O	O
46	O	O
)	O	O
as	O	O
containing	O	O
the	O	O
optimum	O	O
bridging	O	O
element	O	O
(	O	O
19	O	O
-	O	O
membered	O	O
ring	O	O
)	O	O
in	O	O
this	O	O
region	O	O
of	O	O
the	O	O
molecule	O	O
.	O	O
1	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
Naphthyridin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
analogues	B-MODIFIER	B-MODIFIER
bearing	O	O
basic	O	O
aliphatic	O	O
side	O	O
chains	O	O
[	O	O
7	O	O
-	O	O
NH	O	O
(	O	O
CH	O	O
(	O	O
2	O	O
)	O	O
)	O	O
(	O	O
n	O	O
)	O	O
(	O	O
)	O	O
NRR	O	O
,	O	O
7	O	O
-	O	O
NHPhO	O	O
(	O	O
CH	O	O
(	O	O
2	O	O
)	O	O
)	O	O
(	O	O
n	O	O
)	O	O
(	O	O
)	O	O
NRR	O	O
,	O	O
or	O	O
7	O	O
-	O	O
NHPhN	O	O
(	O	O
CH	O	O
(	O	O
2	O	O
)	O	O
)	O	O
(	O	O
4	O	O
)	O	O
NMe	O	O
]	O	O
were	O	O
the	O	O
most	O	O
potent	O	O
against	O	O
c	O	O
-	O	O
Src	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
s	O	O
of	O	O
10-80	O	O
nM	O	O
)	O	O
,	O	O
showing	O	O
good	O	O
selectivity	O	O
with	O	O
respect	O	O
to	O	O
PDGFR	O	O
(	O	O
10-300	O	O
-	O	O
fold	O	O
)	O	O
but	O	O
less	O	O
with	O	O
respect	O	O
to	O	O
FGFR	O	O
.	O	O
By	O	O
means	O	O
of	O	O
the	O	O
pharmacological	O	O
results	O	O
obtained	O	O
on	O	O
pancreatic	O	O
B	O	O
-	O	O
cells	O	O
,	O	O
structure	O	O
-	O	O
-	O	O
activity	O	O
relationships	O	O
were	O	O
deduced	O	O
and	O	O
a	O	O
pharmacophoric	O	O
model	O	O
for	O	O
the	O	O
interaction	O	O
of	O	O
these	O	O
drugs	O	O
with	O	O
their	O	O
receptor	O	O
site	O	O
associated	O	O
to	O	O
the	O	O
pancreatic	O	O
K	O	O
(	O	O
ATP	O	O
)	O	O
channel	O	O
was	O	O
proposed	O	O
.	O	O
In	O	O
functional	O	O
in	O	O
vitro	O	O
studies	O	O
on	O	O
histamine	O	O
H2	O	O
,	O	O
H3	O	O
,	O	O
and	O	O
other	O	O
neurotransmitter	O	O
receptors	O	O
the	O	O
selectivity	O	O
of	O	O
39	O	O
was	O	O
found	O	O
to	O	O
be	O	O
2138	O	O
(	O	O
H1	O	O
:	O	O
H2	O	O
)	O	O
,	O	O
&	O	O
gt	O	O
;	O	O
64	O	O
(	O	O
H1	O	O
:	O	O
H3	O	O
)	O	O
,	O	O
1000	O	O
(	O	O
H1	O	O
:	O	O
M3	O	O
)	O	O
,	O	O
105	O	O
(	O	O
H1	O	O
:	O	O
alpha	O	O
1	O	O
)	O	O
,	O	O
708	O	O
(	O	O
H1	O	O
:	O	O
beta	O	O
1	O	O
)	O	O
,	O	O
and	O	O
71	O	O
(	O	O
H1	O	O
:	O	O
5HT2A	O	O
)	O	O
.	O	O
The	O	O
suppressive	O	O
effect	O	O
of	O	O
5l	O	O
was	O	O
the	O	O
same	O	O
as	O	O
that	O	O
of	O	O
trimethoprim	O	O
(	O	O
10	O	O
microgram	O	O
/	O	O
mL	O	O
)	O	O
+	O	O
sulfamethoxazole	O	O
(	O	O
250	O	O
microgram	O	O
/	O	O
mL	O	O
)	O	O
,	O	O
a	O	O
standard	O	O
clinical	O	O
combination	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
P	O	O
.	O	O
Dog	O	O
adrenal	O	O
medullae	O	O
were	O	O
used	O	O
as	O	O
a	O	O
model	O	O
to	O	O
test	O	O
radiotracer	O	O
affinity	O	O
for	O	O
catecholamine	O	O
storage	O	O
tissue	O	O
.	O	O
These	O	O
compounds	O	O
are	O	O
structurally	O	O
related	O	O
to	O	O
the	O	O
pyrido	B-PARTIUPAC	B-PARTIUPAC
[	I-PARTIUPAC	I-PARTIUPAC
3,2	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
d	I-PARTIUPAC	I-PARTIUPAC
]	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
and	O	O
pyrido	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrimidines	I-IUPAC	I-IUPAC
previously	O	O
shown	O	O
to	O	O
be	O	O
EGFR	O	O
inhibitors	O	O
.	O	O
Hypoxic	O	O
cells	O	O
of	O	O
solid	O	O
tumors	O	O
are	O	O
an	O	O
obstacle	O	O
to	O	O
effective	O	O
cancer	O	O
therapy	O	O
.	O	O
This	O	O
synthesis	O	O
strategy	O	O
led	O	O
to	O	O
4	O	O
out	O	O
of	O	O
16	O	O
possible	O	O
stereoisomers	O	O
,	O	O
which	O	O
were	O	O
isolated	O	O
in	O	O
the	O	O
case	O	O
of	O	O
(	O	O
-	O	O
)	O	O
-	O	O
3	O	O
,	O	O
(	O	O
+	O	O
)	O	O
-	O	O
3	O	O
,	O	O
(	O	O
-	O	O
)	O	O
-	O	O
4	O	O
,	O	O
and	O	O
(	O	O
+	O	O
)	O	O
-	O	O
4	O	O
and	O	O
whose	O	O
absolute	O	O
configuration	O	O
was	O	O
assigned	O	O
using	O	O
a	O	O
chiral	O	O
building	O	O
block	O	O
for	O	O
the	O	O
synthesis	O	O
of	O	O
(	O	O
-	O	O
)	O	O
-	O	O
3	O	O
starting	O	O
from	O	O
(	B-IUPAC	B-IUPAC
+	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzodioxine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
(	O	O
+	O	O
)	O	O
-	O	O
9	O	O
)	O	O
and	O	O
(	B-IUPAC	B-IUPAC
1S	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
2S	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
5S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenoxycyclopentan	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ol	I-IUPAC	I-IUPAC
(	O	O
(	O	O
+	O	O
)	O	O
-	O	O
10	O	O
)	O	O
.	O	O
When	O	O
assayed	O	O
in	O	O
vivo	O	O
in	O	O
the	O	O
treated	O	O
rats	O	O
,	O	O
the	O	O
above	O	O
mentioned	O	O
isoornithines	O	O
were	O	O
also	O	O
found	O	O
to	O	O
inhibit	O	O
liver	O	O
ODC	O	O
when	O	O
administered	O	O
1	O	O
h	O	O
before	O	O
sacrifice	O	O
.	O	O
The	O	O
compounds	O	O
were	O	O
inactive	O	O
as	O	O
antimalarials	O	O
.	O	O
Compound	O	O
9	O	O
also	O	O
showed	O	O
anticonvulsant	O	O
activity	O	O
when	O	O
administered	O	O
intracerebroventricularly	O	O
(	O	O
ED	O	O
(	O	O
50	O	O
)	O	O
=	O	O
59	O	O
nmol	O	O
)	O	O
.	O	O
On	O	O
incubation	O	O
with	O	O
rat	O	O
plasma	O	O
,	O	O
1c	O	O
liberated	O	O
nitroxyl	B-IUPAC	O
,	O	O
a	O	O
potent	O	O
inhibitor	O	O
of	O	O
AlDH	O	O
.	O	O
Competition	O	O
binding	O	O
experiments	O	O
clearly	O	O
indicated	O	O
that	O	O
the	O	O
new	O	O
ligand	O	O
displayed	O	O
the	O	O
expected	O	O
5	O	O
-	O	O
HT1A	O	O
receptor	O	O
binding	O	O
profile	O	O
.	O	O
Unlike	O	O
the	O	O
case	O	O
for	O	O
theophylline	O	O
,	O	O
the	O	O
presence	O	O
of	O	O
a	O	O
phenyl	O	O
substituent	O	O
in	O	O
the	O	O
five	O	O
-	O	O
membered	O	O
ring	O	O
did	O	O
not	O	O
enhance	O	O
the	O	O
potency	O	O
of	O	O
a	O	O
mesoionic	O	O
thiadiazolopyrimidine	O	O
.	O	O
The	O	O
rest	O	O
of	O	O
the	O	O
hydroxy	O	O
derivatives	O	O
,	O	O
with	O	O
the	O	O
exception	O	O
of	O	O
4a	O	O
,	O	O
were	O	O
moderately	O	O
effective	O	O
or	O	O
inactive	O	O
as	O	O
antiviral	O	O
agents	O	O
.	O	O
Furthermore	O	O
,	O	O
the	O	O
functional	O	O
activity	O	O
of	O	O
(	O	O
-	O	O
)	O	O
-	O	O
3	O	O
,	O	O
(	O	O
+	O	O
)	O	O
-	O	O
3	O	O
,	O	O
(	O	O
-	O	O
)	O	O
-	O	O
4	O	O
,	O	O
and	O	O
(	O	O
+	O	O
)	O	O
-	O	O
4	O	O
toward	O	O
5	O	O
-	O	O
HT	O	O
(	O	O
1A	O	O
)	O	O
receptors	O	O
was	O	O
evaluated	O	O
by	O	O
determining	O	O
the	O	O
induced	O	O
stimulation	O	O
of	O	O
[	O	O
(	O	O
35	O	O
)	O	O
S	O	O
]	O	O
GTPgammaS	O	O
binding	O	O
in	O	O
cell	O	O
membranes	O	O
from	O	O
HeLa	O	O
cells	O	O
transfected	O	O
with	O	O
human	O	O
cloned	O	O
5	O	O
-	O	O
HT	O	O
(	O	O
1A	O	O
)	O	O
receptors	O	O
.	O	O
Reduction	O	O
of	O	O
6	O	O
to	O	O
7	O	O
and	O	O
treatment	O	O
with	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
trichloroethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
carbonyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzylhydroxylamine	I-IUPAC	I-IUPAC
(	O	O
8	O	O
)	O	O
,	O	O
and	O	O
diethyl	B-IUPAC	O
azodicarboxylate	I-IUPAC	O
and	O	O
triphenylphosphine	O	O
followed	O	O
by	O	O
deprotection	O	O
produced	O	O
the	O	O
protected	O	O
N5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
acetyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ornithine	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
11	O	O
and	O	O
12	O	O
in	O	O
large	O	O
quantities	O	O
(	O	O
10-20	O	O
g	O	O
)	O	O
.	O	O
In	O	O
general	O	O
,	O	O
distal	O	O
modifications	O	O
of	O	O
the	O	O
N5	O	O
-	O	O
substituent	O	O
were	O	O
highly	O	O
modulatory	O	O
to	O	O
potency	O	O
and	O	O
selectivity	O	O
at	O	O
adenosine	O	O
receptors	O	O
,	O	O
as	O	O
determined	O	O
in	O	O
radioligand	O	O
binding	O	O
assays	O	O
at	O	O
rat	O	O
brain	O	O
A1	O	O
and	O	O
A2A	O	O
receptors	O	O
and	O	O
at	O	O
recombinant	O	O
human	O	O
A3	O	O
receptors	O	O
.	O	O
(	B-IUPAC	B-IUPAC
3S	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
4aR	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
6R	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
8aR	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,3,4,4	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
5,6,7,8,8	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
decahydroisoquinoline	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
9	O	O
)	O	O
is	O	O
a	O	O
potent	O	O
,	O	O
selective	O	O
and	O	O
systemically	O	O
active	O	O
AMPA	O	O
antagonist	O	O
.	O	O
In	O	O
this	O	O
report	O	O
,	O	O
we	O	O
describe	O	O
structure	O	O
-	O	O
activity	O	O
studies	O	O
of	O	O
the	O	O
bicyclic	O	O
oxytocin	O	O
antagonist	O	O
[	O	O
Mpa1	O	O
,	O	O
cyclo	O	O
(	O	O
Glu4	O	O
,	O	O
Lys8	O	O
)	O	O
]	O	O
oxytocin	O	O
.	O	O
Consistent	O	O
with	O	O
earlier	O	O
results	O	O
with	O	O
polyamine	O	O
analogues	O	O
,	O	O
these	O	O
studies	O	O
underscore	O	O
the	O	O
importance	O	O
of	O	O
charge	O	O
in	O	O
the	O	O
design	O	O
of	O	O
polyamine	O	O
-	O	O
vectored	O	O
chelators	O	O
.	O	O
This	O	O
compound	O	O
is	O	O
a	O	O
potent	O	O
(	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
1.6	O	O
nM	O	O
)	O	O
and	O	O
selective	O	O
inhibitor	O	O
of	O	O
serotonin	O	O
reuptake	O	O
into	O	O
rat	O	O
midbrain	O	O
synaptosomes	O	O
.	O	O
This	O	O
approach	O	O
found	O	O
an	O	O
isosteric	O	O
amide	O	O
structure	O	O
,	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phenylmethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amide	I-IUPAC	I-IUPAC
,	O	O
suitable	O	O
in	O	O
terms	O	O
of	O	O
potency	O	O
and	O	O
stability	O	O
.	O	O
These	O	O
furanyl	B-IUPAC	O
and	O	O
pyranyl	B-IUPAC	B-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
were	O	O
tested	O	O
for	O	O
antileukemic	O	O
activity	O	O
(	O	O
L	O	O
-	O	O
1210	O	O
,	O	O
in	O	O
vivo	O	O
)	O	O
and	O	O
the	O	O
results	O	O
were	O	O
compared	O	O
with	O	O
the	O	O
results	O	O
obtained	O	O
for	O	O
the	O	O
corresponding	O	O
ribosyl	B-IUPAC	O
derivatives	B-MODIFIER	O
of	O	O
DTIC	O	O
and	O	O
DTPC	O	O
.	O	O
These	O	O
data	O	O
indicate	O	O
that	O	O
such	O	O
compounds	O	O
penetrate	O	O
the	O	O
blood	O	O
-	O	O
brain	O	O
barrier	O	O
but	O	O
their	O	O
MES	O	O
activity	O	O
may	O	O
not	O	O
be	O	O
related	O	O
to	O	O
NMDA	O	O
receptor	O	O
antagonism	O	O
.	O	O
Three	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluoroethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	O
substituted	B-MODIFIER	B-MODIFIER
(	B-IUPAC	B-IUPAC
imidazolylphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
formamidine	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
,	O	O
namely	O	O
,	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluoroethyl	I-IUPAC	I-IUPAC
(	O	O
3b	O	O
)	O	O
,	O	O
2,2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
difluoroethyl	I-IUPAC	I-IUPAC
(	O	O
3c	O	O
)	O	O
,	O	O
and	O	O
2,2,2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
trifluoroethyl	I-IUPAC	I-IUPAC
(	O	O
3d	O	O
)	O	O
,	O	O
were	O	O
prepared	O	O
to	O	O
test	O	O
the	O	O
effect	O	O
of	O	O
fluorine	O	O
substitution	O	O
on	O	O
basicity	O	O
and	O	O
,	O	O
then	O	O
,	O	O
on	O	O
H2	O	O
-	O	O
antagonist	O	O
affinity	O	O
in	O	O
comparison	O	O
with	O	O
the	O	O
unsubstituted	B-MODIFIER	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
(	O	O
3a	O	O
)	O	O
,	O	O
taken	O	O
as	O	O
a	O	O
model	O	O
of	O	O
mifentidine	O	O
.	O	O
The	O	O
(	B-IUPAC	B-IUPAC
N	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methanocarba	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylthio	I-IUPAC	I-IUPAC
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloromonophosphate	I-IUPAC	I-IUPAC
analogues	B-MODIFIER	B-MODIFIER
were	O	O
full	O	O
agonists	O	O
exhibiting	O	O
micromolar	O	O
potency	O	O
at	O	O
P2Y	O	O
(	O	O
1	O	O
)	O	O
receptors	O	O
,	O	O
while	O	O
the	O	O
corresponding	O	O
ribosides	O	O
were	O	O
inactive	O	O
.	O	O
Compound	O	O
13	O	O
,	O	O
which	O	O
showed	O	O
the	O	O
highest	O	O
5	O	O
-	O	O
HT	O	O
(	O	O
1A	O	O
)	O	O
receptor	O	O
affinity	O	O
(	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
1.1	O	O
nM	O	O
)	O	O
,	O	O
was	O	O
50	O	O
-	O	O
fold	O	O
selective	O	O
in	O	O
relation	O	O
to	O	O
alpha	O	O
(	O	O
1	O	O
)	O	O
adrenoceptors	O	O
and	O	O
at	O	O
least	O	O
250	O	O
-	O	O
fold	O	O
over	O	O
5	O	O
-	O	O
HT	O	O
(	O	O
2A	O	O
)	O	O
and	O	O
D	O	O
(	O	O
2	O	O
)	O	O
sites	O	O
.	O	O
The	O	O
simplest	O	O
target	O	O
compounds	O	O
derived	O	O
from	O	O
this	O	O
template	O	O
(	O	O
3e	O	O
and	O	O
3f	O	O
)	O	O
have	O	O
one	O	O
of	O	O
the	O	O
hydroxyl	B-IUPAC	O
moieties	B-MODIFIER	O
functionalized	O	O
either	O	O
as	O	O
a	O	O
myristate	O	O
or	O	O
as	O	O
an	O	O
oleate	O	O
ester	O	O
.	O	O
The	O	O
in	O	O
vitro	O	O
antitumor	O	O
potency	O	O
was	O	O
studied	O	O
in	O	O
two	O	O
human	O	O
cancer	O	O
cell	O	O
lines	O	O
(	O	O
41M	O	O
and	O	O
SK	O	O
-	O	O
BR	O	O
-	O	O
3	O	O
)	O	O
.	O	O
The	O	O
replacement	O	O
of	O	O
the	O	O
X	O	O
=	O	O
bridge	O	O
in	O	O
1a	O	O
with	O	O
the	O	O
X	O	O
=	O	O
N	O	O
(	O	O
CH3	O	O
)	O	O
group	O	O
resulted	O	O
in	O	O
lowering	O	O
of	O	O
the	O	O
anticancer	O	O
activity	O	O
.	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Benzylaminomethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
quinolone	I-IUPAC	I-IUPAC
(	O	O
1e	O	O
)	O	O
and	O	O
3,3	B-IUPAC	B-IUPAC
'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzyliminodimethylene	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
di	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
quinolone	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
(	O	O
6b	O	O
)	O	O
were	O	O
also	O	O
synthesized	O	O
.	O	O
The	O	O
resulting	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
methylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
benzamide	I-IUPAC	I-IUPAC
(	O	O
23	O	O
)	O	O
was	O	O
about	O	O
15	O	O
times	O	O
more	O	O
active	O	O
than	O	O
metoclopramide	O	O
.	O	O
(	B-IUPAC	B-IUPAC
1S	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
3R	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
6S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
Z	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
thienylmethylene	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
azatricyclo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4.3.1.0	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
decane	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
ester	I-IUPAC	I-IUPAC
(	O	O
5h	O	O
)	O	O
exhibits	O	O
reasonable	O	O
activity	O	O
at	O	O
the	O	O
dopamine	O	O
transporter	O	O
(	O	O
DAT	O	O
)	O	O
(	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
268	O	O
nM	O	O
)	O	O
and	O	O
good	O	O
activity	O	O
at	O	O
the	O	O
norepinephrine	O	O
transporter	O	O
(	O	O
NET	O	O
)	O	O
(	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
26	O	O
nM	O	O
)	O	O
.	O	O
Overexpression	O	O
of	O	O
uPA	O	O
and	O	O
uPAR	O	O
in	O	O
cancer	O	O
tissues	O	O
is	O	O
associated	O	O
with	O	O
a	O	O
high	O	O
incidence	O	O
of	O	O
disease	O	O
recurrence	O	O
and	O	O
early	O	O
death	O	O
.	O	O
Similarly	O	O
,	O	O
the	O	O
two	O	O
aporphine	O	O
mustard	O	O
congeners	O	O
(	O	O
1f	O	O
,	O	O
g	O	O
)	O	O
were	O	O
also	O	O
inactive	O	O
in	O	O
the	O	O
P388	O	O
system	O	O
.	O	O
All	O	O
new	O	O
compounds	O	O
are	O	O
N	B-MODIFIER	O
-	I-MODIFIER	O
substituted	I-MODIFIER	B-MODIFIER
-	O	O
omega	B-PARTIUPAC	O
-	I-PARTIUPAC	O
(	I-PARTIUPAC	O
1,2,3,4	I-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
tetrahydronaphthalen	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
1	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
yl	I-PARTIUPAC	I-IUPAC
)	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
or	O	I-IUPAC
-	B-PARTIUPAC	I-IUPAC
omega	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
(	I-PARTIUPAC	I-IUPAC
1,2	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
dihydronaphthalen	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
4	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
yl	I-PARTIUPAC	I-IUPAC
)	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
n	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
alkylamines	I-PARTIUPAC	I-IUPAC
with	O	O
,	O	O
in	O	O
some	O	O
cases	O	O
,	O	O
a	O	O
methoxy	B-IUPAC	O
group	B-MODIFIER	O
on	O	O
the	O	O
tetralin	O	O
moiety	O	O
.	O	O
A	O	O
novel	O	O
series	O	O
of	O	O
10	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
benzylidene	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
10H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
anthracenones	I-IUPAC	I-IUPAC
and	O	O
10	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phenylmethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
10H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
anthracenones	I-IUPAC	I-IUPAC
were	O	O
synthesized	O	O
and	O	O
evaluated	O	O
for	O	O
antiproliferative	O	O
activity	O	O
in	O	O
an	O	O
assay	O	O
based	O	O
on	O	O
K562	O	O
leukemia	O	O
cells	O	O
.	O	O
These	O	O
compounds	O	O
have	O	O
also	O	O
been	O	O
screened	O	O
against	O	O
Litomosoides	O	O
carinii	O	O
,	O	O
and	O	O
of	O	O
these	O	O
only	O	O
3f	O	O
and	O	O
5a	O	O
have	O	O
also	O	O
been	O	O
found	O	O
to	O	O
be	O	O
active	O	O
.	O	O
For	O	O
the	O	O
enantiomers	O	O
(	O	O
+	O	O
)	O	O
-	O	O
4	O	O
and	O	O
(	O	O
-	O	O
)	O	O
-	O	O
4	O	O
also	O	O
a	O	O
remarkable	O	O
selectivity	O	O
was	O	O
achieved	O	O
.	O	O
The	O	O
selectivity	O	O
level	O	O
over	O	O
the	O	O
adenosine	O	O
A1	O	O
receptor	O	O
subtype	O	O
for	O	O
some	O	O
of	O	O
the	O	O
more	O	O
active	O	O
analogues	O	O
is	O	O
also	O	O
fairly	O	O
high	O	O
,	O	O
&	O	O
gt	O	O
;	O	O
400	O	O
-	O	O
fold	O	O
in	O	O
some	O	O
cases	O	O
.	O	O
All	O	O
three	O	O
phospholipids	O	O
were	O	O
synthesized	O	O
from	O	O
the	O	O
versatile	O	O
starting	O	O
material	O	O
(	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzyl	I-IUPAC	I-IUPAC
glycidol	I-IUPAC	I-IUPAC
.	O	O
Pyrrolo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amine	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
which	O	O
were	O	O
simultaneously	O	O
substituted	O	O
at	O	O
N7	O	O
and	O	O
N	O	O
(	O	O
4	O	O
)	O	O
,	O	O
combining	O	O
the	O	O
substitution	O	O
pattern	O	O
of	O	O
ADPEP	O	O
(	O	O
1	O	O
)	O	O
and	O	O
DPEAP	O	O
(	O	O
2	O	O
)	O	O
,	O	O
showed	O	O
very	O	O
low	O	O
affinity	O	O
for	O	O
A	O	O
(	O	O
1	O	O
)	O	O
ARs	O	O
.	O	O
The	O	O
latter	O	O
were	O	O
resolved	O	O
directly	O	O
by	O	O
chromatography	O	O
.	O	O
Imidazolylphenyl	O	O
isothiocyanate	O	O
(	O	O
1	O	O
)	O	O
,	O	O
obtained	O	O
by	O	O
reaction	O	O
of	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
aminophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
imidazole	I-IUPAC	I-IUPAC
with	O	O
carbon	O	O
disulfide	O	O
and	O	O
ethyl	B-IUPAC	B-IUPAC
chloroformate	I-IUPAC	I-IUPAC
,	O	O
was	O	O
condensed	O	O
with	O	O
the	O	O
requisite	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
-	O	O
substituted	B-MODIFIER	O
ethylamines	B-IUPAC	O
to	O	O
give	O	O
the	O	O
intermediate	O	O
thioureas	O	O
(	O	O
2b	O	O
-	O	O
d	O	O
)	O	O
.	O	O
However	O	O
,	O	O
similar	O	O
condensation	O	O
of	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
trifluoroacetyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
14	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
iododaunorubicin	I-IUPAC	I-IUPAC
with	O	O
thiols	O	O
invariably	O	O
led	O	O
to	O	O
a	O	O
redox	O	O
reaction	O	O
,	O	O
with	O	O
the	O	O
formation	O	O
of	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
trifluoroacetyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
daunorubicin	I-IUPAC	I-IUPAC
and	O	O
disulfides	O	O
.	O	O
This	O	O
prodrug	O	O
strategy	O	O
may	O	O
be	O	O
generally	O	O
useful	O	O
for	O	O
introducing	O	O
dianionic	O	O
phosphates	O	O
and	O	O
phosphonates	O	O
into	O	O
cells	O	O
.	O	O
Three	O	O
prodrugs	O	O
of	O	O
AELs	O	O
(	O	O
proAELs	O	O
)	O	O
have	O	O
been	O	O
synthesized	O	O
and	O	O
four	O	O
liposome	O	O
systems	O	O
,	O	O
consisting	O	O
of	O	O
these	O	O
proAELs	O	O
,	O	O
were	O	O
investigated	O	O
for	O	O
enzymatic	O	O
degradation	O	O
by	O	O
secretory	O	O
phospholipase	O	O
A	O	O
(	O	O
2	O	O
)	O	O
(	O	O
sPLA	O	O
(	O	O
2	O	O
)	O	O
)	O	O
,	O	O
resulting	O	O
in	O	O
the	O	O
release	O	O
of	O	O
AELs	O	O
.	O	O
A	O	O
new	O	O
class	O	O
of	O	O
5	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
halo	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
6	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
alkoxy	I-PARTIUPAC	I-PARTIUPAC
(	O	O
or	O	O
azido	B-PARTIUPAC	B-PARTIUPAC
)	O	O
-	B-PARTIUPAC	B-PARTIUPAC
5,6	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
dihydro	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
3'	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
azido	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
3'	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
deoxythymidines	I-PARTIUPAC	I-PARTIUPAC
was	O	O
investigated	O	O
as	O	O
potential	O	O
anti	O	O
-	O	O
AIDS	O	O
drugs	O	O
.	O	O
Although	O	O
without	O	O
significant	O	O
antiviral	O	O
activity	O	O
in	O	O
cell	O	O
cultures	O	O
,	O	O
the	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aminopurines	I-IUPAC	I-IUPAC
(	O	O
13	O	O
,	O	O
14-16	O	O
,	O	O
26-29	O	O
)	O	O
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alkoxypurines	I-IUPAC	I-IUPAC
(	O	O
12	O	O
,	O	O
23-25	O	O
)	O	O
are	O	O
well	O	O
absorbed	O	O
after	O	O
oral	O	O
administration	O	O
to	O	O
mice	O	O
and	O	O
are	O	O
converted	O	O
efficiently	O	O
to	O	O
the	O	O
antiviral	O	O
guanine	O	O
derivatives	O	O
(	O	O
8	O	O
,	O	O
21	O	O
)	O	O
in	O	O
vivo	O	O
.	O	O
(	B-IUPAC	B-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
Amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trifluoromethylphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methan	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
(	O	O
8	O	O
)	O	O
,	O	O
(	B-IUPAC	B-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thienyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methanone	I-IUPAC	I-IUPAC
(	O	O
13	O	O
)	O	O
,	O	O
and	O	O
(	B-IUPAC	B-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
phenylmethanone	I-IUPAC	I-IUPAC
(	O	O
14	O	O
)	O	O
are	O	O
very	O	O
potent	O	O
depressants	O	O
.	O	O
The	O	O
acylated	O	O
bis	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
catecholates	I-IUPAC	I-IUPAC
and	O	O
1,3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
benzoxazine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diones	I-IUPAC	I-IUPAC
were	O	O
coupled	O	O
with	O	O
ampicillin	O	O
or	O	O
amoxicillin	O	O
to	O	O
new	O	O
siderophore	O	O
aminoacylpenicillin	O	O
conjugates	O	O
.	O	O
On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
in	O	O
the	O	O
bioassay	O	O
systems	O	O
,	O	O
[	O	O
(	O	O
2S	O	O
,	O	O
3S	O	O
)	O	O
-	O	O
beta	O	O
-	O	O
Me	O	O
-	O	O
p	O	O
-	O	O
NO2Phe4	O	O
]	O	O
DPDPE	O	O
(	O	O
5	O	O
)	O	O
is	O	O
more	O	O
potent	O	O
than	O	O
DPDPE	O	O
and	O	O
8800	O	O
-	O	O
fold	O	O
selective	O	O
for	O	O
the	O	O
MVD	O	O
(	O	O
delta	O	O
receptor	O	O
)	O	O
vs	O	O
the	O	O
GPI	O	O
(	O	O
mu	O	O
receptor	O	O
)	O	O
,	O	O
making	O	O
it	O	O
the	O	O
most	O	O
highly	O	O
selective	O	O
ligand	O	O
in	O	O
this	O	O
series	O	O
for	O	O
the	O	O
delta	O	O
opioid	O	O
receptor	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
these	O	O
bioassays	O	O
.	O	O
The	O	O
diesters	O	O
of	O	O
the	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
10	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5,10	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dideazapteroic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
types	O	O
so	O	O
obtained	O	O
were	O	O
saponified	O	O
and	O	O
then	O	O
readily	O	O
decarboxylated	O	O
by	O	O
heating	O	O
in	O	O
Me2SO	O	O
solution	O	O
to	O	O
provide	O	O
the	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5,10	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dideazapteroic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
-	O	I-IUPAC
type	O	I-IUPAC
intermediates	O	O
.	O	O
Highly	O	O
potent	O	O
antagonists	O	O
,	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isoquinolone	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzylcarboxamides	I-IUPAC	I-IUPAC
(	O	O
11	O	O
)	O	O
,	O	O
were	O	O
discovered	O	O
from	O	O
the	O	O
structure	O	O
-	O	O
activity	O	O
relationship	O	O
studies	O	O
on	O	O
the	O	O
isoquinolone	O	O
-	O	O
urea	O	O
lead	O	O
1a	O	O
.	O	O
These	O	O
compounds	O	O
showed	O	O
a	O	O
high	O	O
biological	O	O
activity	O	O
in	O	O
the	O	O
hydroosmotic	O	O
toad	O	O
bladder	O	O
assay	O	O
.	O	O
The	O	O
structure	O	O
-	O	O
activity	O	O
relationships	O	O
suggest	O	O
that	O	O
the	O	O
type	O	O
I	O	O
enzyme	O	O
has	O	O
preference	O	O
for	O	O
N	O	O
-	O	O
substituted	O	O
straight	O	O
alkyl	O	O
side	O	O
chains	O	O
of	O	O
four	O	O
to	O	O
five	O	O
carbon	O	O
atoms	O	O
.	O	O
Moreover	O	O
,	O	O
affinity	O	O
and	O	O
relative	O	O
efficacy	O	O
were	O	O
calculated	O	O
in	O	O
vitro	O	O
for	O	O
this	O	O
compound	O	O
at	O	O
M2	O	O
(	O	O
heart	O	O
force	O	O
and	O	O
rate	O	O
)	O	O
and	O	O
M3	O	O
(	O	O
ileum	O	O
and	O	O
bladder	O	O
)	O	O
receptors	O	O
in	O	O
order	O	O
to	O	O
investigate	O	O
muscarinic	O	O
receptor	O	O
heterogeneity	O	O
.	O	O
Similarly	O	O
,	O	O
H	O	O
-	O	O
Dmt	O	O
-	O	O
Tic	O	O
-	O	O
Gly	O	O
-	O	O
NH	O	O
-	O	O
Ph	O	O
(	O	O
5	O	O
)	O	O
had	O	O
nearly	O	O
equivalent	O	O
high	O	O
delta	O	O
-	O	O
agonism	O	O
(	O	O
pEC	O	O
(	O	O
50	O	O
)	O	O
,	O	O
8.52	O	O
)	O	O
and	O	O
mu	O	O
-	O	O
agonism	O	O
(	O	O
pEC	O	O
(	O	O
50	O	O
)	O	O
,	O	O
8.59	O	O
)	O	O
,	O	O
while	O	O
H	O	O
-	O	O
Dmt	O	O
-	O	O
Tic	O	O
-	O	O
Gly	O	O
-	O	O
NH	O	O
-	O	O
CH	O	O
(	O	O
2	O	O
)	O	O
-	O	O
Ph	O	O
(	O	O
6	O	O
)	O	O
whose	O	O
spacer	O	O
was	O	O
longer	O	O
by	O	O
a	O	O
single	O	O
methylene	O	O
group	O	O
exhibited	O	O
potent	O	O
delta	O	O
-	O	O
antagonism	O	O
(	O	O
pA	O	O
(	O	O
2	O	O
)	O	O
,	O	O
9.25	O	O
)	O	O
and	O	O
very	O	O
high	O	O
mu	O	O
-	O	O
agonism	O	O
(	O	O
pEC	O	O
(	O	O
50	O	O
)	O	O
,	O	O
8.57	O	O
)	O	O
.	O	O
22	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
25	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylcholesterol	I-IUPAC	I-IUPAC
(	O	O
4a	O	O
)	O	O
and	O	O
25	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
22	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxycholesterol	I-IUPAC	I-IUPAC
(	O	O
15a	O	O
)	O	O
significantly	O	O
lowered	O	O
serum	O	O
cholesterol	O	O
levels	O	O
when	O	O
administered	O	O
ig	O	O
to	O	O
primates	O	O
;	O	O
25	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
22	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxycholesterol	I-IUPAC	I-IUPAC
(	O	O
15b	O	O
)	O	O
and	O	O
the	O	O
analogue	O	O
with	O	O
a	O	O
cyclopropyl	B-IUPAC	O
terminus	B-MODIFIER	O
,	O	O
20b	O	O
,	O	O
were	O	O
ineffective	O	O
.	O	O
These	O	O
results	O	O
,	O	O
together	O	O
with	O	O
previous	O	O
autoradiographic	O	O
brain	O	O
receptor	O	O
-	O	O
mapping	O	O
studies	O	O
that	O	O
indicate	O	O
similar	O	O
distribution	O	O
of	O	O
[	O	O
(	O	O
3	O	O
)	O	O
H	O	O
]	O	O
-	O	O
(	O	O
-	O	O
)	O	O
-	O	O
trans	O	O
-	O	O
H	O	O
(	O	O
2	O	O
)	O	O
-	O	O
PAT	O	O
sites	O	O
and	O	O
[	O	O
(	O	O
3	O	O
)	O	O
H	O	O
]	O	O
mepyramine	O	O
-	O	O
labeled	O	O
H	O	O
(	O	O
1	O	O
)	O	O
receptors	O	O
,	O	O
suggest	O	O
that	O	O
both	O	O
radioligands	O	O
label	O	O
the	O	O
same	O	O
histamine	O	O
H	O	O
(	O	O
1	O	O
)	O	O
receptors	O	O
in	O	O
rodent	O	O
brain	O	O
.	O	O
The	O	O
basic	O	O
ring	O	O
system	O	O
was	O	O
prepared	O	O
in	O	O
one	O	O
step	O	O
by	O	O
condensation	O	O
of	O	O
dilithiated	B-MODIFIER	O
(	B-IUPAC	B-IUPAC
tert	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butoxycarbonyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
aniline	I-IUPAC	I-IUPAC
(	O	O
3	O	O
)	O	O
with	O	O
(	B-IUPAC	B-IUPAC
tert	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butoxycarbonyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
piperidinone	I-IUPAC	I-IUPAC
.	O	O
The	O	O
high	O	O
acidity	O	O
of	O	O
HOPO	O	O
ligands	O	O
and	O	O
the	O	O
much	O	O
lower	O	O
acidity	O	O
of	O	O
catechol	O	O
(	O	O
CAM	O	O
)	O	O
ligands	O	O
suggested	O	O
that	O	O
mixed	O	O
octadentate	O	O
(	O	O
CAM	O	O
-	O	O
HOPO	O	O
)	O	O
ligands	O	O
containing	O	O
one	O	O
or	O	O
two	O	O
1,2	O	O
-	O	O
HOPO	O	O
and	O	O
three	O	O
(	O	O
or	O	O
two	O	O
)	O	O
catechol	O	O
(	O	O
CAM	O	O
)	O	O
groups	O	O
might	O	O
be	O	O
as	O	O
effective	O	O
for	O	O
Pu	O	O
removal	O	O
[	O	O
fully	O	O
eight	O	O
-	O	O
coordinated	O	O
Pu	O	O
(	O	O
IV	O	O
)	O	O
complexes	O	O
formed	O	O
at	O	O
pH	O	O
&	O	O
gt	O	O
;	O	O
or	O	O
=	O	O
6	O	O
]	O	O
and	O	O
less	O	O
toxic	O	O
than	O	O
3,4,3	O	O
-	O	O
LIHOPO	O	O
.	O	O
Mitotic	O	O
blocking	O	O
appears	O	O
to	O	O
be	O	O
its	O	O
primary	O	O
mechanism	O	O
of	O	O
cytotoxic	O	O
activity	O	O
.	O	O
The	O	O
results	O	O
obtained	O	O
suggest	O	O
that	O	O
(	O	O
a	O	O
)	O	O
analogs	O	O
I	O	O
and	O	O
VI	O	O
are	O	O
potent	O	O
antagonists	O	O
of	O	O
the	O	O
pressor	O	O
response	O	O
of	O	O
angiotensin	O	O
II	O	O
in	O	O
normal	O	O
rat	O	O
,	O	O
VI	O	O
being	O	O
the	O	O
most	O	O
potent	O	O
antagonist	O	O
thus	O	O
far	O	O
synthesized	O	O
;	O	O
(	O	O
b	O	O
)	O	O
replacement	O	O
of	O	O
position	O	O
4	O	O
(	O	O
Tyr	O	O
)	O	O
with	O	O
MeTyr	O	O
or	O	O
position	O	O
5	O	O
and	O	O
/	O	O
or	O	O
8	O	O
(	O	O
Ile	O	O
)	O	O
with	O	O
Melle	O	O
in	O	O
[	B-IUPAC	B-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
sarcosine	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isoleucine	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
angiotensin	I-IUPAC	I-IUPAC
II	I-IUPAC	I-IUPAC
reduced	O	O
the	O	O
antagonist	O	O
activity	O	O
of	O	O
this	O	O
peptide	O	O
(	O	O
rabbit	O	O
aortic	O	O
strips	O	O
and	O	O
rats	O	O
)	O	O
,	O	O
indicating	O	O
that	O	O
steric	O	O
hindrance	O	O
imposed	O	O
due	O	O
to	O	O
N	O	O
-	O	O
methylation	O	O
in	O	O
positions	O	O
4	O	O
,	O	O
5	O	O
,	O	O
or	O	O
8	O	O
was	O	O
not	O	O
favorable	O	O
in	O	O
eliminating	O	O
the	O	O
initial	O	O
pressor	O	O
activity	O	O
or	O	O
prolonging	O	O
the	O	O
duration	O	O
of	O	O
action	O	O
of	O	O
[	O	O
Sar1	O	O
,	O	O
Ile8	O	O
]	O	O
angiotensin	O	O
II	O	O
without	O	O
reducing	O	O
its	O	O
antagonistic	O	O
properties	O	O
;	O	O
(	O	O
c	O	O
)	O	O
except	O	O
II	O	O
,	O	O
none	O	O
of	O	O
the	O	O
analogs	O	O
showed	O	O
any	O	O
enhanced	O	O
duration	O	O
of	O	O
action	O	O
,	O	O
suggesting	O	O
that	O	O
N	O	O
-	O	O
methylation	O	O
in	O	O
positions	O	O
5	O	O
or	O	O
8	O	O
did	O	O
not	O	O
afford	O	O
protection	O	O
against	O	O
proteolytic	O	O
enzymes	O	O
;	O	O
and	O	O
(	O	O
d	O	O
)	O	O
perfusion	O	O
studies	O	O
in	O	O
cat	O	O
adrenals	O	O
indicated	O	O
that	O	O
all	O	O
of	O	O
these	O	O
analogs	O	O
are	O	O
only	O	O
very	O	O
weak	O	O
secretagogues	O	O
.	O	O
Med.	O	O
Chem.	O	O
1998	O	O
,	O	O
41	O	O
)	O	O
.	O	O
Thus	O	O
,	O	O
a	O	O
large	O	O
,	O	O
nondiscriminating	O	O
hydrophobic	O	O
region	O	O
occurs	O	O
in	O	O
the	O	O
A3	O	O
receptor	O	O
in	O	O
proximity	O	O
to	O	O
the	O	O
N5	O	O
-	O	O
substituent	O	O
.	O	O
The	O	O
synthesis	O	O
and	O	O
structure	O	O
-	O	O
activity	O	O
relationships	O	O
(	O	O
SAR	O	O
)	O	O
of	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
alkyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylethylamine	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
5-8	O	O
designed	O	O
from	O	O
N	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dipropyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
ethylamine	I-IUPAC	I-IUPAC
hydrochloride	I-IUPAC	I-IUPAC
(	O	O
1	O	O
,	O	O
NE	O	O
-	O	O
100	O	O
)	O	O
are	O	O
presented	O	O
.	O	O
The	O	O
single	O	O
-	O	O
armed	O	O
aporphine	O	O
nitrogen	O	O
mustard	O	O
(	O	O
1e	O	O
)	O	O
was	O	O
also	O	O
active	O	O
in	O	O
P388	O	O
but	O	O
the	O	O
activity	O	O
was	O	O
less	O	O
than	O	O
that	O	O
observed	O	O
with	O	O
1b	O	O
-	O	O
d	O	O
.	O	O
Thus	O	O
,	O	O
a	O	O
series	O	O
of	O	O
1	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
propananilido	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
perhydroazepine	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
was	O	O
synthesized	O	O
and	O	O
pharmacologically	O	O
evaluated	O	O
in	O	O
mice	O	O
for	O	O
analgesic	O	O
activity	O	O
and	O	O
physical	O	O
-	O	O
dependence	O	O
capacity	O	O
.	O	O
Binding	O	O
studies	O	O
in	O	O
the	O	O
hippocampal	O	O
homogenates	O	O
revealed	O	O
that	O	O
[	O	O
125I	O	O
]	O	O
-	O	O
8	O	O
bound	O	O
to	O	O
a	O	O
single	O	O
high	O	O
-	O	O
affinity	O	O
site	O	O
(	O	O
Kd	O	O
=	O	O
0.38	O	O
+	O	O
/	O	O
-	O	O
0.03	O	O
nM	O	O
,	O	O
Bmax	O	O
=	O	O
310	O	O
+	O	O
/	O	O
-	O	O
20	O	O
fmol	O	O
/	O	O
mg	O	O
of	O	O
protein	O	O
)	O	O
.	O	O
The	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
dihydrofuran	O	O
ring	O	O
in	O	O
6a	O	O
and	O	O
6b	O	O
models	O	O
the	O	O
active	O	O
conformation	O	O
of	O	O
the	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
groups	B-MODIFIER	B-MODIFIER
in	O	O
3	O	O
and	O	O
5	O	O
.	O	O
The	O	O
two	O	O
classes	O	O
of	O	O
inactivators	O	O
(	O	O
O'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
epoxyalkyl	I-IUPAC	I-IUPAC
and	O	O
carboxy	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
epoxyalkyl	I-IUPAC	I-IUPAC
)	O	I-IUPAC
appear	O	I-IUPAC
to	O	O
operate	O	O
by	O	O
different	O	O
mechanisms	O	O
.	O	O
A	O	O
series	O	O
of	O	O
aldehydo	O	O
sugars	O	O
was	O	O
subjected	O	O
to	O	O
condensation	O	O
reactions	O	O
with	O	O
active	O	O
methylene	O	O
compounds	O	O
.	O	O
This	O	O
indicates	O	O
that	O	O
BTCP	O	O
is	O	O
the	O	O
most	O	O
selective	O	O
of	O	O
all	O	O
the	O	O
compounds	O	O
tested	O	O
for	O	O
sites	O	O
labeled	O	O
by	O	O
[	O	O
3H	O	O
]	O	O
BTCP	O	O
whereas	O	O
cocaine	O	O
is	O	O
most	O	O
selective	O	O
for	O	O
sites	O	O
labeled	O	O
by	O	O
[	O	O
3H	O	O
]	O	O
cocaine	O	O
.	O	O
N6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
Nitrobenzyladenosine	I-IUPAC	I-IUPAC
and	O	O
its	O	O
2'	O	B-IUPAC
-	O	I-IUPAC
deoxy	O	I-IUPAC
analog	O	B-MODIFIER
were	O	O
competitive	O	O
inhibitors	O	O
(	O	O
K1	O	O
65	O	O
,	O	O
22	O	O
MUM	O	O
)	O	O
.	O	O
4d	O	O
did	O	O
not	O	O
show	O	O
significant	O	O
affinity	O	O
for	O	O
AMPA	O	O
receptor	O	O
sites	O	O
,	O	O
but	O	O
turned	O	O
out	O	O
to	O	O
be	O	O
a	O	O
weak	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aspartic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
NMDA	O	O
)	O	O
receptor	O	O
antagonist	O	O
.	O	O
In	O	O
each	O	O
case	O	O
,	O	O
the	O	O
activity	O	O
or	O	O
minimal	O	O
activity	O	O
of	O	O
each	O	O
compound	O	O
can	O	O
be	O	O
explained	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
the	O	O
ability	O	O
of	O	O
one	O	O
or	O	O
more	O	O
accessible	O	O
conformer	O	O
of	O	O
each	O	O
molecule	O	O
to	O	O
clear	O	O
the	O	O
REV	O	O
calculated	O	O
here	O	O
.	O	O
Continuing	O	O
studies	O	O
on	O	O
the	O	O
chemical	O	O
modification	O	O
of	O	O
the	O	O
previously	O	O
reported	O	O
novel	O	O
tripeptide	O	O
SP	O	O
antagonist	O	O
,	O	O
N	B-IUPAC	B-IUPAC
alpha	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
tert	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butyloxycarbonyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
glutaminyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
formyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tryptophyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
phenylalanine	I-IUPAC	I-IUPAC
benzyl	I-IUPAC	I-IUPAC
ester	I-IUPAC	I-IUPAC
[	O	O
Boc	O	O
-	O	O
Gln	O	O
-	O	O
D	O	O
-	O	O
Trp	O	O
-	O	O
(	O	O
CHO	O	O
)	O	O
-	O	O
Phe	O	O
-	O	O
OBzl	O	O
(	O	O
1	O	O
)	O	O
]	O	O
,	O	O
are	O	O
described	O	O
herein	O	O
.	O	O
carinii	O	O
or	O	O
T	O	O
.	O	O
A	O	O
surprising	O	O
degree	O	O
of	O	O
conformational	O	O
similarity	O	O
has	O	O
been	O	O
observed	O	O
for	O	O
the	O	O
peptide	O	O
backbone	O	O
.	O	O
Ep	O	O
.	O	O
The	O	O
most	O	O
active	O	O
compounds	O	O
were	O	O
found	O	O
in	O	O
the	O	O
hydroxamic	O	O
derivatives	O	O
of	O	O
cyclohexane	O	O
series	O	O
;	O	O
within	O	O
this	O	O
series	O	O
of	O	O
derivatives	O	O
a	O	O
marked	O	O
increase	O	O
of	O	O
potency	O	O
was	O	O
caused	O	O
by	O	O
alkylation	O	O
of	O	O
the	O	O
amidic	O	O
nitrogen	O	O
with	O	O
a	O	O
methyl	B-IUPAC	O
or	O	O
ethyl	B-IUPAC	O
group	B-MODIFIER	O
.	O	O
Compound	O	O
8	O	O
,	O	O
in	O	O
which	O	O
the	O	O
acidic	O	O
NH	O	O
group	O	O
is	O	O
in	O	O
the	O	O
same	O	O
region	O	O
of	O	O
space	O	O
as	O	O
that	O	O
in	O	O
1	O	O
,	O	O
although	O	O
the	O	O
aminosulfonyl	B-IUPAC	B-IUPAC
group	B-MODIFIER	B-MODIFIER
is	O	O
reversed	O	O
with	O	O
respect	O	O
to	O	O
the	O	O
aromatic	O	O
ring	O	O
,	O	O
showed	O	O
poor	O	O
PNMT	O	O
affinity	O	O
and	O	O
modest	O	O
alpha	O	O
2	O	O
-	O	O
adrenoceptor	O	O
affinity	O	O
(	O	O
PNMT	O	O
Ki	O	O
=	O	O
330	O	O
microM	O	O
,	O	O
alpha	O	O
2	O	O
Ki	O	O
=	O	O
18	O	O
microM	O	O
,	O	O
selectivity	O	O
=	O	O
0.055	O	O
)	O	O
.	O	O
They	O	O
were	O	O
similar	O	O
in	O	O
potency	O	O
in	O	O
blocking	O	O
CAR	O	O
with	O	O
AB50	O	O
values	O	O
of	O	O
39	O	O
,	O	O
32	O	O
,	O	O
and	O	O
42	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
respectively	O	O
.	O	O
Others	O	O
were	O	O
specific	O	O
inhibitors	O	O
for	O	O
calpain	O	O
I	O	O
(	O	O
e.g.	O	O
,	O	O
73	O	O
)	O	O
or	O	O
calpain	O	O
II	O	O
(	O	O
e.g.	O	O
,	O	O
18	O	O
,	O	O
19	O	O
,	O	O
33	O	O
,	O	O
35	O	O
,	O	O
56	O	O
)	O	O
.	O	O
(	B-PARTIUPAC	O
Pivaloyloxy	I-PARTIUPAC	O
)	I-PARTIUPAC	O
methyl	I-PARTIUPAC	O
and	O	O
(	B-IUPAC	B-IUPAC
+	I-IUPAC	I-IUPAC
/	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
cyclohexyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carbonyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
oxy	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
esters	I-IUPAC	I-IUPAC
of	O	O
3	O	O
and	O	O
4	O	O
showed	O	O
marked	O	O
increases	O	O
in	O	O
oral	O	O
bioavailability	O	O
which	O	O
significantly	O	O
potentiated	O	O
the	O	O
inhibitory	O	O
effect	O	O
of	O	O
the	O	O
parent	O	O
compounds	O	O
on	O	O
AII	O	O
-	O	O
induced	O	O
pressor	O	O
response	O	O
.	O	O
Spiropiperidines	O	O
with	O	O
no	O	O
or	O	O
small	O	O
N	O	O
-	O	O
substituents	O	O
(	O	O
H	O	O
,	O	O
Me	O	O
,	O	O
Et	O	O
)	O	O
exert	O	O
very	O	O
low	O	O
affinity	O	O
for	O	O
both	O	O
sigma	O	O
1	O	O
and	O	O
sigma	O	O
2	O	O
binding	O	O
sites	O	O
(	O	O
IC50	O	O
(	O	O
sigma	O	O
1	O	O
,	O	O
sigma	O	O
2	O	O
)	O	O
&	O	O
gt	O	O
;	O	O
100	O	O
nM	O	O
)	O	O
,	O	O
whereas	O	O
medium	O	O
-	O	O
sized	O	O
substituents	O	O
(	O	O
e.g.	O	O
,	O	O
Pr	O	O
,	O	O
Bu	O	O
,	O	O
Ph	O	O
(	O	O
CH2	O	O
)	O	O
2	O	O
)	O	O
result	O	O
in	O	O
potent	O	O
,	O	O
but	O	O
unselective	O	O
compounds	O	O
(	O	O
IC50	O	O
(	O	O
sigma	O	O
1	O	O
,	O	O
sigma	O	O
2	O	O
)	O	O
=	O	O
2-5	O	O
nM	O	O
)	O	O
.	O	O
Analogues	O	O
of	O	O
methotrexate	O	O
(	O	O
MTX	O	O
)	O	O
and	O	O
aminopterin	O	O
(	O	O
AMT	O	O
)	O	O
modified	O	O
at	O	O
the	O	O
gamma	O	O
-	O	O
position	O	O
of	O	O
the	O	O
glutamate	O	O
side	O	O
chain	O	O
were	O	O
synthesized	O	O
and	O	O
evaluated	O	O
as	O	O
dihydrofolate	O	O
reductase	O	O
(	O	O
DHFR	O	O
)	O	O
inhibitors	O	O
and	O	O
tumor	O	O
cell	O	O
growth	O	O
inhibitors	O	O
.	O	O
Evaluation	O	O
of	O	O
physical	O	O
-	O	O
dependence	O	O
capacity	O	O
of	O	O
the	O	O
most	O	O
potent	O	O
1	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
propananilido	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
perhydroazepines	I-IUPAC	I-IUPAC
reveals	O	O
no	O	O
significant	O	O
difference	O	O
for	O	O
these	O	O
compounds	O	O
as	O	O
compared	O	O
with	O	O
morphine	O	O
.	O	O
Structure	O	O
-	O	O
activity	O	O
relationships	O	O
were	O	O
evaluated	O	O
where	O	O
PAF	O	O
antagonist	O	O
activity	O	O
was	O	O
measured	O	O
in	O	O
vitro	O	O
by	O	O
determining	O	O
the	O	O
concentration	O	O
of	O	O
compound	O	O
(	O	O
IC50	O	O
)	O	O
required	O	O
to	O	O
inhibit	O	O
the	O	O
PAF	O	O
-	O	O
induced	O	O
aggregation	O	O
of	O	O
rabbit	O	O
washed	O	O
platelets	O	O
and	O	O
in	O	O
vivo	O	O
by	O	O
determining	O	O
the	O	O
oral	O	O
dose	O	O
(	O	O
ED50	O	O
)	O	O
which	O	O
protected	O	O
mice	O	O
from	O	O
a	O	O
lethal	O	O
injection	O	O
of	O	O
PAF	O	O
.	O	O
3,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5,7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
difluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzoxazolyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phthalazineacetic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
124	O	O
)	O	O
was	O	O
the	O	O
best	O	O
of	O	O
the	O	O
benzoxazole	O	O
series	O	O
(	O	O
IC50	O	O
=	O	O
3.2	O	O
x	O	O
10	O	O
(	O	O
-	O	O
9	O	O
)	O	O
M	O	O
)	O	O
;	O	O
it	O	O
suppressed	O	O
accumulation	O	O
of	O	O
sorbitol	O	O
in	O	O
rat	O	O
sciatic	O	O
nerve	O	O
by	O	O
78%	O	O
at	O	O
an	O	O
oral	O	O
dose	O	O
of	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O
Reaction	O	O
of	O	O
3	O	O
with	O	O
ammonia	O	O
gave	O	O
(	B-IUPAC	B-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bromovinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxycytidine	I-IUPAC	I-IUPAC
(	O	O
1	O	O
)	O	O
,	O	O
the	O	O
overall	O	O
yield	O	O
from	O	O
2	O	O
being	O	O
60%	O	O
.	O	O
This	O	O
structure	O	O
class	O	O
is	O	O
characterized	O	O
by	O	O
the	O	O
boat	O	O
conformation	O	O
of	O	O
the	O	O
tropane	O	O
ring	O	O
and	O	O
the	O	O
orientation	O	O
of	O	O
the	O	O
additional	O	O
bridge	O	O
(	O	O
and	O	O
therefore	O	O
of	O	O
the	O	O
nitrogen	O	O
lone	O	O
pair	O	O
)	O	O
together	O	O
with	O	O
the	O	O
unusual	O	O
placement	O	O
of	O	O
the	O	O
aromatic	O	O
moiety	O	O
.	O	O
(	O	O
2S	O	O
)	O	O
-	O	O
1	O	O
,	O	O
which	O	O
was	O	O
metabolized	O	O
to	O	O
2	O	O
to	O	O
a	O	O
greater	O	O
extent	O	O
than	O	O
(	O	O
2R	O	O
)	O	O
-	O	O
1	O	O
,	O	O
showed	O	O
no	O	O
stereoselectivity	O	O
,	O	O
affording	O	O
about	O	O
equal	O	O
amounts	O	O
of	O	O
(	O	O
2S	O	O
,	O	O
2	O	O
"	O	O
S	O	O
)	O	O
-	O	O
2	O	O
and	O	O
(	O	O
2S	O	O
,	O	O
2	O	O
"	O	O
R	O	O
)	O	O
-	O	O
2	O	O
.	O	O
As	O	O
an	O	O
inhibitor	O	O
of	O	O
Tg	O	O
DHFR	O	O
,	O	O
28	O	O
had	O	O
an	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
of	O	O
5.5	O	O
nM	O	O
(	O	O
510	O	O
-	O	O
fold	O	O
lower	O	O
than	O	O
that	O	O
of	O	O
TMP	O	O
and	O	O
similar	O	O
to	O	O
that	O	O
of	O	O
PTX	O	O
)	O	O
and	O	O
an	O	O
SI	O	O
value	O	O
of	O	O
120	O	O
(	O	O
2	O	O
-	O	O
fold	O	O
better	O	O
than	O	O
TMP	O	O
and	O	O
vastly	O	O
superior	O	O
to	O	O
PTX	O	O
)	O	O
.	O	O
The	O	O
biological	O	O
data	O	O
indicate	O	O
strongly	O	O
that	O	O
the	O	O
aqueous	O	O
solubility	O	O
and	O	O
relatively	O	O
high	O	O
acidity	O	O
of	O	O
the	O	O
octadentate	O	O
HOPO	O	O
ligands	O	O
,	O	O
3,4,3	O	O
-	O	O
LIHOPO	O	O
and	O	O
DFO	O	O
-	O	O
HOPO	O	O
allow	O	O
them	O	O
to	O	O
form	O	O
complete	O	O
eight	O	O
-	O	O
coordinate	O	O
complexes	O	O
with	O	O
Pu	O	O
(	O	O
IV	O	O
)	O	O
ion	O	O
.	O	O
All	O	O
S	O	O
enantiomers	O	O
were	O	O
less	O	O
potent	O	O
than	O	O
the	O	O
R	O	O
ones	O	O
.	O	O
The	O	O
synthesis	O	O
of	O	O
10	B-IUPAC	O
-	I-IUPAC	O
alkyl	I-IUPAC	O
analogues	B-MODIFIER	O
of	O	O
the	O	O
potent	O	O
antitumor	O	O
agent	O	O
8,10	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dideazaminopterin	I-IUPAC	I-IUPAC
is	O	O
described	O	O
.	O	O
A	O	O
change	O	O
of	O	O
the	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
of	O	O
the	O	O
nonselective	O	O
3	O	O
to	O	O
H	O	O
[	O	O
23	O	O
,	O	O
(	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
11	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxynoraporphine	I-IUPAC	I-IUPAC
]	O	I-IUPAC
or	O	O
propyl	O	O
[	O	O
2	O	O
,	O	O
(	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
11	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propylnoraporphine	I-IUPAC	I-IUPAC
]	O	I-IUPAC
increases	O	I-IUPAC
the	O	O
selectivity	O	O
for	O	O
5	O	O
-	O	O
HT1A	O	O
receptors	O	O
(	O	O
100	O	O
-	O	O
fold	O	O
)	O	O
and	O	O
dopamine	O	O
D2A	O	O
receptors	O	O
(	O	O
3	O	O
-	O	O
fold	O	O
)	O	O
,	O	O
respectively	O	O
.	O	O
Treatment	O	O
of	O	O
3'	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
5'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
di	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bromovinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
(	O	O
2	O	O
)	O	O
with	O	O
p	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chlorophenyl	I-IUPAC	I-IUPAC
phosphorodichloridate	I-IUPAC	I-IUPAC
and	O	O
1,2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
triazole	I-IUPAC	I-IUPAC
gave	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
di	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
erythro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pentofuranosyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
br	I-IUPAC	I-IUPAC
o	I-IUPAC	I-IUPAC
movinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1,2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
triazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
pyrimidin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
(	O	O
3	O	O
)	O	O
.	O	O
These	O	O
data	O	O
suggest	O	O
that	O	O
radiolabeled	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
RS	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminopropyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
iodothiophenes	I-IUPAC	I-IUPAC
are	O	O
potentially	O	O
useful	O	O
agents	O	O
for	O	O
cerebral	O	O
perfusion	O	O
imaging	O	O
by	O	O
single	O	O
-	O	O
photon	O	O
-	O	O
emission	O	O
computerized	O	O
tomography	O	O
(	O	O
SPECT	O	O
)	O	O
.	O	O
The	O	O
effects	O	O
of	O	O
hydrophobic	O	O
,	O	O
hydrogen	O	O
-	O	O
bonding	O	O
,	O	O
and	O	O
ionic	O	O
interactions	O	O
with	O	O
the	O	O
AT1	O	O
receptor	O	O
are	O	O
considered	O	O
.	O	O
These	O	O
analogs	O	O
were	O	O
examined	O	O
for	O	O
their	O	O
growth	O	O
inhibitory	O	O
effect	O	O
in	O	O
cultured	O	O
leukemic	O	O
cells	O	O
and	O	O
also	O	O
for	O	O
their	O	O
effect	O	O
on	O	O
adenosine	O	O
aminohydrolase	O	O
activity	O	O
.	O	O
Moreover	O	O
,	O	O
some	O	O
dihydropyrimidines	O	O
[	O	O
1q	O	O
[	O	O
R1	O	O
=	O	O
(	B-PARTIUPAC	O
CH2	I-PARTIUPAC	O
)	I-PARTIUPAC	O
2N	I-PARTIUPAC	O
(	I-PARTIUPAC	B-IUPAC
benzyl	I-PARTIUPAC	I-IUPAC
)	I-PARTIUPAC	I-IUPAC
(	I-PARTIUPAC	I-IUPAC
3	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
phenylpropyl	I-PARTIUPAC	I-IUPAC
)	O	O
,	O	O
R2	O	O
=	O	O
CH2	B-IUPAC	O
(	I-IUPAC	O
cyclopropyl	I-IUPAC	O
)	I-IUPAC	O
,	O	O
X	O	O
=	O	O
0	O	O
-	O	O
NO2	O	O
]	O	O
,	O	O
1s	O	O
,	O	O
and	O	O
1t	O	O
]	O	O
were	O	O
weaker	O	O
in	O	O
blocking	O	O
atrioventricular	O	O
conduction	O	O
in	O	O
anesthetized	O	O
open	O	O
-	O	O
chest	O	O
dogs	O	O
and	O	O
less	O	O
toxic	O	O
than	O	O
the	O	O
dihydropyridines	O	O
.	O	O
(	O	O
S	O	O
)	O	O
-	O	O
(	O	O
-	O	O
)	O	O
-	O	O
7	O	O
was	O	O
the	O	O
most	O	O
potent	O	O
of	O	O
the	O	O
two	O	O
enantiomers	O	O
,	O	O
confirming	O	O
the	O	O
stereospecificity	O	O
of	O	O
the	O	O
interaction	O	O
with	O	O
alpha2	O	O
-	O	O
adrenoreceptors	O	O
.	O	O
Similar	O	O
relative	O	O
orders	O	O
of	O	O
potencies	O	O
are	O	O
also	O	O
found	O	O
in	O	O
the	O	O
other	O	O
two	O	O
bioassays	O	O
.	O	O
Compound	O	O
4a	O	O
was	O	O
obtained	O	O
in	O	O
four	O	O
steps	O	O
starting	O	O
with	O	O
two	O	O
successive	O	O
brominations	O	O
of	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
acetylfuran	I-IUPAC	I-IUPAC
first	O	O
with	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
bromosuccinimide	I-IUPAC	I-IUPAC
,	O	O
and	O	O
second	O	O
with	O	O
bromine	O	O
to	O	O
form	O	O
alpha	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
bromo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bromofuran	I-IUPAC	I-IUPAC
(	O	O
2	O	O
)	O	O
in	O	O
a	O	O
moderate	O	O
yield	O	O
.	O	O
Biological	O	O
studies	O	O
indicated	O	O
that	O	O
the	O	O
target	O	O
compounds	O	O
were	O	O
less	O	O
active	O	O
than	O	O
1	O	O
and	O	O
3	O	O
.	O	O
Carbocyclic	O	O
thymidine	O	O
(	O	O
carba	O	O
-	O	O
T	O	O
,	O	O
13	O	O
)	O	O
was	O	O
used	O	O
as	O	O
a	O	O
reference	O	O
,	O	O
flexible	O	O
carbocyclic	O	O
nucleoside	O	O
.	O	O
Three	O	O
compounds	O	O
(	O	O
5j	O	O
-	O	O
l	O	O
)	O	O
were	O	O
tested	O	O
for	O	O
antiproliferative	O	O
activity	O	O
against	O	O
human	O	O
tumor	O	O
cells	O	O
in	O	O
culture	O	O
.	O	O
The	O	O
results	O	O
obtained	O	O
were	O	O
as	O	O
follows	O	O
:	O	O
greater	O	O
than	O	O
62	O	O
,	O	O
84	O	O
,	O	O
9	O	O
,	O	O
333	O	O
,	O	O
21	O	O
,	O	O
and	O	O
5	O	O
,	O	O
respectively	O	O
.	O	O
The	O	O
kinetic	O	O
parameters	O	O
of	O	O
the	O	O
HLE	O	O
inhibition	O	O
were	O	O
determined	O	O
.	O	O
A	O	O
different	O	O
kinetic	O	O
assay	O	O
(	O	O
Ashani	O	O
,	O	O
Y	O	O
.	O	O
By	O	O
the	O	O
use	O	O
of	O	O
space	O	O
-	O	O
filling	O	O
models	O	O
,	O	O
a	O	O
novel	O	O
compound	O	O
,	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
carbamylmethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyclopenta	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
f	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
isoquinolin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
was	O	O
devised	O	O
which	O	O
would	O	O
be	O	O
expected	O	O
to	O	O
hydrogen	O	O
bond	O	O
specifically	O	O
to	O	O
GC	O	O
pairs	O	O
in	O	O
the	O	O
major	O	O
groove	O	O
of	O	O
the	O	O
double	O	O
helix	O	O
such	O	O
that	O	O
(	O	O
i	O	O
)	O	O
the	O	O
amino	B-IUPAC	O
group	B-MODIFIER	O
of	O	O
the	O	O
cytosine	O	O
molecule	O	O
donates	O	O
a	O	O
hydrogen	O	O
bond	O	O
to	O	O
the	O	O
C	O	O
-	O	O
3	O	O
carbonyl	O	O
of	O	O
the	O	O
isoquinoline	O	O
moiety	O	O
and	O	O
(	O	O
ii	O	O
)	O	O
the	O	O
amide	O	O
proton	O	O
of	O	O
the	O	O
side	O	O
chain	O	O
donates	O	O
a	O	O
hydrogen	O	O
bond	O	O
to	O	O
the	O	O
N	O	O
-	O	O
7	O	O
of	O	O
guanine	O	O
.	O	O
However	O	O
,	O	O
only	O	O
those	O	O
sterols	O	O
with	O	O
a	O	O
modified	O	O
side	O	O
chain	O	O
terminus	O	O
were	O	O
effective	O	O
suppressors	O	O
of	O	O
liver	O	O
reductase	O	O
when	O	O
administered	O	O
ig	O	O
to	O	O
rats	O	O
.	O	O
The	O	O
preliminary	O	O
PET	O	O
experiments	O	O
in	O	O
baboons	O	O
with	O	O
[	O	O
18F	O	O
]	O	O
F	O	O
-	O	O
A	O	O
-	O	O
85380	O	O
show	O	O
an	O	O
accumulation	O	O
of	O	O
the	O	O
radiotracer	O	O
in	O	O
the	O	O
brain	O	O
within	O	O
60	O	O
min	O	O
.	O	O
The	O	O
anticonvulsant	O	O
activity	O	O
of	O	O
diphenylhydantoin	O	O
(	O	O
DPH	O	O
or	O	O
phenytoin	O	O
)	O	O
is	O	O
consistent	O	O
with	O	O
its	O	O
actions	O	O
on	O	O
the	O	O
neuronal	O	O
voltage	O	O
-	O	O
dependent	O	O
sodium	O	O
channel	O	O
.	O	O
In	O	O
general	O	O
,	O	O
the	O	O
antiproliferative	O	O
activity	O	O
correlated	O	O
with	O	O
inhibition	O	O
of	O	O
tubulin	O	O
polymerization	O	O
.	O	O
The	O	O
most	O	O
active	O	O
anti	O	O
-	O	O
DHBV	O	O
agent	O	O
(	O	O
9c	O	O
)	O	O
,	O	O
possessing	O	O
a	O	O
[	B-IUPAC	B-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
hydroxymethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
substituent	B-MODIFIER	B-MODIFIER
at	O	O
N	O	O
-	O	O
1	O	O
,	O	O
exhibited	O	O
an	O	O
activity	O	O
(	O	O
EC	O	O
(	O	O
50	O	O
)	O	O
of	O	O
0.01-0.05	O	O
microg	O	O
/	O	O
mL	O	O
)	O	O
comparable	O	O
to	O	O
that	O	O
of	O	O
reference	O	O
compound	O	O
(	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
3'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dideoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thiacytidine	I-IUPAC	I-IUPAC
(	O	O
3	O	O
-	O	O
TC	O	O
)	O	O
(	O	O
EC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
0.01-0.05	O	O
microg	O	O
/	O	O
mL	O	O
)	O	O
.	O	O
Methyl	B-IUPAC	B-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
isothiocyanatomethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
thiazole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carbamate	I-IUPAC	I-IUPAC
(	O	O
7	O	O
)	O	O
was	O	O
the	O	O
most	O	O
active	O	O
compound	O	O
in	O	O
this	O	O
screen	O	O
,	O	O
inhibiting	O	O
the	O	O
growth	O	O
of	O	O
L1210	O	O
leukemic	O	O
cells	O	O
with	O	O
an	O	O
IC50	O	O
=	O	O
3.2	O	O
microM	O	O
.	O	O
The	O	O
high	O	O
specific	O	O
activity	O	O
one	O	O
-	O	O
step	O	O
radiolabeling	O	O
preparation	O	O
and	O	O
high	O	O
selectivity	O	O
of	O	O
[	O	O
(	O	O
123	O	O
)	O	O
I	O	O
]	O	O
ZIENT	O	O
for	O	O
SERT	O	O
support	O	O
its	O	O
candidacy	O	O
as	O	O
a	O	O
radioligand	O	O
for	O	O
mapping	O	O
brain	O	O
SERT	O	O
sites	O	O
.	O	O
We	O	O
therefore	O	O
concluded	O	O
that	O	O
target	O	O
cysteines	O	O
in	O	O
the	O	O
hormone	O	O
-	O	O
binding	O	O
site	O	O
were	O	O
not	O	O
in	O	O
direct	O	O
contact	O	O
with	O	O
the	O	O
steroid	O	O
but	O	O
probably	O	O
in	O	O
the	O	O
immediate	O	O
neighborhood	O	O
of	O	O
the	O	O
D	O	O
ring	O	O
of	O	O
the	O	O
bound	O	O
steroid	O	O
.	O	O
The	O	O
absolute	O	O
configuration	O	O
of	O	O
the	O	O
respective	O	O
(	O	O
R	O	O
)	O	O
-	O	O
and	O	O
(	O	O
S	O	O
)	O	O
-	O	O
enantiomers	O	O
was	O	O
deduced	O	O
from	O	O
X	O	O
-	O	O
ray	O	O
crystallography	O	O
of	O	O
(	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isopropylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzopyran	I-IUPAC	I-IUPAC
,	O	O
(	O	O
R	O	O
)	O	O
-	O	O
9a	O	O
.	O	O
Cell	O	O
culture	O	O
toxicity	O	O
reversal	O	O
studies	O	O
and	O	O
enzyme	O	O
inhibition	O	O
tests	O	O
showed	O	O
that	O	O
1	O	O
was	O	O
cytotoxic	O	O
but	O	O
not	O	O
by	O	O
the	O	O
mechanism	O	O
of	O	O
the	O	O
dihydrofolate	O	O
reductase	O	O
inhibitor	O	O
aminopterin	O	O
.	O	O
In	O	O
the	O	O
presence	O	O
of	O	O
carboxylate	O	O
esterase	O	O
,	O	O
however	O	O
,	O	O
it	O	O
was	O	O
degraded	O	O
,	O	O
in	O	O
a	O	O
concentration	O	O
-	O	O
dependent	O	O
manner	O	O
,	O	O
to	O	O
FdUMP	O	O
.	O	O
The	O	O
condensation	O	O
of	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aminopyrazole	I-IUPAC	I-IUPAC
with	O	O
symmetrical	O	O
beta	O	O
-	O	O
diketones	O	O
(	O	O
acetylacetone	O	O
,	O	O
heptane	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
3,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dione	I-IUPAC	I-IUPAC
,	O	O
etc	O	O
.	O	O
Particularly	O	O
noteworthy	O	O
was	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
n	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxybenzyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
thio	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
biphenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
triazole	I-IUPAC	I-IUPAC
(	O	O
71	O	O
,	O	O
IC50	O	O
1.4	O	O
nM	O	O
)	O	O
,	O	O
which	O	O
blocked	O	O
the	O	O
AII	O	O
pressor	O	O
response	O	O
in	O	O
conscious	O	O
rats	O	O
at	O	O
0.3	O	O
mg	O	O
/	O	O
kg	O	O
iv	O	O
with	O	O
a	O	O
duration	O	O
of	O	O
action	O	O
of	O	O
approximately	O	O
6	O	O
h	O	O
,	O	O
similar	O	O
to	O	O
that	O	O
of	O	O
DuP	O	O
753	O	O
.	O	O
These	O	O
data	O	O
suggest	O	O
that	O	O
the	O	O
site	O	O
of	O	O
action	O	O
of	O	O
1	O	O
is	O	O
inhibition	O	O
of	O	O
purine	O	O
de	O	O
novo	O	O
biosynthesis	O	O
.	O	O
Metalation	O	O
of	O	O
benzanilide	O	O
with	O	O
n	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
butyllithium	I-IUPAC	I-IUPAC
,	O	O
addition	O	O
of	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
dimethylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
cyclohexanone	I-IUPAC	I-IUPAC
,	O	O
and	O	O
acidification	O	O
afforded	O	O
a	O	O
mixture	O	O
of	O	O
cis	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
and	O	O
trans	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
dimethylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
spiro	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
cyclohexane	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,1	I-IUPAC	I-IUPAC
'	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3'	I-IUPAC	I-IUPAC
H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isobenzofuran	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
(	O	O
1a	O	O
,	O	O
b	O	O
)	O	O
,	O	O
which	O	O
were	O	O
separated	O	O
by	O	O
fractional	O	O
crystallization	O	O
.	O	O
The	O	O
broad	O	O
spectrum	O	O
excitatory	O	O
amino	O	O
acid	O	O
antagonist	O	O
activity	O	O
of	O	O
the	O	O
4	O	O
-	O	O
unsubstituted	O	O
analogue	O	O
21	O	O
(	O	O
KbNMDA	O	O
=	O	O
6.7	O	O
microM	O	O
,	O	O
KbAMPA	O	O
=	O	O
9.2	O	O
microM	O	O
)	O	O
and	O	O
the	O	O
glycine	O	O
/	O	O
NMDA	O	O
selectivity	O	O
of	O	O
the	O	O
other	O	O
3	B-IUPAC	O
-	I-IUPAC	O
nitro	I-IUPAC	O
derivatives	B-MODIFIER	O
allows	O	O
the	O	O
proposal	O	O
of	O	O
a	O	O
model	O	O
for	O	O
AMPA	O	O
receptor	O	O
binding	O	O
which	O	O
differs	O	O
from	O	O
the	O	O
glycine	O	O
binding	O	O
pharmacophore	O	O
in	O	O
that	O	O
there	O	O
is	O	O
bulk	O	O
intolerance	O	O
adjacent	O	O
to	O	O
the	O	O
4	O	O
-	O	O
position	O	O
.	O	O
albicans	O	O
WD	O	O
18-4	O	O
.	O	O
Certain	O	O
congeners	O	O
were	O	O
up	O	O
to	O	O
145	O	O
-	O	O
fold	O	O
more	O	O
active	O	O
at	O	O
A1	O	O
receptors	O	O
than	O	O
at	O	O
A2	O	O
receptors	O	O
.	O	O
Thus	O	O
,	O	O
the	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminopyridin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ylmethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
piperidine	I-IUPAC	I-IUPAC
analogue	B-MODIFIER	B-MODIFIER
15y	O	O
exhibiting	O	O
190	O	O
-	O	O
fold	O	O
selectivity	O	O
for	O	O
M	O	O
(	O	O
3	O	O
)	O	O
receptors	O	O
(	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
2.8	O	O
nM	O	O
)	O	O
over	O	O
M	O	O
(	O	O
2	O	O
)	O	O
receptors	O	O
(	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
530	O	O
nM	O	O
)	O	O
in	O	O
a	O	O
human	O	O
binding	O	O
assay	O	O
and	O	O
good	O	O
in	O	O
vitro	O	O
metabolic	O	O
stability	O	O
in	O	O
dog	O	O
and	O	O
human	O	O
hepatic	O	O
microsomes	O	O
was	O	O
identified	O	O
.	O	O
Various	O	O
derivatives	O	O
of	O	O
the	O	O
congeners	O	O
should	O	O
be	O	O
useful	O	O
as	O	O
receptor	O	O
probes	O	O
and	O	O
for	O	O
radioiodination	O	O
,	O	O
avidin	O	O
binding	O	O
,	O	O
and	O	O
preparation	O	O
of	O	O
affinity	O	O
columns	O	O
.	O	O
The	O	O
8	B-IUPAC	O
-	I-IUPAC	O
vinylchlorins	I-IUPAC	O
obtained	O	O
by	O	O
refluxing	O	O
the	O	O
related	O	O
vic	O	O
-	O	O
dihydroxybacteriochlorins	O	O
in	O	O
o	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dichlorobenzene	I-IUPAC	I-IUPAC
were	O	O
individually	O	O
treated	O	O
with	O	O
dimethylacetylenedicarboxylate	B-IUPAC	O
(	O	O
DMAD	O	O
)	O	O
under	O	O
Diels	O	O
-	O	O
Alder	O	O
reaction	O	O
conditions	O	O
.	O	O
As	O	O
demonstrated	O	O
for	O	O
cyclo	O	O
[	O	O
21,29	O	O
]	O	O
[	O	O
D	O	O
-	O	O
Cys	O	O
(	O	O
21	O	O
)	O	O
Cys	O	O
(	O	O
29	O	O
)	O	O
]	O	O
-	O	O
uPA	O	O
(	O	O
21	O	O
)	O	O
(	O	O
-	O	O
)	O	O
(	O	O
30	O	O
)	O	O
,	O	O
the	O	O
achieved	O	O
peptide	O	O
modifications	O	O
maintained	O	O
receptor	O	O
binding	O	O
activity	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
0.04	O	O
microM	O	O
)	O	O
,	O	O
which	O	O
is	O	O
close	O	O
in	O	O
order	O	O
to	O	O
that	O	O
of	O	O
the	O	O
parent	O	O
protein	O	O
ligand	O	O
,	O	O
uPA	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
0.01	O	O
microM	O	O
)	O	O
.	O	O
A	O	O
molecular	O	O
model	O	O
of	O	O
the	O	O
27	O	O
-	O	O
A2B	O	O
receptor	O	O
complex	O	O
based	O	O
on	O	O
the	O	O
structure	O	O
of	O	O
rhodopsin	O	O
utilizing	O	O
a	O	O
"	O	O
cross	O	O
-	O	O
docking	O	O
"	O	O
procedure	O	O
was	O	O
developed	O	O
in	O	O
order	O	O
to	O	O
visualize	O	O
the	O	O
environment	O	O
of	O	O
the	O	O
ligand	O	O
binding	O	O
site	O	O
.	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Aminoadipic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
3	O	O
)	O	O
,	O	O
which	O	O
shows	O	O
a	O	O
complex	O	O
excitatory	O	O
amino	O	O
acid	O	O
synaptic	O	O
pharmacology	O	O
,	O	O
was	O	O
an	O	O
agonist	O	O
at	O	O
mGlu6	O	O
as	O	O
well	O	O
as	O	O
mGlu2	O	O
.	O	O
Surprisingly	O	O
,	O	O
one	O	O
analog	O	O
with	O	O
D	O	O
-	O	O
stereochemistry	O	O
in	O	O
residue	O	O
3	O	O
,	O	O
the	O	O
(	O	O
2R	O	O
,	O	O
3R	O	O
)	O	O
-	O	O
MePhe3	O	O
analog	O	O
,	O	O
also	O	O
displays	O	O
high	O	O
affinity	O	O
for	O	O
the	O	O
delta	O	O
receptor	O	O
and	O	O
is	O	O
extraordinarily	O	O
selective	O	O
for	O	O
this	O	O
receptor	O	O
.	O	O
The	O	O
development	O	O
of	O	O
a	O	O
prostaglandin	O	O
PGF2	O	O
alpha	O	O
photoaffinity	O	O
probe	O	O
led	O	O
to	O	O
the	O	O
synthesis	O	O
and	O	O
biological	O	O
evaluation	O	O
of	O	O
azide	B-MODIFIER	O
-	I-MODIFIER	O
substituted	I-MODIFIER	B-MODIFIER
17	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
18,19,20	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trinorprostaglandin	I-IUPAC	I-IUPAC
F2	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
and	O	O
16	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
17,18,19,20	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetranorprostaglandin	I-IUPAC	I-IUPAC
F2	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
derivatives	O	B-MODIFIER
.	O	O
Because	O	O
of	O	O
the	O	O
susceptibility	O	O
to	O	O
acid	O	O
-	O	O
catalyzed	O	O
hydrolysis	O	O
of	O	O
these	O	O
tertiary	O	O
enamines	O	O
,	O	O
however	O	O
,	O	O
these	O	O
compounds	O	O
serve	O	O
only	O	O
as	O	O
model	O	O
compounds	O	O
for	O	O
their	O	O
structure	O	O
-	O	O
activity	O	O
evaluation	O	O
.	O	O
The	O	O
analog	O	O
was	O	O
found	O	O
to	O	O
be	O	O
a	O	O
potent	O	O
inhibitor	O	O
of	O	O
the	O	O
oxytocic	O	O
and	O	O
avian	O	O
vasodepressor	O	O
effects	O	O
of	O	O
oxytocin	O	O
(	O	O
pA2	O	O
values	O	O
of	O	O
7.43	O	O
and	O	O
8.30	O	O
,	O	O
respectively	O	O
)	O	O
but	O	O
was	O	O
only	O	O
a	O	O
weak	O	O
inhibitor	O	O
of	O	O
the	O	O
rat	O	O
pressor	O	O
effect	O	O
of	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
lysine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
vasopressin	I-IUPAC	I-IUPAC
.	O	O
The	O	O
two	O	O
most	O	O
active	O	O
members	O	O
of	O	O
this	O	O
series	O	O
,	O	O
39	O	O
and	O	O
63	O	O
,	O	O
were	O	O
active	O	O
against	O	O
the	O	O
gastrointestinal	O	O
nematodes	O	O
of	O	O
sheep	O	O
at	O	O
100	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O
This	O	O
derivative	O	O
,	O	O
(	B-IUPAC	B-IUPAC
S	I-IUPAC	I-IUPAC
*	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
R	I-IUPAC	I-IUPAC
*	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
mercaptopropyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tert	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
leucyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isoquinolinyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carbonyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
glutamine	I-IUPAC	I-IUPAC
,	O	O
was	O	O
evaluated	O	O
in	O	O
vivo	O	O
along	O	O
with	O	O
(	B-IUPAC	B-IUPAC
S	I-IUPAC	I-IUPAC
*	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
R	I-IUPAC	I-IUPAC
*	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
mercaptopropyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tert	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
leucyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isoquinolinyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
carbonyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methionine	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
ester	I-IUPAC	I-IUPAC
for	O	O
antitumor	O	O
activity	O	O
in	O	O
an	O	O
athymic	O	O
mouse	O	O
model	O	O
implanted	O	O
ip	O	O
with	O	O
H	O	O
-	O	O
ras	O	O
-	O	O
transformed	O	O
rat	O	O
-	O	O
1	O	O
tumor	O	O
cells	O	O
.	O	O
Ring	O	O
closure	O	O
of	O	O
ethyl	B-IUPAC	B-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminopyrazole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylate	I-IUPAC	I-IUPAC
with	O	O
sulfamoyl	O	O
chloride	O	O
gave	O	O
1,7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydropyrazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
c	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,2,6	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
thiadiazine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
2,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dioxide	I-IUPAC	I-IUPAC
.	O	O
The	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
propananilido	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
perhydroazepines	I-IUPAC	I-IUPAC
having	O	O
1	O	O
-	O	O
substitutents	O	O
in	O	O
common	O	O
with	O	O
known	O	O
opiate	O	O
antagonists	O	O
failed	O	O
to	O	O
exhibit	O	O
antagonism	O	O
of	O	O
morphine	O	O
analgesia	O	O
.	O	O
Preliminary	O	O
indications	O	O
are	O	O
that	O	O
9	O	O
may	O	O
act	O	O
by	O	O
both	O	O
central	O	O
and	O	O
peripheral	O	O
mechanisms	O	O
.	O	O
The	O	O
anti	O	O
-	O	O
HIV	O	O
potency	O	O
of	O	O
purine	O	O
analogues	O	O
was	O	O
found	O	O
to	O	O
be	O	O
in	O	O
the	O	O
following	O	O
decreasing	O	O
order	O	O
:	O	O
2,6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diaminopurine	I-IUPAC	I-IUPAC
(	O	O
beta	O	O
-	O	O
isomer	O	O
)	O	O
&	O	O
gt	O	O
;	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloroadenine	I-IUPAC	I-IUPAC
(	O	O
alpha	O	O
-	O	O
isomer	O	O
)	O	O
&	O	O
gt	O	O
;	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluoroadenine	I-IUPAC	I-IUPAC
(	O	O
beta	O	O
-	O	O
isomer	O	O
)	O	O
&	O	O
gt	O	O
;	O	O
adenine	O	O
(	O	O
beta	O	O
-	O	O
isomer	O	O
)	O	O
&	O	O
gt	O	O
;	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloropurine	I-IUPAC	I-IUPAC
(	O	O
alpha	O	O
-	O	O
isomer	O	O
)	O	O
&	O	O
gt	O	O
;	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloropurine	I-IUPAC	I-IUPAC
(	O	O
beta	O	O
-	O	O
isomer	O	O
)	O	O
&	O	O
gt	O	O
;	O	O
guanine	O	O
(	O	O
beta	O	O
-	O	O
isomer	O	O
)	O	O
&	O	O
gt	O	O
;	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluoroadenine	I-IUPAC	I-IUPAC
(	O	O
alpha	O	O
-	O	O
isomer	O	O
)	O	O
&	O	O
gt	O	O
;	O	O
adenine	O	O
(	O	O
alpha	O	O
-	O	O
isomer	O	O
)	O	O
&	O	O
gt	O	O
;	O	O
2,6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diaminopurine	I-IUPAC	I-IUPAC
(	O	O
alpha	O	O
-	O	O
isomer	O	O
)	O	O
&	O	O
gt	O	O
;	O	O
N6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyladenine	I-IUPAC	I-IUPAC
(	O	O
beta	O	O
-	O	O
isomer	O	O
)	O	O
.	O	O
Affinity	O	O
labeling	O	O
was	O	O
directly	O	O
demonstrated	O	O
by	O	O
ethanol	O	O
-	O	O
resistant	O	O
binding	O	O
of	O	O
[	B-IUPAC	B-IUPAC
3H	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
iodoacetamido	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
estradiol	I-IUPAC	I-IUPAC
to	O	O
the	O	O
receptor	O	O
.	O	O
The	O	O
aforementioned	O	O
products	O	O
,	O	O
plus	O	O
two	O	O
related	O	O
phenylselena	O	O
derivatives	O	O
,	O	O
were	O	O
examined	O	O
for	O	O
in	O	O
vitro	O	O
growth	O	O
inhibition	O	O
,	O	O
in	O	O
vivo	O	O
antitumor	O	O
activity	O	O
,	O	O
and	O	O
,	O	O
where	O	O
appropriate	O	O
,	O	O
DNA	O	O
binding	O	O
.	O	O
CCK	O	O
-	O	O
B	O	O
and	O	O
CCK	O	O
-	O	O
A	O	O
binding	O	O
affinities	O	O
of	O	O
these	O	O
analogues	O	O
are	O	O
described	O	O
and	O	O
their	O	O
CCK	O	O
-	O	O
B	O	O
affinity	O	O
and	O	O
selectivity	O	O
rationalized	O	O
by	O	O
consideration	O	O
of	O	O
the	O	O
pK	O	O
(	O	O
a	O	O
)	O	O
values	O	O
,	O	O
charge	O	O
distribution	O	O
,	O	O
and	O	O
geometry	O	O
of	O	O
the	O	O
respective	O	O
acid	O	O
mimics	O	O
.	O	O
The	O	O
design	O	O
,	O	O
synthesis	O	O
,	O	O
and	O	O
pharmacological	O	O
properties	O	O
of	O	O
a	O	O
novel	O	O
type	O	O
of	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1,2,5,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alkyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thiazolamine	I-IUPAC	I-IUPAC
with	O	O
dopaminergic	O	O
properties	O	O
are	O	O
described	O	O
.	O	O
falciparum	O	O
(	O	O
P	O	O
.	O	O
The	O	O
studies	O	O
suggest	O	O
that	O	O
the	O	O
nitrogen	O	O
lone	O	O
pair	O	O
orientation	O	O
found	O	O
in	O	O
the	O	O
piperazines	O	O
affords	O	O
the	O	O
strongest	O	O
binding	O	O
interaction	O	O
.	O	O
A	O	O
primary	O	O
action	O	O
of	O	O
the	O	O
compound	O	O
on	O	O
cyclooxygenase	O	O
is	O	O
excluded	O	O
,	O	O
as	O	O
a	O	O
stable	O	O
epoxymethano	O	O
analogue	O	O
of	O	O
prostaglandin	O	O
H2	O	O
does	O	O
not	O	O
reverse	O	O
the	O	O
inhibitory	O	O
effect	O	O
of	O	O
10a	O	O
.	O	O
A	O	O
series	O	O
of	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyphenethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
aryloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propan	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ols	I-IUPAC	I-IUPAC
was	O	O
synthesized	O	O
together	O	O
with	O	O
several	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethoxyphenethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
aryloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propan	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ols	I-IUPAC	I-IUPAC
.	O	O
Single	O	O
-	O	O
crystal	O	O
X	O	O
-	O	O
ray	O	O
analysis	O	O
of	O	O
(	B-IUPAC	B-IUPAC
+	I-IUPAC	I-IUPAC
/	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
picrate	I-IUPAC	I-IUPAC
confirmed	O	O
its	O	O
trans	O	O
configuration	O	O
and	O	O
provided	O	O
conformational	O	O
data	O	O
.	O	O
In	O	O
the	O	O
5	O	B-IUPAC
-	O	I-IUPAC
bromo	O	I-IUPAC
series	O	B-MODIFIER
of	O	O
compounds	O	O
,	O	O
the	O	O
C	O	O
-	O	O
6	O	O
substituent	O	O
was	O	O
also	O	O
a	O	O
determinant	O	O
of	O	O
activity	O	O
where	O	O
6	O	O
-	O	O
OMe	O	O
and	O	O
6	O	O
-	O	O
OEt	O	O
substituents	O	O
exhibited	O	O
a	O	O
greater	O	O
potency	O	O
than	O	O
the	O	O
corresponding	O	O
6	O	O
-	O	O
i	O	O
-	O	O
PrO	O	O
,	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
octyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
,	O	I-IUPAC
6	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hexadecyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	O
,	O	O
and	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
azido	I-IUPAC	I-IUPAC
analogs	B-MODIFIER	B-MODIFIER
.	O	O
For	O	O
1	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
cyclopropyl	I-PARTIUPAC	I-IUPAC
7	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
(	I-PARTIUPAC	I-IUPAC
2,6	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
dimethyl	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
4	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
pyridinyl	I-PARTIUPAC	I-IUPAC
)	I-PARTIUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
,	O	O
the	O	O
6	B-PARTIUPAC	O
-	I-PARTIUPAC	O
fluoro	I-PARTIUPAC	O
4a	O	O
,	O	O
8	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
fluoro	I-PARTIUPAC	I-IUPAC
10d	O	O
,	O	O
6,8	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
difluoro	I-PARTIUPAC	I-IUPAC
10b	O	O
,	O	O
and	O	O
5,6,8	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
trifluoro	I-PARTIUPAC	I-IUPAC
8	O	O
,	O	O
all	O	O
provided	O	O
equal	O	O
antibacterial	O	O
activity	O	O
against	O	O
Staphylococcus	O	O
aureus	O	O
ATCC	O	O
29213	O	O
.	O	O
It	O	O
is	O	O
concluded	O	O
that	O	O
homo	O	O
-	O	O
AMPA	O	O
(	O	O
8	O	O
)	O	O
is	O	O
likely	O	O
to	O	O
be	O	O
a	O	O
useful	O	O
tool	O	O
for	O	O
studies	O	O
of	O	O
the	O	O
pharmacology	O	O
and	O	O
physiological	O	O
role	O	O
of	O	O
mGlu6	O	O
.	O	O
A	O	O
number	O	O
of	O	O
17	B-PARTIUPAC	B-IUPAC
beta	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
(	I-PARTIUPAC	I-IUPAC
N	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
alkyl	I-PARTIUPAC	I-IUPAC
/	I-PARTIUPAC	O
arylformamido	I-PARTIUPAC	O
)	I-PARTIUPAC	O
-	I-PARTIUPAC	O
and	O	O
17	B-PARTIUPAC	B-IUPAC
beta	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
[	I-PARTIUPAC	I-IUPAC
(	I-PARTIUPAC	I-IUPAC
N	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
alkyl	I-PARTIUPAC	I-IUPAC
/	I-PARTIUPAC	I-IUPAC
aryl	I-PARTIUPAC	I-IUPAC
)	I-PARTIUPAC	I-IUPAC
alkyl	I-PARTIUPAC	I-IUPAC
/	I-PARTIUPAC	I-IUPAC
arylamido	I-PARTIUPAC	I-IUPAC
]	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
3	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
oxo	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
4	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
aza	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
5	I-PARTIUPAC	I-IUPAC
alpha	I-PARTIUPAC	I-IUPAC
-	O	I-IUPAC
steroids	B-MODIFIER	I-IUPAC
were	O	O
prepared	O	O
from	O	O
17	B-IUPAC	B-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
azasteroids	I-IUPAC	I-IUPAC
and	O	O
evaluated	O	O
as	O	O
inhibitors	O	O
of	O	O
human	O	O
5	O	O
alpha	O	O
-	O	O
reductase	O	O
and	O	O
antagonists	O	O
of	O	O
the	O	O
androgen	O	O
receptor	O	O
.	O	O
rhodesiense	O	O
(	O	O
T	O	O
.	O	O
To	O	O
provide	O	O
targeted	O	O
accumulation	O	O
of	O	O
MGMT	O	O
inhibitors	O	O
in	O	O
tumor	O	O
tissue	O	O
as	O	O
well	O	O
as	O	O
tools	O	O
for	O	O
in	O	O
vivo	O	O
imaging	O	O
,	O	O
we	O	O
synthesized	O	O
iodinated	O	O
C	O	O
(	O	O
8	O	O
)	O	O
-	O	O
alkyl	O	O
-	O	O
linked	O	O
glucose	O	O
conjugates	O	O
of	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
iodothenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
purine	I-IUPAC	I-IUPAC
(	O	I-IUPAC
O	B-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
iodothenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
guanine	I-IUPAC	I-IUPAC
,	O	O
ITG	O	O
)	O	O
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
iodobenzyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
purine	I-IUPAC	I-IUPAC
(	O	I-IUPAC
O	B-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
iodobenzyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
guanine	I-IUPAC	I-IUPAC
,	O	O
IBG	O	O
)	O	O
.	O	O
The	O	O
fluorine	O	O
substituent	O	O
markedly	O	O
increases	O	O
the	O	O
phenolic	O	O
acidities	O	O
of	O	O
these	O	O
analogues	O	O
.	O	O
The	O	O
delta	O	O
Tm	O	O
values	O	O
for	O	O
the	O	O
5H	O	O
series	O	O
were	O	O
found	O	O
to	O	O
be	O	O
about	O	O
10	O	O
times	O	O
as	O	O
high	O	O
as	O	O
those	O	O
for	O	O
the	O	O
6H	O	O
compounds	O	O
.	O	O
[	B-IUPAC	B-IUPAC
1	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
Benzothieno	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
c	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyridines	I-IUPAC	I-IUPAC
(	O	O
10a	O	O
-	O	O
c	O	O
,	O	O
11	O	O
,	O	O
12a	O	O
-	O	O
t	O	O
,	O	O
and	O	O
13a	O	O
,	O	O
b	O	O
)	O	O
and	O	O
1,2,3,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
benzothieno	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
c	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyridines	I-IUPAC	I-IUPAC
(	O	O
3a	O	O
-	O	O
c	O	O
,	O	O
7	O	O
,	O	O
8a	O	O
-	O	O
c	O	O
,	O	O
and	O	O
9	O	O
)	O	O
were	O	O
synthesized	O	O
.	O	O
In	O	O
the	O	O
ODC	O	O
assay	O	O
,	O	O
all	O	O
thirteen	O	O
compounds	O	O
were	O	O
screened	O	O
.	O	O
Several	O	O
3beta	B-PARTIUPAC	O
-	I-PARTIUPAC	O
(	O	O
substituted	B-MODIFIER	B-MODIFIER
phenyl	B-PARTIUPAC	B-PARTIUPAC
)	O	O
-	B-PARTIUPAC	I-PARTIUPAC
2beta	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
(	I-PARTIUPAC	I-PARTIUPAC
3	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
isoxazol	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
5	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
yl	I-PARTIUPAC	I-IUPAC
)	I-PARTIUPAC	I-IUPAC
tropanes	I-PARTIUPAC	I-IUPAC
(	O	O
3a	O	O
-	O	O
t	O	O
)	O	O
were	O	O
evaluated	O	O
for	O	O
their	O	O
ability	O	O
to	O	O
inhibit	O	O
radioligand	O	O
binding	O	O
at	O	O
the	O	O
DAT	O	O
,	O	O
5	O	O
-	O	O
HTT	O	O
,	O	O
and	O	O
NET	O	O
as	O	O
well	O	O
as	O	O
in	O	O
gross	O	O
observation	O	O
and	O	O
locomotor	O	O
activity	O	O
in	O	O
mice	O	O
and	O	O
in	O	O
rats	O	O
trained	O	O
to	O	O
discriminate	O	O
cocaine	O	O
.	O	O
The	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alkyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isoxazolyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propionic	I-IUPAC	I-IUPAC
acids	I-IUPAC	I-IUPAC
4a	O	O
,	O	O
b	O	O
,	O	O
i	O	O
,	O	O
which	O	O
are	O	O
regioisosteric	O	O
analogues	O	O
of	O	O
3a	O	O
,	O	O
b	O	O
,	O	O
i	O	O
,	O	O
showed	O	O
negligible	O	O
interaction	O	O
with	O	O
AMPA	O	O
recognition	O	O
sites	O	O
.	O	O
No	O	O
affinity	O	O
for	O	O
NMDA	O	O
receptors	O	O
(	O	O
NMDA	O	O
-	O	O
sensitive	O	O
[	O	O
3H	O	O
]	O	O
glutamic	O	O
acid	O	O
binding	O	O
)	O	O
was	O	O
found	O	O
,	O	O
and	O	O
only	O	O
weak	O	O
affinity	O	O
in	O	O
[	O	O
3H	O	O
]	O	O
kainic	O	O
acid	O	O
binding	O	O
(	O	O
IC50	O	O
=	O	O
6.3	O	O
microM	O	O
)	O	O
was	O	O
detected	O	O
.	O	O
This	O	O
derivative	O	O
of	O	O
homofolate	O	O
may	O	O
be	O	O
responsible	O	O
for	O	O
its	O	O
inhibition	O	O
of	O	O
purine	O	O
biosynthesis	O	O
in	O	O
Sarcoma	O	O
180	O	O
cells	O	O
.	O	O
The	O	O
compounds	O	O
were	O	O
equally	O	O
active	O	O
after	O	O
oral	O	O
and	O	O
subcutaneous	O	O
administration	O	O
and	O	O
showed	O	O
a	O	O
long	O	O
duration	O	O
of	O	O
action	O	O
(	O	O
&	O	O
gt	O	O
;	O	O
24	O	O
h	O	O
)	O	O
.	O	O
These	O	O
analogues	O	O
of	O	O
vasotocin	O	O
are	O	O
the	O	O
most	O	O
potent	O	O
that	O	O
have	O	O
been	O	O
synthesized	O	O
to	O	O
date	O	O
,	O	O
and	O	O
they	O	O
should	O	O
serve	O	O
as	O	O
useful	O	O
probes	O	O
in	O	O
the	O	O
isolation	O	O
and	O	O
characterization	O	O
of	O	O
vasotocin	O	O
receptors	O	O
in	O	O
toad	O	O
bladders	O	O
and	O	O
tissues	O	O
from	O	O
other	O	O
species	O	O
that	O	O
use	O	O
vasotocin	O	O
as	O	O
an	O	O
antidiuretic	O	O
/	O	O
pressor	O	O
principle	O	O
.	O	O
New	O	O
compounds	O	O
in	O	O
the	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
deaza	I-IUPAC	I-IUPAC
series	B-MODIFIER	B-MODIFIER
were	O	O
prepared	O	O
by	O	O
alkylation	O	O
of	O	O
an	O	O
appropriate	O	O
N	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
(	B-IUPAC	B-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminobenzoyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
glutamic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
dialkyl	I-IUPAC	I-IUPAC
ester	I-IUPAC	I-IUPAC
or	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thenoyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
glutamate	I-IUPAC	I-IUPAC
diester	I-IUPAC	I-IUPAC
with	O	O
a	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alkyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
bromomethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deazapteridine	I-IUPAC	I-IUPAC
.	O	O
The	O	O
pharmacology	O	O
of	O	O
THHBADs	O	O
was	O	O
characterized	O	O
by	O	O
electrical	O	O
recordings	O	O
in	O	O
Xenopus	O	O
oocytes	O	O
expressing	O	O
rat	O	O
brain	O	O
NMDA	O	O
and	O	O
AMPA	O	O
receptors	O	O
.	O	O
Generally	O	O
poor	O	O
potency	O	O
at	O	O
the	O	O
glycine	O	O
site	O	O
is	O	O
observed	O	O
when	O	O
a	O	O
variety	O	O
of	O	O
electron	O	O
-	O	O
withdrawing	O	O
substituents	O	O
are	O	O
attached	O	O
to	O	O
the	O	O
3	O	O
-	O	O
position	O	O
of	O	O
3,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
quinolones	I-IUPAC	I-IUPAC
.	O	O
[	O	O
18F	O	O
]	O	O
4b	O	O
and	O	O
[	O	O
18F	O	O
]	O	O
4c	O	O
showed	O	O
lower	O	O
specific	O	O
binding	O	O
ratios	O	O
than	O	O
[	O	O
carbonyl	O	O
-	O	O
11C	O	O
]	O	O
4a	O	O
and	O	O
[	O	O
18F	O	O
]	O	O
4d	O	O
.	O	O
The	O	O
highest	O	O
cytotoxic	O	O
activity	O	O
was	O	O
observed	O	O
for	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methylenefuranones	I-IUPAC	I-IUPAC
13d	O	O
,	O	O
e	O	O
bearing	O	O
benzyl	B-IUPAC	O
or	O	O
3,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dimethoxyphenylmethyl	I-IUPAC	I-IUPAC
substituents	B-MODIFIER	B-MODIFIER
at	O	O
position	O	O
5	O	O
,	O	O
with	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
values	O	O
of	O	O
5.4	O	O
and	O	O
6.0	O	O
microM	O	O
,	O	O
respectively	O	O
.	O	O
Peptide	O	O
coupling	O	O
with	O	O
diethyl	O	B-IUPAC
L	O	I-IUPAC
-	O	I-IUPAC
glutamate	O	I-IUPAC
followed	O	O
by	O	O
ester	O	O
hydrolysis	O	O
at	O	O
room	O	O
temperature	O	O
afforded	O	O
the	O	O
new	O	O
5,10	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dideazaaminopterin	I-IUPAC	I-IUPAC
analogues	B-MODIFIER	B-MODIFIER
.	O	O
The	O	O
syntheses	O	O
start	O	O
either	O	O
from	O	O
the	O	O
corresponding	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aryl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydroisoquinolines	I-IUPAC	I-IUPAC
or	O	O
from	O	O
the	O	O
corresponding	O	O
noncyclized	O	O
amino	O	O
alcohols	O	O
.	O	O
Compound	O	O
3	O	O
also	O	O
inhibited	O	O
the	O	O
growth	O	O
of	O	O
several	O	O
human	O	O
tumor	O	O
cell	O	O
lines	O	O
in	O	O
culture	O	O
with	O	O
GI50	O	O
&	O	O
lt	O	O
;	O	O
10	O	O
(	O	O
-	O	O
8	O	O
)	O	O
M	O	O
.	O	O
Anthelmintic	O	O
efficacies	O	O
of	O	O
a	O	O
series	O	O
of	O	O
6	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
methyl	B-IUPAC	B-IUPAC
imidazo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyridine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carbamates	I-IUPAC	I-IUPAC
were	O	O
compared	O	O
to	O	O
similarly	O	O
substituted	B-MODIFIER	B-MODIFIER
benzimidazole	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carbamates	I-IUPAC	I-IUPAC
.	O	O
The	O	O
induction	O	O
of	O	O
7	B-IUPAC	O
-	I-IUPAC	O
ethoxycoumarin	I-IUPAC	O
deethylase	O	O
activity	O	O
in	O	O
the	O	O
microsomal	O	O
fraction	O	O
from	O	O
rat	O	O
liver	O	O
by	O	O
alpha	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
naphthoflavone	I-IUPAC	I-IUPAC
,	O	O
beta	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
naphthoflavone	I-IUPAC	I-IUPAC
,	O	O
and	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methylcholanthrene	I-IUPAC	I-IUPAC
and	O	O
the	O	O
inhibition	O	O
of	O	O
these	O	O
activities	O	O
by	O	O
flavone	O	O
and	O	O
alpha	B-PARTIUPAC	O
-	I-PARTIUPAC	O
,	O	O
beta	B-PARTIUPAC	O
,	O	O
and	O	O
gamma	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
naphthoflavone	I-IUPAC	I-IUPAC
have	O	O
also	O	O
been	O	O
examined	O	O
.	O	O
Within	O	O
the	O	O
series	O	O
of	O	O
derivatives	O	O
submitted	O	O
to	O	O
investigation	O	O
,	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butylcarbamoyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6,7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylenedioxyphthalazin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
(	O	O
21	O	O
)	O	O
proved	O	O
to	O	O
be	O	O
the	O	O
most	O	O
active	O	O
compound	O	O
and	O	O
is	O	O
11	O	O
-	O	O
fold	O	O
more	O	O
potent	O	O
than	O	O
1	O	O
(	O	O
i.e.	O	O
,	O	O
ED50	O	O
3.25	O	O
micromol	O	O
/	O	O
kg	O	O
for	O	O
21	O	O
versus	O	O
ED50	O	O
35.8	O	O
micromol	O	O
/	O	O
kg	O	O
for	O	O
1	O	O
)	O	O
.	O	O
WB	O	O
4101	O	O
(	O	O
1	O	O
)	O	O
-	O	O
related	O	O
benzodioxanes	O	O
were	O	O
synthesized	O	O
by	O	O
replacing	O	O
the	O	O
ethylene	O	O
chain	O	O
separating	O	O
the	O	O
amine	O	O
and	O	O
the	O	O
phenoxy	O	O
units	O	O
of	O	O
1	O	O
with	O	O
a	O	O
cyclopentanol	B-IUPAC	O
moiety	I-IUPAC	O
,	O	O
a	O	O
feature	O	O
of	O	O
6	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
cis	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trans	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenoxycyclopentyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
meth	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylbenzo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
thiophen	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
that	O	O
was	O	O
reported	O	O
to	O	O
display	O	O
an	O	O
intriguing	O	O
selectivity	O	O
profile	O	O
at	O	O
alpha	O	O
(	O	O
1	O	O
)	O	O
-	O	O
adrenoreceptors	O	O
.	O	O
Reduction	O	O
of	O	O
the	O	O
acid	O	O
group	O	O
of	O	O
5	O	O
gave	O	O
the	O	O
first	O	O
nonacidic	O	O
ETA	O	O
antagonist	O	O
in	O	O
our	O	O
series	O	O
,	O	O
(	B-IUPAC	B-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzyloxyphenoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
prop2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
enol	I-IUPAC	I-IUPAC
6	O	O
with	O	O
an	O	O
IC50	O	O
of	O	O
20	O	O
microM	O	O
.	O	O
The	O	O
analogues	O	O
were	O	O
evaluated	O	O
(	O	O
1	O	O
)	O	O
.	O	O
The	O	O
results	O	O
establish	O	O
that	O	O
the	O	O
presence	O	O
of	O	O
an	O	O
imidazole	O	O
N	O	O
-	O	O
3	O	O
nitrogen	O	O
substituent	O	O
is	O	O
not	O	O
required	O	O
to	O	O
inhibit	O	O
the	O	O
monooxygenase	O	O
activity	O	O
measured	O	O
by	O	O
the	O	O
deethylation	O	O
of	O	O
7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
ethoxycoumarin	I-IUPAC	I-IUPAC
.	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
Benzoyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
C	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
threo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pentofuranosyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
thymine	I-IUPAC	I-IUPAC
was	O	O
converted	O	O
to	O	O
a	O	O
mixture	O	O
of	O	O
3'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
C	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylidene	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
3'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dideoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyluridine	I-IUPAC	I-IUPAC
and	O	O
3'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
C	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
3'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dideoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
3'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
didehydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyluridine	I-IUPAC	I-IUPAC
,	O	O
which	O	O
were	O	O
separated	O	O
.	O	O
In	O	O
the	O	O
present	O	O
series	O	O
of	O	O
compounds	O	O
,	O	O
both	O	O
full	O	O
and	O	O
partial	O	O
agonists	O	O
were	O	O
found	O	O
.	O	O
Reaction	O	O
of	O	O
33	O	O
and	O	O
34	O	O
with	O	O
HCO2H	O	O
led	O	O
to	O	O
guanine	O	O
analogues	O	O
15	O	O
and	O	O
17	O	O
.	O	O
The	O	O
brominated	O	O
primary	O	O
amines	O	O
4c	O	O
,	O	O
d	O	O
were	O	O
assayed	O	O
initially	O	O
for	O	O
activity	O	O
in	O	O
the	O	O
two	O	O
-	O	O
lever	O	O
drug	O	O
discrimination	O	O
(	O	O
DD	O	O
)	O	O
paradigm	O	O
in	O	O
rats	O	O
trained	O	O
to	O	O
discriminate	O	O
saline	O	O
from	O	O
LSD	O	O
tartrate	O	O
(	O	O
0	O	O
.	O	O
The	O	O
most	O	O
active	O	O
compounds	O	O
are	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxoethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phenylmethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
indol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
propenoic+	I-IUPAC	I-IUPAC
+	I-IUPAC	I-IUPAC
+	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
4g	O	O
)	O	O
of	O	O
the	O	O
indolyl	O	O
series	O	O
and	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxoethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phenylmethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthalenecarboxylic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
2a	O	O
)	O	O
or	O	O
the	O	O
naphthyl	B-IUPAC	O
series	B-MODIFIER	O
,	O	O
with	O	O
IC50	O	O
of	O	O
8	O	O
and	O	O
4.7	O	O
nM	O	O
respectively	O	O
,	O	O
in	O	O
the	O	O
receptor	O	O
binding	O	O
assay	O	O
using	O	O
intact	O	O
human	O	O
neutrophils	O	O
.	O	O
Replacement	O	O
with	O	O
a	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
imidazolidinon	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
side	B-MODIFIER	B-MODIFIER
chain	I-MODIFIER	I-MODIFIER
reduced	O	O
binding	O	O
to	O	O
alpha	O	O
1	O	O
adrenoceptors	O	O
with	O	O
a	O	O
factor	O	O
of	O	O
four	O	O
,	O	O
while	O	O
affinities	O	O
for	O	O
5	O	O
-	O	O
HT2	O	O
and	O	O
D2	O	O
receptors	O	O
were	O	O
retained	O	O
,	O	O
compared	O	O
to	O	O
the	O	O
3	B-MODIFIER	O
-	I-MODIFIER	O
unsubstituted	I-MODIFIER	O
imidazolidinone	B-IUPAC	O
.	O	O
The	O	O
homoanalog	O	O
,	O	O
methyl	B-IUPAC	B-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isothiocyanatoethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
thiazole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carbamate	I-IUPAC	I-IUPAC
,	O	O
was	O	O
prepared	O	O
from	O	O
(	B-IUPAC	B-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminothiazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
acetic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
.	O	O
Two	O	O
distinct	O	O
sets	O	O
of	O	O
signals	O	O
for	O	O
the	O	O
tomaymycin	O	O
molecule	O	O
are	O	O
present	O	O
in	O	O
the	O	O
proton	O	O
NMR	O	O
spectrum	O	O
of	O	O
the	O	O
tomaymycin	O	O
-	O	O
d	O	O
(	O	O
ATGCAT	O	O
)	O	O
2	O	O
duplex	O	O
adduct	O	O
.	O	O
casei	O	O
thymidylate	O	O
synthase	O	O
compared	O	O
to	O	O
PDDF	O	O
.	O	O
The	O	O
second	O	O
set	O	O
of	O	O
compounds	O	O
includes	O	O
some	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenylalkyl	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
of	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydronaphthalen	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
n	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propylamine	I-IUPAC	I-IUPAC
that	O	O
can	O	O
be	O	O
considered	O	O
to	O	O
be	O	O
open	O	O
-	O	O
chain	O	O
derivatives	O	O
of	O	O
4	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
-	O	O
1	B-IUPAC	O
-	I-IUPAC	O
arylpiperazines	I-IUPAC	O
.	O	O
Phosphorylation	O	O
and	O	O
deblocking	O	O
gave	O	O
the	O	O
D	O	O
-	O	O
and	O	O
L	O	O
-	O	O
enantiomers	O	O
of	O	O
myo	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
inositol	I-IUPAC	I-IUPAC
1,3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trisphosphate	I-IUPAC	I-IUPAC
.	O	O
Preparation	O	O
of	O	O
the	O	O
target	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
alkyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
alkoxymethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzyluracil	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
27-34	O	O
was	O	O
carried	O	O
out	O	O
by	O	O
acetylation	O	O
of	O	O
9-14	O	O
followed	O	O
by	O	O
Pd	O	O
-	O	O
catalyzed	O	O
hydrogenolysis	O	O
.	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
Chromon	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
were	O	O
less	O	O
potent	O	O
than	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxochroman	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
.	O	O
Selectivity	O	O
of	O	O
the	O	O
new	O	O
analogues	O	O
for	O	O
cloned	O	O
human	O	O
A3	O	O
adenosine	O	O
receptors	O	O
was	O	O
determined	O	O
vs	O	O
radioligand	O	O
binding	O	O
at	O	O
rat	O	O
brain	O	O
A1	O	O
and	O	O
A2A	O	O
receptors	O	O
.	O	O
Characterization	O	O
via	O	O
elemental	O	O
,	O	O
IR	O	O
,	O	O
1H	O	O
NMR	O	O
,	O	O
and	O	O
13C	O	O
NMR	O	O
analyses	O	O
was	O	O
completed	O	O
for	O	O
these	O	O
heterocycles	O	O
.	O	O
(	B-IUPAC	B-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
Bromovinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
(	O	O
BVDU	O	O
)	O	O
when	O	O
similarly	O	O
treated	O	O
gave	O	O
the	O	O
corresponding	O	O
(	B-IUPAC	B-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bromovinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
compound	B-MODIFIER	B-MODIFIER
7	O	O
.	O	O
Out	O	O
of	O	O
seven	O	O
natural	O	O
analogues	O	O
and	O	O
18	O	O
chemical	O	O
derivatives	O	O
of	O	O
AbA	O	O
,	O	O
several	O	O
were	O	O
shown	O	O
to	O	O
display	O	O
even	O	O
more	O	O
potent	O	O
Pgp	O	O
-	O	O
inhibitory	O	O
activity	O	O
.	O	O
The	O	O
structure	O	O
of	O	O
the	O	O
[	O	O
99mTc	O	O
]	O	O
TRODAT	O	O
-	O	O
1	O	O
complexes	O	O
was	O	O
deduced	O	O
using	O	O
nonradioactive	O	O
rhenium	O	O
as	O	O
a	O	O
surrogate	O	O
for	O	O
radioactive	O	O
technetium	O	O
complex	O	O
.	O	O
Although	O	O
71	O	O
was	O	O
active	O	O
orally	O	O
only	O	O
at	O	O
a	O	O
10	O	O
-	O	O
fold	O	O
higher	O	O
dose	O	O
level	O	O
,	O	O
good	O	O
oral	O	O
bioavailability	O	O
was	O	O
demonstrated	O	O
for	O	O
a	O	O
monoacidic	O	O
analogue	O	O
62	O	O
.	O	O
(	O	O
ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
400	O	O
WORDS	O	O
)	O	O
The	O	O
synthesis	O	O
of	O	O
certain	O	O
heteroarotinoids	O	O
has	O	O
been	O	O
achieved	O	O
,	O	O
namely	O	O
the	O	O
systems	O	O
(	B-IUPAC	O
2E	I-IUPAC	O
,	I-IUPAC	O
4E	I-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
6E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3,7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1,2,3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thiochromanyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,4,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
heptatrienoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
1a	O	O
)	O	O
,	O	O
ethyl	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
2E	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
4E	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
6E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3,7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1,2,3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
teterahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thiochromanyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,4,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
heptatrienoate	I-IUPAC	I-IUPAC
(	O	O
1b	O	O
)	O	O
,	O	O
(	B-IUPAC	B-IUPAC
2E	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
4E	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
6E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3,7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1,2,3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chromanyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,4,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
heptatrienoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
1c	O	O
)	O	O
,	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phthalimidoethyl	I-IUPAC	I-IUPAC
3,7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1,2,3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thiochromanyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,4,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
heptatrienoate	I-IUPAC	I-IUPAC
(	O	O
1d	O	O
)	O	O
,	O	O
methyl	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chromanyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propenyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
benzoate	I-IUPAC	I-IUPAC
(	O	O
2a	O	O
)	O	O
,	O	O
(	B-IUPAC	B-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chromanyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propenyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
benzyl	I-IUPAC	I-IUPAC
alcohol	I-IUPAC	I-IUPAC
(	O	O
2b	O	O
)	O	O
,	O	O
(	B-IUPAC	B-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chromanyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propenyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
benzonitrile	I-IUPAC	I-IUPAC
(	O	O
2c	O	O
)	O	O
,	O	O
(	B-IUPAC	B-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chromanyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propenyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
benzaldehyde	I-IUPAC	I-IUPAC
(	O	O
2d	O	O
)	O	O
,	O	O
methyl	B-IUPAC	B-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzofuranyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propenyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
benzoate	I-IUPAC	I-IUPAC
(	O	O
3a	O	O
)	O	O
,	O	O
and	O	O
(	B-IUPAC	B-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzofuranyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propenyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
benzoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
3b	O	O
)	O	O
.	O	O
Among	O	O
the	O	O
25	O	O
cell	O	O
lines	O	O
in	O	O
the	O	O
National	O	O
Cancer	O	O
Institute	O	O
panel	O	O
for	O	O
which	O	O
data	O	O
were	O	O
confirmed	O	O
in	O	O
two	O	O
independent	O	O
experiments	O	O
,	O	O
the	O	O
IC50	O	O
for	O	O
at	O	O
least	O	O
two	O	O
of	O	O
these	O	O
compounds	O	O
was	O	O
&	O	O
lt	O	O
;	O	O
10	O	O
microM	O	O
against	O	O
17	O	O
cell	O	O
lines	O	O
(	O	O
68%	O	O
)	O	O
and	O	O
in	O	O
the	O	O
0	O	O
.	O	O
Various	O	O
5	O	O
-	O	O
substituents	O	O
were	O	O
introduced	O	O
via	O	O
palladium	O	O
-	O	O
catalyzed	O	O
carbonylation	O	O
of	O	O
N	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trifluoromethanesulfonyloxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzopyran	I-IUPAC	I-IUPAC
.	O	O
Antagonistic	O	O
and	O	O
agonistic	O	O
properties	O	O
of	O	O
the	O	O
analogues	O	O
were	O	O
studied	O	O
using	O	O
an	O	O
in	O	O
vitro	O	O
functional	O	O
assay	O	O
with	O	O
hamster	O	O
tracheal	O	O
rings	O	O
.	O	O
Surprisingly	O	O
,	O	O
two	O	O
compounds	O	O
,	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
morpholino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dibenzofuranyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chromen	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
(	O	O
NU7427	O	O
,	O	O
32	O	O
{	O	O
38	O	O
}	O	O
)	O	O
and	O	O
the	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
morpholino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dibenzothiophenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chromen	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
(	O	O
NU7441	O	O
,	O	O
32	O	O
{	O	O
26	O	O
}	O	O
)	O	O
were	O	O
excellent	O	O
inhibitors	O	O
(	O	O
IC50	O	O
vs	O	O
DNA	O	O
-	O	O
PK	O	O
=	O	O
40	O	O
and	O	O
13	O	O
nM	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O
A	O	O
Horners	O	O
-	O	O
Emmons	O	O
condensation	O	O
with	O	O
this	O	O
aldehyde	O	O
then	O	O
produced	O	O
retinoic	O	O
acid	O	O
analogs	O	O
with	O	O
both	O	O
9Z	O	O
-	O	O
and	O	O
9Z	O	O
,	O	O
13Z	O	O
-	O	O
configurations	O	O
.	O	O
Two	O	O
analogues	O	O
,	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthylthio	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
furo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
(	O	O
5	O	O
)	O	O
and	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylanilino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
furo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
(	O	O
11	O	O
)	O	O
showed	O	O
significant	O	O
selectivity	O	O
and	O	O
potency	O	O
for	O	O
pcDHFR	O	O
compared	O	O
to	O	O
trimethoprim	O	O
.	O	O
The	O	O
greater	O	O
potency	O	O
of	O	O
8	O	O
and	O	O
12	O	O
,	O	O
as	O	O
compared	O	O
to	O	O
the	O	O
parent	O	O
unsubstituted	O	O
analogues	O	O
exo	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
2	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
amino	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
and	O	O
anti	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzonorbornene	I-IUPAC	I-IUPAC
(	O	O
4	O	O
and	O	O
5	O	O
,	O	O
respectively	O	O
)	O	O
,	O	O
indicates	O	O
the	O	O
presence	O	O
of	O	O
a	O	O
spatially	O	O
compact	O	O
hydrophilic	O	O
pocket	O	O
within	O	O
the	O	O
aromatic	O	O
ring	O	O
binding	O	O
region	O	O
of	O	O
the	O	O
active	O	O
site	O	O
of	O	O
the	O	O
enzyme	O	O
.	O	O
Two	O	O
novel	O	O
classical	O	O
antifolates	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
{	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4,7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrrolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
thio	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
benzoyl	I-IUPAC	I-IUPAC
}	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
glutamic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
3	O	O
and	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
{	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4,7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrrolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
thio	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
benzoyl	I-IUPAC	I-IUPAC
}	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
glutamic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
4	O	O
were	O	O
designed	O	O
,	O	O
synthesized	O	O
,	O	O
and	O	O
evaluated	O	O
as	O	O
antitumor	O	O
agents	O	O
.	O	O
However	O	O
,	O	O
this	O	O
was	O	O
not	O	O
the	O	O
case	O	O
when	O	O
the	O	O
cargo	O	O
fragments	O	O
were	O	O
negatively	O	O
charged	O	O
.	O	O
To	O	O
this	O	O
end	O	O
,	O	O
we	O	O
have	O	O
prepared	O	O
(	O	O
9	O	B-IUPAC
-	O	I-IUPAC
fluorenylmethoxycarbonyl	O	I-IUPAC
-	O	I-IUPAC
SO	O	I-IUPAC
(	O	O
3	O	O
)	O	O
H	O	O
)	O	O
(	O	O
3	O	O
)	O	O
-	O	O
insulin	O	O
(	O	O
(	O	O
FMS	O	O
)	O	O
(	O	O
3	O	O
)	O	O
-	O	O
insulin	O	O
)	O	O
,	O	O
a	O	O
derivative	O	O
having	O	O
three	O	O
9	O	B-IUPAC
-	O	I-IUPAC
fluorenylmethoxycarbonyl	O	I-IUPAC
-	O	I-IUPAC
SO	O	I-IUPAC
(	O	O
3	O	O
)	O	O
H	O	O
(	O	O
FMS	O	O
)	O	O
moieties	O	O
covalently	O	O
linked	O	O
to	O	O
the	O	O
three	O	O
amino	O	O
side	O	O
chains	O	O
of	O	O
insulin	O	O
.	O	O
The	O	O
size	O	O
of	O	O
the	O	O
N	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
arylmethyl	I-IUPAC	I-IUPAC
substituent	B-MODIFIER	B-MODIFIER
had	O	O
direct	O	O
bearing	O	O
on	O	O
the	O	O
observed	O	O
cytotoxicity	O	O
in	O	O
CHO	O	O
-	O	O
MG	O	O
cells	O	O
.	O	O
carinii	O	O
,	O	O
Toxoplasma	O	O
gondii	O	O
,	O	O
and	O	O
rat	O	O
liver	O	O
.	O	O
The	O	O
highest	O	O
CNS	O	O
activity	O	O
was	O	O
achieved	O	O
when	O	O
pyroglutamic	O	O
acid	O	O
was	O	O
replaced	O	O
by	O	O
pyro	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminoadipic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
at	O	O
the	O	O
N	O	O
-	O	O
terminus	O	O
[	O	O
pAad	O	O
-	O	O
Leu	O	O
-	O	O
Pro	O	O
-	O	O
NH2	O	O
,	O	O
1	O	O
(	O	O
RGH	O	O
2202	O	O
)	O	O
,	O	O
and	O	O
pAad	O	O
-	O	O
Nva	O	O
-	O	O
Pro	O	O
-	O	O
NH2	O	O
,	O	O
2	O	O
]	O	O
.	O	O
Compound	O	O
18	O	O
(	O	O
L	O	O
-	O	O
162,223	O	O
)	O	O
displayed	O	O
very	O	O
prolonged	O	O
AII	O	O
antagonism	O	O
in	O	O
the	O	O
rat	O	O
model	O	O
(	O	O
&	O	O
gt	O	O
;	O	O
24	O	O
h	O	O
at	O	O
1	O	O
mg	O	O
/	O	O
kg	O	O
iv	O	O
)	O	O
.	O	O
Compound	O	O
28	O	O
(	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
benzyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
dimethylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrimidinecarboxylic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
)	O	O
was	O	O
the	O	O
most	O	O
effective	O	O
positive	O	O
inotropic	O	O
agent	O	O
,	O	O
while	O	O
the	O	O
corresponding	O	O
methyl	O	B-IUPAC
ester	O	I-IUPAC
17	O	O
reduced	O	O
both	O	O
the	O	O
contractile	O	O
force	O	O
and	O	O
the	O	O
frequency	O	O
of	O	O
guinea	O	O
pig	O	O
atria	O	O
.	O	O
(	O	O
FMS	O	O
)	O	O
(	O	O
3	O	O
)	O	O
-	O	O
insulin	O	O
is	O	O
soluble	O	O
in	O	O
aqueous	O	O
buffers	O	O
at	O	O
neutral	O	O
pH	O	O
,	O	O
at	O	O
a	O	O
concentration	O	O
range	O	O
of	O	O
0.15-0.60	O	O
mM	O	O
,	O	O
and	O	O
has	O	O
about	O	O
1%	O	O
of	O	O
both	O	O
the	O	O
biological	O	O
potency	O	O
and	O	O
the	O	O
receptor	O	O
-	O	O
binding	O	O
affinity	O	O
of	O	O
the	O	O
native	O	O
hormone	O	O
.	O	O
To	O	O
establish	O	O
if	O	O
the	O	O
potent	O	O
antagonistic	O	O
effects	O	O
of	O	O
these	O	O
bicyclic	O	O
compounds	O	O
was	O	O
because	O	O
of	O	O
the	O	O
lactam	O	O
ring	O	O
or	O	O
merely	O	O
the	O	O
result	O	O
of	O	O
obtaining	O	O
an	O	O
optimal	O	O
degree	O	O
of	O	O
lipophilicity	O	O
of	O	O
the	O	O
side	O	O
chains	O	O
in	O	O
positions	O	O
4	O	O
and	O	O
8	O	O
,	O	O
we	O	O
synthesized	O	O
a	O	O
series	O	O
of	O	O
analogues	O	O
containing	O	O
neutral	O	O
and	O	O
/	O	O
or	O	O
charged	O	O
groups	O	O
on	O	O
these	O	O
side	O	O
chains	O	O
.	O	O
While	O	O
these	O	O
solubilized	O	O
pyrimido	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
5,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
analogues	B-MODIFIER	B-MODIFIER
were	O	O
less	O	O
potent	O	O
than	O	O
the	O	O
NHMe	O	O
derivative	O	O
5c	O	O
in	O	O
the	O	O
isolated	O	O
enzyme	O	O
assay	O	O
,	O	O
some	O	O
were	O	O
considerably	O	O
superior	O	O
to	O	O
5c	O	O
(	O	O
and	O	O
among	O	O
the	O	O
most	O	O
potent	O	O
ever	O	O
reported	O	O
)	O	O
as	O	O
inhibitors	O	O
of	O	O
EGFR	O	O
autophosphorylation	O	O
in	O	O
cellular	O	O
assays	O	O
.	O	O
The	O	O
photoaffinity	O	O
and	O	O
biotinyl	O	O
analogues	O	O
had	O	O
a	O	O
rat	O	O
antidiuretic	O	O
activity	O	O
of	O	O
66	O	O
and	O	O
40	O	O
units	O	O
/	O	O
mg	O	O
,	O	O
respectively	O	O
.	O	O
In	O	O
this	O	O
regard	O	O
,	O	O
a	O	O
cytotoxicity	O	O
model	O	O
was	O	O
proposed	O	O
,	O	O
which	O	O
describes	O	O
a	O	O
hydrophobic	O	O
pocket	O	O
of	O	O
set	O	O
dimensions	O	O
adjacent	O	O
to	O	O
the	O	O
putative	O	O
PAT	O	O
polyamine	O	O
-	O	O
binding	O	O
site	O	O
.	O	O
Since	O	O
the	O	O
proximal	O	O
nitrogen	O	O
atom	O	O
of	O	O
the	O	O
piperazine	O	O
ring	O	O
is	O	O
redundant	O	O
for	O	O
biological	O	O
activity	O	O
,	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propylidene	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
10	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dibenzo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
cycloh	I-IUPAC	I-IUPAC
eptene	I-IUPAC	I-IUPAC
and	O	O
its	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
are	O	O
excellent	O	O
candidates	O	O
for	O	O
resolution	O	O
into	O	O
enantiomers	O	O
as	O	O
a	O	O
means	O	O
to	O	O
separate	O	O
antimuscarinic	O	O
and	O	O
antidopaminergic	O	O
activity	O	O
,	O	O
respectively	O	O
,	O	O
associated	O	O
with	O	O
only	O	O
a	O	O
single	O	O
stereoisomer	O	O
.	O	O
The	O	O
key	O	O
step	O	O
in	O	O
the	O	O
synthetic	O	O
route	O	O
to	O	O
12a	O	O
was	O	O
Wittig	O	O
condensation	O	O
of	O	O
the	O	O
tributylphosphorane	O	O
derived	O	O
from	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
bromomethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylpyrido	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
(	O	O
7a	O	O
)	O	O
with	O	O
methyl	B-IUPAC	B-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propionylbenzoate	I-IUPAC	I-IUPAC
.	O	O
As	O	O
the	O	O
structure	O	O
of	O	O
the	O	O
polyamines	O	O
was	O	O
varied	O	O
,	O	O
their	O	O
binding	O	O
at	O	O
sigma	O	O
-	O	O
1	O	O
and	O	O
sigma	O	O
-	O	O
2	O	O
subtypes	O	O
showed	O	O
quite	O	O
different	O	O
and	O	O
in	O	O
some	O	O
cases	O	O
opposite	O	O
trends	O	O
,	O	O
supporting	O	O
the	O	O
belief	O	O
that	O	O
these	O	O
are	O	O
pharmacologically	O	O
distinct	O	O
entities	O	O
.	O	O
Substrate	O	O
and	O	O
inhibitor	O	O
properties	O	O
indicated	O	O
that	O	O
the	O	O
compounds	O	O
possessed	O	O
affinity	O	O
for	O	O
the	O	O
ATP	O	O
sites	O	O
of	O	O
the	O	O
muscle	O	O
(	O	O
M	O	O
)	O	O
,	O	O
kidney	O	O
(	O	O
K	O	O
)	O	O
,	O	O
and	O	O
liver	O	O
(	O	O
L	O	O
)	O	O
isozymes	O	O
of	O	O
rat	O	O
pyruvate	O	O
kinase	O	O
(	O	O
PK	O	O
)	O	O
,	O	O
of	O	O
E	O	O
.	O	O
Novel	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxochroman	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amide	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
1	O	O
were	O	O
synthesized	O	O
and	O	O
tested	O	O
for	O	O
their	O	O
ability	O	O
to	O	O
inhibit	O	O
rabbit	O	O
small	O	O
intestinal	O	O
ACAT	O	O
(	O	O
acyl	O	O
-	O	O
CoA	O	O
:	O	O
cholesterol	O	O
acyltransferase	O	O
)	O	O
in	O	O
vitro	O	O
and	O	O
to	O	O
lower	O	O
serum	O	O
total	O	O
cholesterol	O	O
in	O	O
cholesterol	O	O
-	O	O
fed	O	O
rats	O	O
in	O	O
vivo	O	O
.	O	O
Replacement	O	O
of	O	O
the	O	O
ureido	O	B-IUPAC
moiety	O	B-MODIFIER
of	O	O
the	O	O
lead	O	O
compound	O	O
with	O	O
hydroxyguanidine	O	O
provided	O	O
a	O	O
stable	O	O
cytotoxic	O	O
agent	O	O
.	O	O
Compounds	O	O
having	O	O
an	O	O
i	O	O
-	O	O
Pr	O	O
ester	O	O
substituent	O	O
acted	O	O
as	O	O
dual	O	O
cardioselective	O	O
calcium	O	O
channel	O	O
agonists	O	O
(	O	O
GPLA	O	O
)	O	O
/	O	O
smooth	O	O
muscle	O	O
-	O	O
selective	O	O
calcium	O	O
channel	O	O
antagonists	O	O
(	O	O
GPILSM	O	O
)	O	O
,	O	O
except	O	O
for	O	O
the	O	O
C	O	O
-	O	O
4	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
nitro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridyl	I-IUPAC	I-IUPAC
compound	B-MODIFIER	B-MODIFIER
which	O	O
exhibited	O	O
an	O	O
antagonist	O	O
effect	O	O
on	O	O
both	O	O
GPLA	O	O
and	O	O
GPILSM	O	O
.	O	O
N	O	B-IUPAC
-	O	I-IUPAC
(	O	I-IUPAC
2	O	I-IUPAC
-	O	I-IUPAC
Naphthyl	O	I-IUPAC
)	O	I-IUPAC
glycine	O	I-IUPAC
hydrazide	O	I-IUPAC
analogues	B-MODIFIER	B-MODIFIER
were	O	O
synthesized	O	O
and	O	O
tested	O	O
for	O	O
possible	O	O
in	O	O
vitro	O	O
antitubercular	O	O
activity	O	O
.	O	O
The	O	O
DTPA	O	O
-	O	O
conjugated	O	O
,	O	O
side	O	O
-	O	O
chain	O	O
-	O	O
protected	O	O
peptide	O	O
was	O	O
cleaved	O	O
from	O	O
the	O	O
resin	O	O
by	O	O
aminolysis	O	O
with	O	O
threoninol	O	O
,	O	O
side	O	O
-	O	O
chain	O	O
deprotected	O	O
with	O	O
trifluoroacetic	O	O
acid	O	O
,	O	O
and	O	O
purified	O	O
by	O	O
semipreparative	O	O
RP	O	O
-	O	O
HPLC	O	O
.	O	O
A	O	O
series	O	O
of	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydronaphthalenes	I-IUPAC	I-IUPAC
(	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminotetralins	I-IUPAC	I-IUPAC
,	O	O
PATs	O	O
)	O	O
previously	O	O
was	O	O
found	O	O
to	O	O
modulate	O	O
tyrosine	O	O
hydroxylase	O	O
activity	O	O
and	O	O
dopamine	O	O
synthesis	O	O
in	O	O
rodent	O	O
forebrain	O	O
through	O	O
interaction	O	O
with	O	O
a	O	O
binding	O	O
site	O	O
labeled	O	O
by	O	O
[	O	O
(	O	O
3	O	O
)	O	O
H	O	O
]	O	O
-	O	O
(	O	O
-	O	O
)	O	O
-	O	O
(	O	O
1R	O	O
,	O	O
3S	O	O
)	O	O
-	O	O
trans	O	O
-	O	O
H	O	O
(	O	O
2	O	O
)	O	O
-	O	O
PAT	O	O
.	O	O
Thus	O	O
,	O	O
certain	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydronaphthalenes	I-IUPAC	I-IUPAC
appear	O	O
to	O	O
be	O	O
selective	O	O
probes	O	O
of	O	O
a	O	O
novel	O	O
receptor	O	O
type	O	O
that	O	O
mediates	O	O
sigma	O	O
-	O	O
like	O	O
neuromodulatory	O	O
activity	O	O
and	O	O
may	O	O
have	O	O
pharmacotherapeutic	O	O
utility	O	O
in	O	O
conditions	O	O
in	O	O
which	O	O
modulation	O	O
of	O	O
dopamine	O	O
function	O	O
is	O	O
important	O	O
.	O	O
A	O	O
new	O	O
class	O	O
of	O	O
histamine	O	O
analogues	O	O
characterized	O	O
by	O	O
a	O	O
3	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diphenylpropyl	I-IUPAC	I-IUPAC
substituent	B-MODIFIER	B-MODIFIER
at	O	O
the	O	O
2	O	O
-	O	O
position	O	O
of	O	O
the	O	O
imidazole	O	O
nucleus	O	O
has	O	O
been	O	O
prepared	O	O
outgoing	O	O
from	O	O
4,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diphenylbutyronitrile	I-IUPAC	I-IUPAC
(	O	O
4b	O	O
)	O	O
via	O	O
cyclization	O	O
of	O	O
the	O	O
corresponding	O	O
methyl	O	O
imidate	O	O
5b	O	O
with	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
oxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phthalimido	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
acetate	I-IUPAC	I-IUPAC
or	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
oxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butandiol	I-IUPAC	I-IUPAC
in	O	O
liquid	O	O
ammonia	O	O
,	O	O
followed	O	O
by	O	O
standard	O	O
reactions	O	O
.	O	O
A	O	O
synthesis	O	O
scheme	O	O
for	O	O
3'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
C	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxynucleosides	I-IUPAC	I-IUPAC
and	O	O
3'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
C	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylidene	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
3'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dideoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyluridine	I-IUPAC	I-IUPAC
has	O	O
been	O	O
proposed	O	O
with	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
deoxyribose	I-IUPAC	I-IUPAC
as	O	O
the	O	O
starting	O	O
material	O	O
.	O	O
The	O	O
GABA	O	O
ratios	O	O
close	O	O
to	O	O
unity	O	O
exhibited	O	O
by	O	O
all	O	O
the	O	O
tested	O	O
compounds	O	O
on	O	O
each	O	O
BzR	O	O
subtype	O	O
were	O	O
predictive	O	O
of	O	O
an	O	O
efficacy	O	O
profile	O	O
typical	O	O
of	O	O
antagonists	O	O
.	O	O
Molecular	O	O
modeling	O	O
of	O	O
the	O	O
interaction	O	O
of	O	O
these	O	O
compounds	O	O
with	O	O
AChE	O	O
from	O	O
Torpedo	O	O
californica	O	O
showed	O	O
them	O	O
to	O	O
interact	O	O
as	O	O
truly	O	O
THA	O	O
-	O	O
huperzine	O	O
A	O	O
hybrids	O	O
:	O	O
the	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aminoquinoline	I-IUPAC	I-IUPAC
subunit	B-MODIFIER	B-MODIFIER
of	O	O
(	O	O
-	O	O
)	O	O
-	O	O
19	O	O
occupies	O	O
the	O	O
same	O	O
position	O	O
of	O	O
the	O	O
corresponding	O	O
subunit	O	O
in	O	O
THA	O	O
,	O	O
while	O	O
its	O	O
bicyclo	O	B-IUPAC
[	O	I-IUPAC
3.3.1	O	I-IUPAC
]	O	I-IUPAC
nonadiene	O	I-IUPAC
substructure	O	B-MODIFIER
roughly	O	O
occupies	O	O
the	O	O
same	O	O
position	O	O
of	O	O
the	O	O
corresponding	O	O
substructure	O	O
in	O	O
(	O	O
-	O	O
)	O	O
-	O	O
huperzine	O	O
A	O	O
,	O	O
in	O	O
agreement	O	O
with	O	O
the	O	O
absolute	O	O
configurations	O	O
of	O	O
(	O	O
-	O	O
)	O	O
-	O	O
19	O	O
and	O	O
(	O	O
-	O	O
)	O	O
-	O	O
huperzine	O	O
A	O	O
.	O	O
The	O	O
active	O	O
enantiomers	O	O
both	O	O
of	O	O
the	O	O
cis	O	O
series	O	O
(	O	O
21a	O	O
,	O	O
21c	O	O
)	O	O
and	O	O
trans	O	O
series	O	O
(	O	O
16b	O	O
,	O	O
16d	O	O
)	O	O
were	O	O
found	O	O
to	O	O
have	O	O
all	O	O
R	O	O
configuration	O	O
at	O	O
the	O	O
C	O	O
-	O	O
2	O	O
and	O	O
R	O	O
or	O	O
S	O	O
configuration	O	O
at	O	O
the	O	O
C	O	O
-	O	O
1	O	O
,	O	O
while	O	O
in	O	O
the	O	O
classical	O	O
ACE	O	O
inhibitors	O	O
S	O	O
configuration	O	O
at	O	O
the	O	O
terminal	O	O
carboxylate	O	O
(	O	O
corresponding	O	O
to	O	O
the	O	O
C	O	O
-	O	O
1	O	O
of	O	O
our	O	O
compounds	O	O
)	O	O
is	O	O
strictly	O	O
required	O	O
for	O	O
activity	O	O
.	O	O
Molecular	O	O
interactions	O	O
between	O	O
RGD	O	O
peptides	O	O
and	O	O
integrins	O	O
are	O	O
known	O	O
to	O	O
mediate	O	O
many	O	O
biological	O	O
and	O	O
pathological	O	O
processes	O	O
.	O	O
The	O	O
affinity	O	O
of	O	O
10	O	O
and	O	O
13-17	O	O
for	O	O
guinea	O	O
-	O	O
pig	O	O
H	O	O
(	O	O
1	O	O
)	O	O
receptors	O	O
increased	O	O
20	O	O
-	O	O
to	O	O
100	O	O
-	O	O
fold	O	O
compared	O	O
with	O	O
1	O	O
.	O	O
In	O	O
the	O	O
5	O	O
-	O	O
substituted	O	O
series	O	O
(	O	O
R1	O	O
in	O	O
3	O	O
)	O	O
,	O	O
the	O	O
trans	O	O
isomers	O	O
were	O	O
found	O	O
to	O	O
possess	O	O
higher	O	O
levels	O	O
of	O	O
pharmacological	O	O
activity	O	O
then	O	O
the	O	O
corresponding	O	O
cis	O	O
isomers	O	O
.	O	O
Ten	O	O
heretofore	O	O
undescribed	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloroquinazoline	I-IUPAC	I-IUPAC
analogues	B-MODIFIER	B-MODIFIER
of	O	O
trimetrexate	O	O
(	O	O
TMQ	O	O
)	O	O
and	O	O
piritrexim	O	O
(	O	O
PTX	O	O
)	O	O
were	O	O
synthesized	O	O
and	O	O
tested	O	O
as	O	O
inhibitors	O	O
of	O	O
dihydrofolate	O	O
reductase	O	O
(	O	O
DHFR	O	O
)	O	O
from	O	O
rat	O	O
liver	O	O
,	O	O
Pneumocystis	O	O
carinii	O	O
,	O	O
and	O	O
Toxoplasma	O	O
gondii	O	O
.	O	O
In	O	O
comparison	O	O
,	O	O
the	O	O
ID50	O	O
value	O	O
for	O	O
trans	O	O
-	O	O
retinoic	O	O
acid	O	O
(	O	O
1	O	O
)	O	O
was	O	O
0.12	O	O
nmol	O	O
while	O	O
the	O	O
ID50	O	O
values	O	O
for	O	O
acids	O	O
7	O	O
and	O	O
9	O	O
,	O	O
namely	O	O
(	B-IUPAC	B-IUPAC
2Z	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
4E	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
6E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3,7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thiochroman	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,4,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
heptatrienoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
and	O	O
(	B-IUPAC	B-IUPAC
2E	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
4E	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
6E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3,7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2,2,4,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetramethylthiochroman	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,4,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
heptatrienoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
,	O	O
respectively	O	O
,	O	O
were	O	O
about	O	O
3.5	O	O
nmol	O	O
.	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9,11	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
seco	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
17beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetoxyestra	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,3,5	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
10	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trien	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
11	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
2	O	O
)	O	O
,	O	O
prepared	O	O
by	O	O
CrO3	O	O
oxidation	O	O
of	O	O
1	O	O
,	O	O
on	O	O
hydrogenolysis	O	O
gave	O	O
methyl	B-IUPAC	B-IUPAC
17beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9,11	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
secoestra	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,3,5	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
10	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
triene	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
11	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylate	I-IUPAC	I-IUPAC
(	O	O
3	O	O
)	O	O
.	O	O
Cisplatin	O	O
was	O	O
more	O	O
efficacious	O	O
than	O	O
both	O	O
trans	O	O
-	O	O
[	O	O
PtCl2	O	O
(	O	O
NH3	O	O
)	O	O
(	O	O
pip	O	O
-	O	O
pip	O	O
)	O	O
]	O	O
x	O	O
HCl	O	O
and	O	O
trans	O	O
-	O	O
[	O	O
PtCl2	O	O
(	O	O
NBA	O	O
)	O	O
(	O	O
pip	O	O
-	O	O
pip	O	O
)	O	O
]	O	O
x	O	O
HCl	O	O
in	O	O
the	O	O
A2780	O	O
and	O	O
A2780cisR	O	O
tumor	O	O
xenograft	O	O
models	O	O
,	O	O
consistent	O	O
with	O	O
its	O	O
lower	O	O
IC50	O	O
values	O	O
in	O	O
A2780	O	O
cells	O	O
but	O	O
contrary	O	O
to	O	O
the	O	O
higher	O	O
IC50	O	O
values	O	O
in	O	O
A2780cisR	O	O
cells	O	O
.	O	O
These	O	O
results	O	O
establish	O	O
that	O	O
the	O	O
MAO	O	O
-	O	O
catalyzed	O	O
bioactivation	O	O
of	O	O
MPTP	O	O
leads	O	O
to	O	O
the	O	O
formation	O	O
of	O	O
a	O	O
variety	O	O
of	O	O
reactive	O	O
molecules	O	O
that	O	O
are	O	O
potentially	O	O
cytotoxic	O	O
to	O	O
nigrostriatal	O	O
cells	O	O
.	O	O
Substitution	O	O
of	O	O
propanoic	O	O
or	O	O
propenoic	O	O
acid	O	O
moieties	O	O
for	O	O
the	O	O
acidic	O	O
heterocyclic	O	O
units	O	O
of	O	O
these	O	O
compounds	O	O
gave	O	O
the	O	O
monocyclic	O	O
amino	O	O
acids	O	O
15-18	O	O
,	O	O
which	O	O
have	O	O
very	O	O
little	O	O
or	O	O
no	O	O
affinity	O	O
for	O	O
GABAA	O	O
receptor	O	O
sites	O	O
.	O	O
gondii	O	O
versus	O	O
rat	O	O
liver	O	O
DHFR	O	O
was	O	O
observed	O	O
with	O	O
five	O	O
compounds	O	O
,	O	O
the	O	O
best	O	O
combination	O	O
of	O	O
potency	O	O
and	O	O
selectivity	O	O
being	O	O
achieved	O	O
with	O	O
the	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methoxybenzyl	I-IUPAC	I-IUPAC
analogue	B-MODIFIER	B-MODIFIER
5d	O	O
,	O	O
which	O	O
had	O	O
an	O	O
IC50	O	O
of	O	O
0.014	O	O
microM	O	O
and	O	O
a	O	O
selectivity	O	O
ratio	O	O
of	O	O
8.6	O	O
.	O	O
As	O	O
hybrids	O	O
between	O	O
tropanes	O	O
and	O	O
quinuclidines	O	O
,	O	O
these	O	O
tropaquinuclidines	O	O
represent	O	O
a	O	O
significant	O	O
structural	O	O
departure	O	O
from	O	O
many	O	O
of	O	O
the	O	O
other	O	O
classes	O	O
of	O	O
tropane	O	O
ligands	O	O
synthesized	O	O
to	O	O
date	O	O
.	O	O
The	O	O
diverse	O	O
binding	O	O
properties	O	O
of	O	O
these	O	O
compounds	O	O
at	O	O
the	O	O
DA	O	O
-	O	O
uptake	O	O
site	O	O
and	O	O
their	O	O
spectrum	O	O
of	O	O
inhibitory	O	O
activities	O	O
for	O	O
[	O	O
3H	O	O
]	O	O
DA	O	O
uptake	O	O
identifies	O	O
them	O	O
as	O	O
a	O	O
useful	O	O
base	O	O
for	O	O
the	O	O
development	O	O
of	O	O
subtype	O	O
selective	O	O
probes	O	O
at	O	O
this	O	O
site	O	O
.	O	O
The	O	O
esters	O	O
of	O	O
the	O	O
appropriate	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aminophenyl	I-IUPAC	I-IUPAC
(	O	O
benzoyl	B-PARTIUPAC	O
)	O	O
starting	O	O
materials	O	O
were	O	O
sequentially	O	O
alkylated	O	O
upon	O	O
nitrogen	O	O
,	O	O
first	O	O
with	O	O
a	O	O
propargyl	O	O
halide	O	O
and	O	O
then	O	O
with	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
bromomethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyquinazoline	I-IUPAC	I-IUPAC
hydrobromide	I-IUPAC	I-IUPAC
.	O	O
The	O	O
results	O	O
observed	O	O
for	O	O
the	O	O
t	O	O
-	O	O
Hpp1	O	O
and	O	O
c	O	O
-	O	O
Hpp1	O	O
analogues	O	O
are	O	O
particularly	O	O
significant	O	O
since	O	O
these	O	O
two	O	O
residues	O	O
have	O	O
little	O	O
accessible	O	O
conformational	O	O
space	O	O
in	O	O
common	O	O
.	O	O
Analogs	O	O
of	O	O
CVFM	O	O
(	O	O
a	O	O
known	O	O
nonsubstrate	O	O
farnesyltransferase	O	O
(	O	O
FT	O	O
)	O	O
inhibitor	O	O
derived	O	O
from	O	O
a	O	O
CA1A2X	O	O
sequence	O	O
where	O	O
C	O	O
is	O	O
cysteine	O	O
,	O	O
A	O	O
is	O	O
an	O	O
aliphatic	O	O
residue	O	O
,	O	O
and	O	O
X	O	O
is	O	O
any	O	O
residue	O	O
)	O	O
were	O	O
prepared	O	O
where	O	O
phenylalanine	O	O
was	O	O
replaced	O	O
by	O	O
(	B-IUPAC	B-IUPAC
Z	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dehydrophenylalanine	I-IUPAC	I-IUPAC
,	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aminoindan	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylate	I-IUPAC	I-IUPAC
,	O	O
1,2,3,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydroisoquinoline	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylate	I-IUPAC	I-IUPAC
(	O	O
Tic	O	O
)	O	O
,	O	O
and	O	O
indoline	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylate	I-IUPAC	I-IUPAC
.	O	O
A	O	O
series	O	O
of	O	O
2,3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diaryl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzopyran	I-IUPAC	I-IUPAC
analogues	B-MODIFIER	B-MODIFIER
substituted	B-MODIFIER	O
at	O	O
position	O	O
4	O	O
of	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
with	O	O
a	O	O
hydroxy	B-IUPAC	O
or	O	O
pyrrolidinoethoxy	B-IUPAC	O
residue	B-MODIFIER	O
were	O	O
synthesized	O	O
as	O	O
models	O	O
for	O	O
(	B-IUPAC	O
E	I-IUPAC	O
)	I-IUPAC	O
-	I-IUPAC	O
triarylpropenones	I-IUPAC	O
constrained	O	O
in	O	O
the	O	O
s	O	O
-	O	O
trans	O	O
conformation	O	O
.	O	O
A	O	O
similar	O	O
transformation	O	O
of	O	O
the	O	O
aglycone	O	O
of	O	O
toyocamycin	O	O
(	O	O
4m	O	O
)	O	O
furnished	O	O
the	O	O
corresponding	O	O
aglycone	O	O
of	O	O
thiosangivamycin	O	O
(	O	O
6m	O	O
)	O	O
.	O	O
The	O	O
binding	O	O
ability	O	O
of	O	O
[	O	O
(	O	O
131	O	O
)	O	O
I	O	O
]	O	O
ITGG	O	O
,	O	O
[	O	O
(	O	O
131	O	O
)	O	O
]	O	O
IBGG	O	O
,	O	O
[	O	O
(	O	O
131	O	O
)	O	O
I	O	O
]	O	O
ITG	O	O
,	O	O
and	O	O
[	O	O
(	O	O
131	O	O
)	O	O
I	O	O
]	O	O
IBG	O	O
to	O	O
purified	O	O
MGMT	O	O
was	O	O
tested	O	O
.	O	O
Compound	O	O
(	O	O
-	O	O
)	O	O
-	O	O
1	O	O
exhibited	O	O
a	O	O
Ki	O	O
of	O	O
81	O	O
+	O	O
/	O	O
-	O	O
13	O	O
nM	O	O
at	O	O
sigma	O	O
receptors	O	O
[	O	O
[	O	O
3H	O	O
]	O	O
-	O	O
(	O	O
+	O	O
)	O	O
-	O	O
3	O	O
-	O	O
PPP	O	O
]	O	O
and	O	O
250	O	O
+	O	O
/	O	O
-	O	O
8	O	O
nM	O	O
(	O	O
[	O	O
3H	O	O
]	O	O
DTG	O	O
)	O	O
.	O	O
Synthesis	O	O
methodology	O	O
was	O	O
developed	O	O
for	O	O
compounds	O	O
combining	O	O
three	O	O
moieties	O	O
:	O	O
pyridin	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ylmethyl	I-IUPAC	I-IUPAC
or	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloropyridin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ylmethyl	I-IUPAC	I-IUPAC
and	O	O
their	O	O
4	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
and	O	O
5	B-IUPAC	O
-	I-IUPAC	O
azido	I-IUPAC	O
analogues	B-MODIFIER	O
;	O	O
imidazolidine	B-IUPAC	B-IUPAC
,	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
imidazoline	I-IUPAC	I-IUPAC
or	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
thiazoline	I-IUPAC	I-IUPAC
;	O	O
and	O	O
N	B-MODIFIER	O
-	I-MODIFIER	O
unsubstituted	I-MODIFIER	O
imine	B-IUPAC	O
,	O	O
nitroimine	O	O
,	O	O
cyanoimine	O	O
,	O	O
or	O	O
nitromethylene	O	O
.	O	O
Cyclization	O	O
of	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloroanilino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminomethylquinoline	I-IUPAC	I-IUPAC
(	O	O
3a	O	O
)	O	O
and	O	O
its	O	O
6	O	O
-	O	O
OCH3	O	O
derivative	O	O
with	O	O
paraformaldehyde	O	O
gave	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chlorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3,9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethyltetrahydropyrimido	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
5,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
c	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
quinoline	I-IUPAC	I-IUPAC
(	O	O
4a	O	O
)	O	O
and	O	O
the	O	O
9	O	O
-	O	O
OCH3	O	O
derivative	O	O
4b	O	O
.	O	O
The	O	O
E	O	O
-	O	O
isomer	O	O
16	O	O
was	O	O
more	O	O
reactive	O	O
than	O	O
Z	O	O
-	O	O
isomer	O	O
14	O	O
.	O	O
The	O	O
reaction	O	O
of	O	O
2,4	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dinitroimidazole	I-IUPAC	I-IUPAC
(	O	O
2	O	O
)	O	O
with	O	O
chloroethanol	O	O
or	O	O
hydrochloric	O	O
acid	O	O
yielded	O	O
4	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
nitro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloroimidazole	I-IUPAC	I-IUPAC
(	O	O
3	O	O
)	O	O
,	O	O
which	O	O
upon	O	O
reaction	O	O
with	O	O
ethylene	O	O
oxide	O	O
yielded	O	O
the	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
nitro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloroimidazole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethanol	I-IUPAC	I-IUPAC
(	O	O
6	O	O
)	O	O
.	O	O
The	O	O
structure	O	O
-	O	O
activity	O	O
relationships	O	O
in	O	O
this	O	O
series	O	O
of	O	O
antagonists	O	O
indicate	O	O
that	O	O
the	O	O
(	O	O
R	O	O
)	O	O
-	O	O
configuration	O	O
at	O	O
the	O	O
axial	O	O
bond	O	O
and	O	O
the	O	O
stacking	O	O
(	O	O
or	O	O
stacking	O	O
-	O	O
like	O	O
)	O	O
conformation	O	O
between	O	O
the	O	O
two	O	O
phenyl	B-IUPAC	O
rings	B-MODIFIER	O
as	O	O
shown	O	O
in	O	O
1t	O	O
-	O	O
A	O	O
and	O	O
3a	O	O
-	O	O
A	O	O
are	O	O
essential	O	O
for	O	O
high	O	O
-	O	O
affinity	O	O
binding	O	O
and	O	O
suggest	O	O
that	O	O
the	O	O
amide	B-IUPAC	O
moiety	B-MODIFIER	O
functions	O	O
as	O	O
a	O	O
hydrogen	O	O
bond	O	O
acceptor	O	O
in	O	O
the	O	O
interaction	O	O
with	O	O
the	O	O
receptor	O	O
.	O	O
Whereas	O	O
compounds	O	O
4-6	O	O
and	O	O
8	O	O
did	O	O
not	O	O
exhibit	O	O
a	O	O
selective	O	O
antiviral	O	O
effect	O	O
,	O	O
compounds	O	O
1-3	O	O
and	O	O
7	O	O
proved	O	O
almost	O	O
as	O	O
active	O	O
as	O	O
the	O	O
reference	O	O
compound	O	O
BVDU	O	O
.	O	O
In	O	O
preliminary	O	O
in	O	O
vitro	O	O
(	O	O
RIF	O	O
tumor	O	O
cells	O	O
)	O	O
and	O	O
in	O	O
vivo	O	O
screening	O	O
(	O	O
C3H	O	O
/	O	O
HeJ	O	O
mice	O	O
bearing	O	O
RIF	O	O
tumors	O	O
)	O	O
,	O	O
some	O	O
of	O	O
these	O	O
compounds	O	O
were	O	O
found	O	O
to	O	O
be	O	O
quite	O	O
effective	O	O
.	O	O
r	O	O
.	O	O
In	O	O
addition	O	O
,	O	O
compound	O	O
37	O	O
inhibited	O	O
apomorphine	O	O
-	O	O
induced	O	O
climbing	O	O
behavior	O	O
much	O	O
more	O	O
potently	O	O
(	O	O
ED50	O	O
of	O	O
3.4	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
than	O	O
stereotyped	O	O
behavior	O	O
(	O	O
ED50	O	O
of	O	O
32.2	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
and	O	O
will	O	O
be	O	O
evaluated	O	O
further	O	O
.	O	O
The	O	O
ability	O	O
of	O	O
conjugates	O	O
of	O	O
peptides	O	O
and	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluorocytosine	I-IUPAC	I-IUPAC
or	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluoroorotic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
to	O	O
enter	O	O
Candida	O	O
albicans	O	O
was	O	O
investigated	O	O
.	O	O
With	O	O
a	O	O
novel	O	O
assay	O	O
using	O	O
isolated	O	O
ferret	O	O
detrusor	O	O
to	O	O
estimate	O	O
beta	O	O
(	O	O
3	O	O
)	O	O
-	O	O
adrenoceptor	O	O
agonistic	O	O
activity	O	O
,	O	O
we	O	O
found	O	O
that	O	O
a	O	O
series	O	O
of	O	O
glycine	O	O
derivatives	O	O
of	O	O
ritodrine	O	O
,	O	O
a	O	O
beta	O	O
(	O	O
2	O	O
)	O	O
-	O	O
adrenoceptor	O	O
agonist	O	O
,	O	O
are	O	O
potent	O	O
beta	O	O
(	O	O
3	O	O
)	O	O
-	O	O
adrenoceptor	O	O
agonists	O	O
,	O	O
with	O	O
excellent	O	O
selectivity	O	O
versus	O	O
beta	O	O
(	O	O
1	O	O
)	O	O
and	O	O
beta	O	O
(	O	O
2	O	O
)	O	O
subtypes	O	O
.	O	O
Rings	O	O
of	O	O
rat	O	O
aorta	O	O
were	O	O
used	O	O
as	O	O
a	O	O
"	O	O
negative	O	O
screen	O	O
"	O	O
for	O	O
the	O	O
test	O	O
antagonists	O	O
.	O	O
f	O	O
.	O	O
Selective	O	O
acetylation	O	O
at	O	O
the	O	O
primary	O	O
amine	O	O
position	O	O
of	O	O
6	O	O
,	O	O
to	O	O
give	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzopyran	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylbutyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxoethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
acetylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
butan	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
olide	I-IUPAC	I-IUPAC
(	O	O
7	O	O
)	O	O
,	O	O
led	O	O
to	O	O
a	O	O
considerable	O	O
decrease	O	O
in	O	O
activity	O	O
.	O	O
The	O	O
synthesis	O	O
of	O	O
a	O	O
series	O	O
of	O	O
diaryl	B-IUPAC	B-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
prolylpyrrolidine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
R	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phosphonates	I-IUPAC	I-IUPAC
with	O	O
different	O	O
substituents	O	O
on	O	O
the	O	O
aryl	O	O
rings	O	O
(	O	O
hydroxyl	B-IUPAC	O
,	O	O
methoxy	B-IUPAC	O
,	O	O
acylamino	B-IUPAC	O
,	O	O
sulfonylamino	B-IUPAC	O
,	O	O
ureyl	B-IUPAC	O
,	O	O
methoxycarbonyl	B-IUPAC	B-IUPAC
,	O	O
and	O	O
alkylaminocarbonyl	B-IUPAC	O
)	O	O
started	O	O
from	O	O
the	O	O
corresponding	O	O
phosphites	O	O
.	O	O
Bioassay	O	O
results	O	O
from	O	O
guinea	O	O
pig	O	O
ileum	O	O
and	O	O
mouse	O	O
vas	O	O
deferens	O	O
preparations	O	O
are	O	O
in	O	O
general	O	O
agreement	O	O
with	O	O
the	O	O
binding	O	O
results	O	O
;	O	O
however	O	O
some	O	O
potency	O	O
discrepancies	O	O
are	O	O
observed	O	O
.	O	O
1H	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Benzimidazole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxamides	I-IUPAC	I-IUPAC
,	O	O
particularly	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aryl	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
,	O	O
are	O	O
identified	O	O
as	O	O
a	O	O
class	O	O
of	O	O
potent	O	O
PARP	O	O
inhibitors	O	O
.	O	O
The	O	O
=	O	O
N	O	O
-	O	O
OH	O	O
substituent	O	O
of	O	O
the	O	O
pyrimidine	O	O
C	O	O
(	O	O
4	O	O
)	O	O
prevented	O	O
the	O	O
enzyme	O	O
-	O	O
catalyzed	O	O
release	O	O
from	O	O
the	O	O
C	O	O
(	O	O
5	O	O
)	O	O
of	O	O
Br	O	O
(	O	O
-	O	O
)	O	O
and	O	O
I	O	O
(	O	O
-	O	O
)	O	O
(	O	O
the	O	O
same	O	O
shown	O	O
previously	O	O
for	O	O
H	O	O
(	O	O
+	O	O
)	O	O
)	O	O
.	O	O
Compounds	O	O
9a	O	O
-	O	O
c	O	O
and	O	O
10a	O	O
,	O	O
b	O	O
,	O	O
possessing	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyimidazole	I-IUPAC	I-IUPAC
as	O	O
the	O	O
terminal	O	O
acidic	O	O
function	O	O
,	O	O
were	O	O
devoid	O	O
of	O	O
activity	O	O
in	O	O
all	O	O
of	O	O
the	O	O
systems	O	O
tested	O	O
.	O	O

